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Abstract 
Tumour formation and metastasis are distinct processes that arise from cumulative 
alterations of genomic and epigenetic regulation. Uncontrolled modulation of cell cycle-
related genes is crucial to tumour growth and additional genetic modifications provide cancer 
cells with motile and invasive phenotypes, leading to metastatic dissemination.  
The cytoskeleton constitutes the structural support to cell motility, invasion and adhesion. 
Among the best-characterised cytoskeletal modulators are the p21-activated kinases (PAKs). 
In breast cancer (BC), the HER2 pathway controls the cytoskeletal dynamics and cell motility 
via PAK activation, through distinct downstream signaling mechanisms.  
MicroRNAs (miRNAs) are small, non-coding RNAs that modulate gene expression post-
transcriptionally. MiRNAs dysregulation can contribute to tumorigenicity, cell motility and 
metastasis by affecting relevant signaling pathways.  
We identified PAK2 as target of both miR-23b and miR-26a, implicating a direct role for 
these miRNAs in cytoskeletal remodeling. Experimentally, expression of miR-23b and miR-
26a in BC cells promotes focal adhesions and cell spreading on substrates, but miR-23b alone 
controls cell-cell junctions and lamellipodia formation.  
Despite sharing the same target, the two miRNAs show additional distinct functions. MiR-26a 
overexpression in BC leads to formation of aneuploid cells associated with higher 
tumorigenicity. On the other hand, miR-23b inhibition enhances BC cell migration, invasion 
and metastasis in vivo. Clinically, low miR-23b levels correlate with metastatic development 
in BC patients. Mechanistically, growth factor-mediated signal transductions activate the 
transcription factor AP-1 and we show that this transcriptionally reduces miR-23b expression 
thus releasing PAK2 from its translational inhibition. The distinct cellular phenotypes 
described by the two miRNAs indicate that their global functions depend upon all the genes 
they regulate. Using RNA-sequencing and luciferase reporter assays, we validated a subset of 
genes as direct targets of either the two miRNAs. These genes are crucial to distinct molecular 
pathways and contribute to elucidate the observed phenotypes induced by miR-23b and miR-
26a modulation.  
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&DQFHU
&DQFHULVDOHDGLQJFDXVHRIGLVHDVHDQGGHDWK
&DQFHULVDPDMRUSXEOLFKHDOWKSUREOHPZLWKDQHVWLPDWHGPLOOLRQSHRSOHKDYLQJ
EHHQGLDJQRVHGZLWKFDQFHUZRUOGZLGHLQ7KHFDQFHUEXUGHQRQWKHJOREDOSRSXODWLRQ
LV VR VHYHUH WKDW DERXW RI DOO GHDWKV WKDW RFFXUUHGZRUOGZLGH LQ ZHUH FDXVHGE\
FDQFHU>@'XHWRSHUVLVWHQWGHPRJUDSKLFJURZWKDQGDJLQJFDQFHUUHODWHGGHDWKVDUHSUHGLFWHG
WRLQFUHDVHIURPPLOOLRQLQXSWRDQHVWLPDWHGPLOOLRQFDVHVE\DFURVVWKH
ZRUOG>@
,Q WKH8QLWHG.LQJGRPPRUH WKDQRQH LQ IRXUGHDWKV LV GXH WR FDQFHU LQGLYLGXDOV
ZHUH GLDJQRVHG ZLWK FDQFHU LQ WKH 8. LQ  DQG  FDQFHUUHODWHG GHDWKV ZHUH
HVWLPDWHG LQ WKH VDPH \HDU'HVSLWH VPDOO LQFUHDVHV LQ FDQFHU LQFLGHQFHPRUWDOLW\ UDWHV DUH
GHFUHDVLQJLQWKH8.6LQFHHDUO\VWKHQXPEHURISHRSOHWKDWGLHGIURPFDQFHUVWDUWHG
WR IDOO RYHU WKH WLPH DQG FDQFHUPRUWDOLW\ UDWHV DUH SUHGLFWHG WR GHFUHDVH RI D IXUWKHU 
EHWZHHQDQG>@)LJXUH



)LJXUH  &DQFHU VWDWLVWLFV LQ WKH 8. $OO FDQFHUV (XURSHDQ DJHVWDQGDUGL]HG LQFLGHQFH DQG
PRUWDOLW\UDWHVDQGSURMHFWLRQVIRUERWK3HUVRQV8.0RGLILHGIURP>@ 
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1.1.1.1         Breast cancer  
For women, breast cancer (BC) is the most common malignancy seen across the world with 
1.38 million cases diagnosed each year, representing the 23% of all cancers afflicting women 
worldwide[8]. Female BC is by far the most prevalent cancer in Western Countries with over 
45,000 and 200,000 new cases estimated in 2010 in the UK and in the United States, 
respectively, representing the 31% and 28% of all cancers diagnosed in women in these 
populations[4, 8]. While fewer than 1% of BC diagnoses each year are male, one out of eight 
women will develop BC in her life time in the UK, a highly significant gender bias[9]. Over 
the past three decades, BC incidence rates have increased progressively, partly due to 
improved public awareness of BC disease and implemented BC screening programs, which 
allow earlier diagnosis and treatment. Along with these factors, advances in research and the 
development of more effective treatments, which combine improved surgery techniques, 
radiotherapy approaches and use of adjuvant endocrine therapies, have led to a marked 
decline of BC-associated mortality rates. Indeed, compared to mid-1980s, when BC-related 
deaths peaked in the UK, the mortality rates have decreased by about 39% in 2008-2010, with 
12,000 women dying of BC in the UK each year[5] [10]. The major cause of mortality in BC 
patients resides in tumour progression and metastasis at distant sites, with a specific 
dissemination pattern involving the regional lymph nodes, lungs, bones and liver. BC 
metastasis is frequently associated with de novo or acquired resistance to therapies and/or 
secondary manifestations following relapse[10]. Thus development of new therapies directed to 
impede early steps of BC progression and dissemination to different organs is of crucial 
importance in order to abolish BC-associated mortality.  
 
 
1.1.2          The hallmarks of cancer  
In 400 BC, Hippocrates, a Greek physician and father of the Western medicine, gave 
cancer its name. He described chronic ulcers or growths that resembled malignant tumours as 
moving crabs and referred to them with the Greek words “carcinos” (from the Ancient Greek 
karkinos: crab) and “carcinoma”. He believed that cancer originated from a systemic excess 
of black bile, one of the four bodily humors (blood, phlegm, yellow and black bile)[11]. This 
simplistic view of cancer as humoral imbalance remained in force for the next 1400 years. It 
was only in the 19th century that Rudolph Virchow, father of the modern cellular pathology, 
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with his theory that all cells derive from other cells, led to the concept that cancer arises from 
a disordered multiplication of cells[12].  
Nowadays, technological advances mean we are able to detect the exact localisation of 
molecules of about 20 nanometers in size inside a human cell and yet, a holistic understanding 
of cancer biology remains beyond our reach. Nevertheless, the scientific community has been 
able to define human tumour pathogenesis as a multistep process characterised by several 
hallmark traits that enable a normal cell to become cancer.  These include: 
 
 uncontrolled proliferative capabilities;  
 adapting energy metabolism (to sustain cell proliferation); 
 escape from tumour suppressor signals; 
 resistance to cell death; 
 unlimited replicative immortality; 
 stimulation of the formation of new vessels (neoangiogenesis); 
 accumulation of genome instability and mutation; 
 tumour-promoting immune system stimulation (inflammation);  
 overcome immune surveillance and 
 activating invasion and metastasis. 
 
 
Focusing on the main scope of this thesis, we will here elaborate some aspects of cancer 
pathogenesis, particularly highlighting the metastatic process and outlining the main features 
of chromosomal instability and aneuploidy. We will then introduce microRNAs (miRNAs), 
illustrating their biological features and their functional relevance in cancer development and 
progression. 
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1.2            Metastasis 
 Metastasis accounts for 90% of cancer-associated mortality, yet it remains the most 
poorly understood component of cancer pathogenesis. The formation of metastases is a highly 
complex, multistep process that requires the movement of tumour cells from one organ (the 
primary site) to a distant location and the development into a metastatic lesion[13].  
Although it is believed that metastatic dissemination occurs in advanced steps of cancer 
progression, systematic spread of tumour cells was recently detected during the earliest pre-
invasive phases of tumourigenesis both in mice and humans[14]. In rare cases (2 to 5% of all 
cancer cases), the primary tumour is no longer detectable at initial presentation so that the 
derived metastastic lesions are considered cancers of unknown primary site (CUPs)[15]. 
The molecular basis for traits such as invasiveness and metastatic dissemination has yet to be 
fully understood.  The model of the clonal selection suggests that progressive accumulation of 
mutations in a given cell results in a clonal expansion, subject to microenvironmental 
pressures that select for tumour cells expressing traits advantageous for the primary 
tumour[16]. However, the discovery that populations of cells within a tumour are organised 
hierarchically, similar to normal tissues, led to the formulation of the cancer stem cell (CSC) 
model[17]. CSCs are distinguished by their capacities of self-renewal, tumourigenesis, and 
operationally defined as that subset capable of regenerating populations of cancer cells when 
xenografted into immunocompromised mice[18].  Their inherent resistance to chemotherapies 
and tumour seeding abilities may explain the high recurrence rates observed in many cancers; 
accordingly, specific targeting of this population has become an area of focus in basic 
research and drug development. As only a subset of cancer cells can overcome the numerous 
challenges encountered during metastatic progression, metastasis is generally an inefficient 
process[19, 20].  
Simplistically, the metastatic cascade goes through a sequence of different steps[21] (Figure 2) 
that include: 
 
 cancer cell motility, invasion and infiltration into the surrounding tissue; 
 intravasation into blood or lymphatic vessels; 
 survival and transit in the colonised vessels; 
 arrest and extravasation;  
 colonisation at a new site.  
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7XPRXUFHOOVDWWKHRULJLQVLWHVWDUWWRORFDOO\LQYDGHWKHVXUURXQGLQJWLVVXHPRYLQJDORQJWKH
H[WUDFHOOXODUPDWUL[(&06XEVHTXHQWO\ LQWUDYDVDWLRQRFFXUVZKHQ WXPRXUFHOOVSHQHWUDWH
WKHFDSLOODU\V\VWHPKHDPDWRJHQRXVRUO\PSKDWLFDQGWUDQVLWLQWKHV\VWHPDWLFFLUFXODWLRQDV
FLUFXODWLQJ WXPRXU FHOOV &7&V &7&V WKDW DUH FDSDEOH RI VXUYLYLQJ H[WUDYDVDWH LQWR WKH
SDUHQFK\PD RI VXUURXQGLQJ WLVVXHV DW GLVWDQW VLWHV DQG IRUP PLFURPHWDVWDVLV WKDW PD\
HYHQWXDOO\JURZLQWRPDFURVFRSLFVHFRQGDU\WXPRXUV>@)LJXUH



)LJXUH  7KH PHWDVWDWLF FDVFDGH  $ 0RWLOLW\ DQG LQYDVLRQ RI SULPDU\ WXPRXU FHOOV LQWR WKH
VXUURXQGLQJWLVVXHDQGDWWUDFWLRQWRZDUGVQHDUE\EORRGRUO\PSKDWLFYHVVHOV%,QWUDYDVDWLRQLQWRWKH
OXPHQRIWKHFRORQLVHGYHVVHOVZKHUHFLUFXODWLQJWXPRXUFHOOV&7&VFDQLQWHUDFWZLWKFLUFXODWLQJ
KRVW FHOOV LQFOXGLQJ OHXNRF\WHV DQG SODWHOHWV & 7UDQVSRUW RI WXPRXU FHOOV YLD KHPDWRJHQRXV RU
O\PSKDWLFURXWH'($UUHVWLQWKHFDSLOODU\EHGVRIDGLVWDQWRUJDQVDQGVXEVHTXHQWH[WUDYDVDWLRQE\
HYHQWXDOIRUPDWLRQRIPLFURHPEROLGXH WRLQWHUDFWLRQZLWKKRVWFHOOV)&RORQLVDWLRQRI WKHGLVWDO
RUJDQDQGPHWDVWDWLFIRUPDWLRQKHUHLOOXVWUDWHGLQWKHOXQJ)LJXUHDGDSWHGIURP>@
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1.2.1           Step by step overview of the metastatic process 
To unravel the complexity that lies behind each step of the metastatic process, it is 
essential to understand the biology and environment of tumour cells. As the majority (~85%) 
of cancer cases is represented by carcinomas that arise from epithelial tissues, we first 
elucidate the structural traits of a normal epithelium. 
 
1.2.1.1         General structure of a normal epithelium 
The epithelium is formed of coherent multicellular sheets called epithelia. Epithelial 
tissues can be constituted of a single epithelium or be stratified; some can cover the external 
surface of an organism, such as the epidermal covering of the skin, and others line internal 
organs and cavities, such as the acini in the mammary gland[23, 24]. A prototypic monolayer 
epithelium (figure 3), as well as its individual cells, is structurally characterised by an apical-
basal polarisation. The apical region of the epithelia faces the outer surface or the lumen 
(generally filled by extracellular fluid) in case of epithelial cavities; on the other side, 
epithelia are anchored to the underlying tissue through the mechanical support of a 
heterogeneous mixture of extracellular matrix (ECM) material that includes: 
 
 The basement membrane : a semi-permeable layer of an acellular mixture composed 
of laminin, nonfibrillar amorphous collagen (mostly type IV), heparan sulphate 
proteoglycans, and other glycoproteins, which are secreted by both the epithelial and 
the underlying mesenchymal cells[25] (Figure 3); 
 The stroma (from the Greek word for “bed” or “bed covering”): also referred as 
mesenchymal connective tissue, is a supportive framework of ECM consisting of a 
ground substance, a porous, well-hydrated gel made of proteoglycan aggregates, 
tangled to a network of connective tissue fibers, such as collagen type I (the most 
abundant), elastic and collagen type III (reticular) fibers. Various types of cells are 
freely embedded in the stromal ECM, among these are fibroblasts, immune and 
inflammatory cells as well as nervous elements.  The stromal tissue is also infiltrated 
by blood and lymphatic vessels that permit the rapid diffusion of nutrients, wastes and 
other chemicals between the local blood supply and the epithelium[26] (Figure 3).  
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7KH FKDUDFWHULVWLF SRODULVHG RULHQWDWLRQ RI HSLWKHOLDO FHOOV LV HVVHQWLDO WRJXDUDQWHH WKHPDLQ
IXQFWLRQ RI WKH HSLWKHOLXP WKH\ IRUP HIIHFWLYH EDUULHUV WKDW SURWHFW IURP SDWKRJHQV DQG
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RU WKH
H[WHUQDO HQYLURQPHQW RQ WKHLU DSLFDO VLGH>@ 'XULQJ WKH DVVHPEO\ RI WKH HSLWKHOLDO OD\HU
LQGLYLGXDOFHOOV VWDUW WR LQVWDWHDGKHVLYHFRQWDFWVEHWZHHQHDFKRWKHURUZLWK WKHXQGHUO\LQJ
(&0 WKDW FRQWULEXWH WR WKH HVWDEOLVKPHQW RI WKH DSLFREDVDO SRODULVDWLRQ 7KH VXFFHVVLYH
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UHVSRQVLEOH IRU WKH VFDQW PRELOLW\ RI WKH HSLWKHOLDO FHOOV DQG WKHLU FKDUDFWHULVWLF SRO\JRQDO
VKDSH LQ ZKLFK YHUWLFHV DUH SRLQWV RI FRQWDFWV EHWZHHQ WZR RU PRUH FHOOV DQG HGJHV DUH
FRQWDFWV EHWZHHQ DGMDFHQW FHOOV>@ 7KH HSLWKHOLDO DGKHVLYH FRQWDFWV VKRZ GHPDUFDWHG
GLIIHUHQFHV LQ PRUSKRORJ\ VWUXFWXUH DQG SK\VLFDO IXQFWLRQ WKXV WKH\ DUH FRPPRQO\
GLVWLQJXLVKHGLQFHOOFHOODGKHVLRQVLQFOXGLQJWLJKWMXQFWLRQV7-VDGKHUHQVMXQFWLRQV$-V
DQG GHVPRVRPHV DQG FHOOPDWUL[ DGKHVLRQV DPRQJVW ZKLFK IRFDO DGKHVLRQV 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
)LJXUH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SLQN
UHVSHFWLYHO\RIQRUPDOEUHDVWHSLWKHOLDODFLQL0RGLILHGIURP>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1.2.2           Cell motility and invasion 
Cell motility encompasses cell invasion and together represent the first hallmark of 
metastasis. The ability of cells to migrate underlies varied physiological process, including 
embryogenesis, wound healing, inflammation and tissue regeneration. Despite that, 
deregulated migration contributes to several pathological processes, such as vascular disease, 
osteoporosis, chronic inflammation, mental retardation and cancer[29, 30].  Indeed, aberrant 
migration and acquired invasive capability allow cancer cells to break away from the primary 
tumour, make their way through the surrounding tissue and penetrate the capillary vessels 
during the first steps of the metastatic process (Figure 4). Thus, identification of signalling 
events, temporal triggers and/or spatial cues that modulate cell migration and invasion during 
metastasis is critical for the development of new therapeutic strategies.  
Over the past decade, great progress has been made in understanding how tumour cells move 
in their physiological conditions in vivo. Until then, the cell migration model, derived from in 
vitro studies on different 2-dimensional (2D) cell cultures, was conceived as a cyclic process 
of coordinated steps required to migrate. These include: (1) extension of protrusion at the 
leading edge of the cell, (2) formation of adhesion to the substratum, (3) focalised proteolysis 
and degradation of ECM and (4) retraction of the trailing edge[30]. 
Development of new experimental approaches in the study of cell migration/invasion have 
highlighted important differences between the way in which tumour cells move in vivo 
compared with in vitro. Analysis of stimulated 3-dimensional (3D) cancer cell cultures and 
intravital imaging of primary tumours in live animals have shown that tumour cells can adopt 
different strategies of cell migration/invasion with increased speed and persistent 
directionality as compared to their slow, random mode of migration in vitro. These 
differences may be explained by the production of chemotactic signals (i.e., growth factors) 
by the tumour microenvironment and by the presence of specific ECM components that 
provide optimal adhesive substrates for cancer cell migration in physiological conditions[31]. 
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pushing migration mode[34, 35] (Figure 5A). Mesenchymal cancer cells adopt a polarised, 
fibroblast-like shape and typically move via the multistep migration cyclic model. At the 
leading edge of the cells, the extension of membrane protrusions, such as lamellipodia and 
filopodia, is stabilised by assembly of new cell adhesion on the ECM (i.e., focal adhesions, 
FAs) and associated with stress fibers. Integrins, metalloproteinases (MMPs) and other 
proteases, such as the urokinase-type plasminogen activator (uPA), co-localise at FAs to 
execute pericellular proteolysis.  Thus, ECM-cell contacts and ECM degradation allow the 
cell to retract the cell body by actomyosin-based contractility. Finally, the cell retracts its 
trailing edge by disassembly the adhesions at the rear.[36, 37] (Figure 5A and B).  
Collective migration is a common feature of many different types of cancer, including both 
carcinomas (i.e., melanoma and BC) and tumours of the connective tissue, such as 
rhabdomyosarcoma and fibrosarcoma[38].  Individual motile tumour cells can originate from 
most solid stromal tumours, such as sarcomas[39] and gliomas[40], from leukemias and 
lymphomas[41], as well as from epithelial tumour sources, such as in situ carcinomas or 
multicellular sheets or clusters in cohesive migration[32]. This dual capacity can explain the 
observation that both collective and single migrating cells are simultaneously present in vivo, 
and that individual and collective migration modes are interconvertible. As a matter of fact, 
after departing from the primary site, tumour cells can adopt a different migration mode to 
suit modifications in the microenvironment or in their molecular scenario[42]. A well-studied 
model of tumour cell plasticity is represented by the process of epithelial-to-mesenchymal 
transition (EMT). 
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1.2.2.1.1       Epithelial-mesenchymal transition 
 
 The epithelial-to-mesenchymal transition (EMT) describes a complex program through 
which epithelial cells lose their cell-cell contacts and switch from a collective migration 
pattern to a single cell mode of migration[36]. One of the characteristic findings in EMT is the 
loss of cell-cell adhesion with decreased expression of E-cadherin, the main cell-cell adhesion 
molecule[43]. E-cadherin expression is regulated by several transcription repressors, such as 
the zinc finger E-box-binding homeobox proteins 1 (ZEB1) and 2 (ZEB2), TWIST and the 
Snail family of zinc finger proteins SNAIL and SLUG[44-48]. In the process of EMT, SNAIL 
and ZEB2 initiate downregulation of E-cadherin whose repression is then maintained by 
SLUG and ZEB1 activity[49]. Various signal pathways, such as transforming growth factor 
(TGF)-β, the Wingless-int (Wnt) cascade and phosphatidylinositol 3‟kinase-serine/threonine 
kinase (PI3K/AKT) axis are connected with these transcriptional repressors of E-cadherin[50, 
51]. TGF-β stimulation activates the PI3K/AKT axis and transcription factors of the SMAD 
family leading to expression of ZEBs, TWIST and SNAILs. The Wnt cascade releases β-
catenin from degradation which can enter in the nucleus where it up-regulates SLUG and 
SNAIL. Alongside a cell‟s loss of epithelial properties, required in order to initiate an EMT, 
there is also the acquisition of a mesenchymal phenotype. In fact cancer cells undergoing to 
EMT de novo express several mesenchymal markers such as N-cadherin, Vimentin, and 
Fibronectin[52].  
EMT has a major role in the initial step of the metastatic cascade: once tumour cells have 
spontaneously differentiated into a of single-cell state of migration, metastatic dissemination 
is promoted, resulting in poor prognosis[43]. In line with EMT as event of cancer cell plasticity 
in the initiation of metastatic spread, a process termed mesenchymal-to-epithelial transition 
(MET) has been proposed for tumour cells at later stages of the metastatic process. Studies 
have shown that tumour cells in the secondary organ can undergo „redifferentiation‟ to an 
epithelial phenotype and form metastases with similar histological characteristics as the 
primary tumour[53]. The tendency of disseminated cancer cells to undergo MET likely reflects 
the local microenvironment that they encounter after extravasation, i.e., the absence of the 
heterotypic signals responsible for the induction of EMT in the first site after departing from 
the primary tumour[41].  
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1.2.2.2         Proteolytic degradation of ECM 
 
 During the metastatic process, the ECM constitutes a mechanical support allowing 
malignant cells to adhere and migrate and, at the same time, serving as a physical barrier that 
prevents cell invasion of the surrounding tissue. Migrating cells overcome the ECM obstacle 
using different approaches depending on the type of migration modes adopted and the 
molecular and cellular composition of the 3D environment.   
Typically, both mesenchymal and collectively migrating cells, as well as stromal cells, 
upregulate multiple protease systems that mediate proteolytic degradation of the ECM. Two 
major protease systems are represented by matrix metalloprotinases (MMPs) and the serine 
protease, plasmin, that requires activation by two proteases: the urokinase-like plasminogen 
activator (uPA) and the tissue-type plasminogen activator (tPA)[54] . Membrane-type MMPs 
(MT-MMPs) and uPAs are heavily found at focal adhesion sites to promote pericellular 
proteolysis during mesenchymal migration in vitro and in vivo[55-57]. On the other side, 
multicellular migrating clusters are led by motile cells that are associated with high proteolitic 
activity, mainly mediated by membrane type 1 metalloprotease (MT1-MMP) and 
metalloproteinase-2 (MMP-2)[58]. MMPs, plasmin and uPAs catabolise contact-dependent 
proteolysis of different ECM proteins, including fibrillar and nonfibrillar collagens, 
fibronectin, laminins. For example, in vivo, MT-MMP1 is essential for degradation and 
redistribution of collagen fibers generating tube-like matrix gaps that allow single cells to 
move in collagen-rich interstitial tissues. Further collagen proteolysis leads to remodelling of 
existing matrix gaps in larger tracks that accommodate collective invasion of multicellular 
clusters[59]. In contrast, ameoboid type migration is generally promoted in microenvironments 
with low collagen fiber concentrations. Amoeboid cells do not require proteolytic activity, as 
they squeeze through collagen fibers by filling available spaces with their body. Eventual 
increase of collagen density can either block migration of amoeboid cells through the ECM or 
induce them to adopt a proteolytic approach to invasion, switching for example from 
amoeboid to mesenchymal migration mode[60]. The presence of stromal cells in the tumour 
microenvironment supports degradation and remodelling of the ECM, thereby assisting cancer 
cell migration. Stromal cells, such as fibroblasts and microphages, in fact, express a 
proteolytic repertoire, responsible for the formation of migration tracks between the tumour 
and the nearby vessels; once formed, these tracks can be followed by tumour cells lacking of 
intrinsic proteolytic activity, further promoting tumour cell dissemination[61]. 
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1.2.2.2.1       Plasmin activation cascade and its implication in cancer metastasis  
 Plasmin is a serine protease that mediates proteolytic degradation of a wide spectrum of 
ECM components, including fibronectin, vitronectin and fibrin. It is secreted by cells as 
inactive precursor called plasminogen (or zymogen), produced mainly by the liver, and it is 
found at high levels in the plasma and also in interstitial fluids that surround most of the 
tissues[62]. Plasminogen is locally converted into active proteinase plasmin by proteolitic 
cleavage mediated by either of two plasminogen activators (PA): the protease urokinase-like 
PA (uPA) and tissue-type PA (tPA) (Figure 6). uPA is expressed and secreted into the 
extracellular environment by various tumour cells and tumour-associated stromal cells, in a 
pro-enzymatic form, pro-uPA, that is activated by proteolysis by plasmin itself and other 
proteases, such as cathepsin B[63]. Secreted pro-uPA and uPA bind to cell-surface uPA 
receptor (u-PAR), which localises at focal adhesion sites at the leading edge of migrating cells 
(Figure 6)[64]. u-PAR accumulates protease uPA at these regions where it catalyses activation 
of plasminogen into plasmin, promoting proteolysis of the ECM and tumour cell invasion. 
Increased expression and secretion of uPA correlates with metastasis in many types of cancer 
and predicts poor survival and high risk of relapse in BC[64, 65]. Consistent with this concept, 
inhibition of uPA activity has been shown to abrogate BC invasion and metastasis in vivo[66].  
The other pathway that leads to activation of plasminogen into plasmin implies the function of 
tPA and its binding receptor annexin II (Figure 6)[67] [68]. Along with its involvement in 
thrombolysis, tPA has been also clinically implicated in neoplastic transformation and 
invasive phenotypes of different tumours, including BC[69]. tPA is secreted by endothelial 
cells and tumour cells of various types and interacts with its cell surface receptor annexin II 
(Figure 6). Annexin II is a phospholipid-binding protein that exists on the cell surface as both 
a monomer and a heterotetramer, the latter called annexin II tetramer (AIIt). AIIt is composed 
of two annexin II molecules and two molecules of an 11-kDa regulatory subunit known as the 
p11 light chain (Figure 6)[68]. AIIt functions as a protein scaffold for the localisation of serine 
preoteases, such as tPA, plasminogen and the inactive form of the cysteine protease cathepsin 
B (pro-cathepsin B [pro-CB])[70]. AIIt-bound tPA converts pro-CB into active CB and 
plasminogen into plasmin. This activates a proteolytic cascade which results in plasmin/CB-
mediated uPA activation, ECM degradation and proteolytic activation of pro-
metalloproteinases (pro-MMPs) (Figure 6)[70, 71]. In addition, AIIt interacts on the cell surface 
with collagen I fibers, known to regulate cell migration, and the ECM protein tenascin C 
(TNC), which is found in sites of active tissue regeneration and migration, as is also found in 
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a large variety of tumours[72]. By offering docking sites to several protease systems and matrix 
molecules, AIIt not only participates to cell-ECM interaction, but provides also a structural 
linkage between proteases and matrix components at the cell surface, thereby facilitating 
extracellular matrix remodelling. As annexin II has been found overexpressed in many 
tumours, including BC, its function in mediating localised proteolytic activity at the surface of 
tumour cells largely correlates with increased invasiveness and metastatic potential[73] [74]. 
 
 
1.2.3           Cancer cell dissemination 
 
 After migration and invasion into the surrounding of the primary tumour, malignant 
cells need to spread throughout the body in order to reach distant sites and form metastatic 
colonies. Cancer cell dissemination can occur through three major routes: blood circulation, 
lymphatic vessels and serosal surfaces. Metastatic spread established via these three routes is 
referred to as hematogenous, lymphatic and transcoleomic, respectively[75].  
Figure 6: Plasmin activation cascade. The phospholipid-binding protein annexin II forms a 
heterotetramer AIIt at the cell surface which serves as scaffold for the interaction of tPA, pro-
cathepsin B (Pro-CB), plasminogen, collagen I and tenascin C (TNC). tPA converts pro-CB into 
cathepsin B (CB).  The urokinase-lyke plasminogen activator receptor (uPAR) accumulates uPA 
proenzyme (Pro-uPA) that is converted into uPA by CB. uPA and tPA catalyses proteolityc cleavage 
of plasminogen which results in the formation of the serine protease plasmin. Plasmin enhances 
activation of uPA and, together with CB, converts pro-metalloproteinases (Pro-MMPs) into active 
MMPs. Modified from[67]  
Figure 6: Plasmin activation cascade 
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Lymphatic and the hematogenous dissemination is facilitated by reinforced vascularisation of 
the primary tumour, a process known as angiogenesis that correlates with metastatic 
occurrence and worsening prognosis[76]. Angiogenesis is the result of the increased expression 
of angiogenic factors induced by cancer cells to promote tumour progression. The family of 
vascular endothelial growth factors (VEGFs) represents the major proangiogenic component 
produced by the tumour. VEGFs are expressed and deposited by cancer cells in the ECM, 
where they stimulate “de novo” formation of blood or lymphatic vessels (neoangiogenesis) or 
outgrowth of preexisting ones. The loosely-formed structure of these newly formed vessels 
renders them weak barriers for invading tumour cells to overcome.  Tumour-associated 
vessels are in fact characterised by a discontinuous basement membrane, a lack of 
surrounding perycite barrier, and insufficient cell-cell contacts in the endothelial walls. 
Lymphatic vessels lack also of tight junction formation between their endothelial cells, which 
confers them a leakier phenotype compared to blood vessels. This may explain why cancer 
cells derived from carcinomas commonly enter the lymphatic system to disseminate into 
distant sites. Carcinomas in fact form initial metastases in the lymph nodes, which represents 
an early prognostic marker of invasiveness and metastatic progression[77]. In later stages, 
carcinomas achieve colonisation of other organs through distal hematogenous dissemination. 
This occurs as result of both blood vessel intravasation by cancer cells at the primary site and 
cancer cell transport from the colonised lymphatic system to the hematogenous circulation. 
However, other types of malignancies, such as sarcoma, metastasise to distant sites via 
hematogenous spread, without prior dissemination into local lymph nodes. These evidences 
suggest that hematogeneous dissemination is required for the metastatic colonisation of 
distant organs (lymph node excluded)[78].  
Along with the weak nature of tumour-associated vessels, others factor contribute to facilitate 
the mechanical intravasation of cancer cells, including invasive membrane protrusions, and 
assistance from stromal cells (Figure 7). Proteolytic cell protrusions, such as invadopodia, 
allow migrating cancer cells to degrade the basement membrane surrounding vessels and 
breach the endothelial wall to intravasate into the systematic circulation[79]. On the other side, 
tumour-associated macrophages (TAMs) enhance tumour cell invasion and intravasation by 
secreting paracrine factors, such as epithelial growth factors (EGFs) and colony-stimulating 
factor 1 (CSF1)[80]. Moreover, TAM-derived EGFs have been shown to promote invadopodia 
formation and recruitment of BC cells at blood vessels[79].   
Cancer cells can also disseminate via transcoleomic spread by invading the serosal membrane 
of an organ. This can occur either by a primary cancer established within the cavity of the 
,QWURGXFWLRQ
38 
 
RUJDQ VXFK DV OXQJV DQG RYDU\ SOHXUDO DQ SHOYLF FDYLWLHV UHVSHFWLYHO\ RU DV UHVXOW RI
V\VWHPLFPHWDVWDVLV GHULYHG IURP KHPDWRJHQRXV DQG O\PSKDWLF GLVVHPLQDWLRQ RI D SULPDU\
FDQFHUHJDGYDQFHG%&>@,QGHHGDODUJHYDULHW\RI%&FHOOOLQHVFRPPRQO\XVHGIRU LQ
YLWURH[SHULPHQWDWLRQKDYHEHHQHVWDEOLVKHGIURPSDWLHQWVெSOHXUDOHIIXVLRQV>@
 
 
 
 
 
6XUYLYDOLQWKHFLUFXODWLRQ

6XFFHVVIXOFRQTXHVWRIWKHV\VWHPDWLFFLUFXODWLRQFRQIHUVPDOLJQDQWFHOOVWKHDELOLW\WR
YLUWXDOO\ UHDFK DQ\ SDUW RI WKH ERG\ +RZHYHU FLUFXODWLQJ WXPRXU FHOOV &7&V HQFRXQWHU
VWUHVVIXOFRQGLWLRQVLQFOXGLQJSK\VLFDOGDPDJHVKHDUIRUFHVODFNRIFHOOPDWUL[FRQWDFWVDQG
WKHLPPXQHVXUYHLOODQFH>@7KXVVXUYLYDORI&7&VFDQEHDYHU\LQHIILFLHQWHYHQWZLWKOHVV
WKDQRIFHOOVVXFFHVVIXOO\LQLWLDWLQJDVHFRQGDU\WXPRXURYHUWKHVHYHUDOPLOOLRQFHOOV
WKDW FDQ VSUHDG IURP D JUDP RI WXPRXU GDLO\ LQWR WKH FLUFXODWLRQ> @ 7KH SRSXODWLRQ RI
&7&VLQFUHDVHVZLWKGLVHDVHSURJUHVVLRQDQGLVDVVRFLDWHGZLWKSRRUSURJQRVLV>@

)LJXUH  ,QWUDYDVDWLRQ RI SULPDU\ WXPRXU FHOOV 6FKHPDWLF UHSUHVHQWDWLRQ RI LQWUDYDVDWLRQ RI
SULPDU\WXPRXUFHOOVLQWRWKHFDSLOODU\V\VWHPDIWHULQYDVLRQLQWRWKHVXUURXQGLQJWLVVXHOHIWSDQHO
'LIIHUHQWFHOOW\SHVDUHKLJKOLJKWHGDORQJZLWKVWUXFWXUDOHOHPHQWVPRGLILHGIURP>@2QWKHULJKW
O\PSKDWLF YDVFXODU FRORQLVDWLRQ WRS DQG EORRG YHVVHO LQWUDYDVDWLRQ ERWWRP RI %& FHOOV DUH
LQGLFDWHG E\ EODFN DUURZV LQ%& VSHFLPHQV VWDLQHGZLWK KHPDWR[\OLQ DQG HRVLQ +	(0RGLILHG
IURP >@ 
Introduction 
39 
 
1.2.4.1          Anoikis  
 
Among the stresses that affect tumour cells in the circulation system is loss of 
adherence to the substratum. In normal conditions, integrin-mediated anchorage to the ECM 
ensures both survival and viability of epithelial cells[88]. Absent or inappropriate cell adhesion 
lead cells to undergo to a cell death program, called anoikis. Anoikis is a specialised form of 
apoptosis that occurs when cells are deprived of their substratum and are maintained in 
suspension[89]. Metastatic cells, streaming along with the circulation flow, experience 
abnormal physiological conditions that favorite anoikis.  In order to resist to anoikis and 
survive during their dissemination journey, metastatic cells deregulate crucial apoptotic 
modulators by adopting different strategies. Among these, overexpression of the anti-
apoptotic protein B-cell lymphoma 2 (BCL2), observed in many types of cancer, was early 
shown able to prevent cell apoptosis in absence of anchorage to the substratum[90]. Resistance 
to anoikis is accomplished also through activation of pro-survival signals, such as the 
phosphatidylinositide 3-kinase (PI3K)-AKT pathways, expression of a different pattern of 
cell-surface integrins that protect cells from anoikis by providing survival signals and 
overexpression of the neurotrophic tyrosine kinase receptor TrkB, that has been shown to be a 
key mediator in anoikis suppression[89, 91]. Ectopic expression of TrkB in intestinal epithelial 
cells is able not only to prevent anoikis, but also to confer transforming and metastatic 
capabilities to these cells that are normally non tumourigenic[91]. This evidence is a fine 
illustration of the tight association between resistance to anoikis, tumourigenicity and 
ultimately metastasis. Indeed, most cell lines derived from solid tumours are able to grow in 
anchorage-independent conditions, such as soft agar or suspension cultures[92]. Moreover, 
abolition of the ability to overcome anoikis in transformed cells is able to inhibit their 
tumourigenic and metastatic potential both in vitro and in vivo[93, 94].  
   
1.2.5           Arrest, extravasation and colonisation at a new site 
 
Having endured the adverse conditions of the systematic circulation, CTCs must 
escape the vasculature in order to colonise distal organs and develop a secondary tumour. 
Theoretically, CTCs are able to reach a wide variety of organs, which suggests that arrest in 
the capillary beds of a specific organ may be a passive event determined by anatomy and 
haemodynamics of the vasculature at that site. Indeed, physical constraints imposed by 
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reduced blood vessels size impede passage of CTCs and force their arrest in certain distant 
organs, a case frequently observed in the liver, where its more restricted microvessels 
physically trap colorectal carcinoma cells directly drained into this organ by the portal 
vein[95]. Another possibility is that passive arrest in the capillary bed at a certain site results 
from aggregation of CTCs with leukocites and platelets forming micro-emboli that obstruct 
vessels. Following arrest in the capillary, tumour cell growth can occur into the intravascular 
space until disruption of the capillary wall allows dissemination into the surrounding 
parenchyma[96].  Despite mechanical arrest into the vasculature can occur in all organs, CTCs 
frequently exhibit the capacity to actively home to a specific pattern of organs. For example, 
BC preferentially metastasises to lung, bone, liver and brain, whereas colorectal cancer cells 
disseminate to liver and lungs[97]. Organ-specificity in tumour cell homing has been widely 
investigated and experimental evidences suggest that various mechanisms can determine 
where tumour cells will arrest and disseminate. Chemokine receptors-mediated chemotaxis 
represents one of these mechanisms: surface chemokine receptors expressed by tumour cells 
respond to chemotattic signals (i.e stromal cell-derived factors) secreted by fibroblasts of the 
local tissue, thus determining the localisation of metastasis of certain tumour types. Using 
several models of mouse metastasis, it has been observed that primary tumours are able to 
distally modulate the microevironment of distant sites in order to accommodate circulating 
tumour cells.  Indeed, factors secreted by the primary tumour (e.g., VEGF and placenta 
growth factor, PIGF) can induce the formation of premetastatic sites by recruiting bone 
marrow-derived cells at the relative organ prior the tumour cell arrival. Cell within 
„premetastatic niches‟ then release chemokines (e.g., stromal cell-derived factor-1, SDF-1, 
and the calprotectin S100A8/9) that direct chemotaxis of disseminating tumour cells[98, 99]. 
Furthermore, gene expression profile studies have revealed that changes in gene expression 
patterns can contribute to organ-specific homing of tumour cells. For example, the human 
breast cancer MDA-MB-231 cell line, originally isolated from the pleural effusion of a 
metastatic patient, expresses a set of 54 genes that determine eventual BC metastasis to the 
lungs[100]. 
Following arrest in the circulation at a certain distant site, CTCs need to extravasate in order 
to gain access to the organ parenchyma. Extravasation, the physical passage of tumour cells 
out the vessel lumina is facilitated by vasculature hyperpermeability. This can be either an 
intrinsic characteristic of the capillary system, i.e loose cell-cell interactions of certain 
microvessel walls allow “diffusion” of tumour cells, or induced by tumour cells themselves 
through proteolytic action of metalloproteinases expressed at the tip of invadopodia or 
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secretion of factors, like angiopoietin-like proteins, that disrupt endothelial cell-cell junctions 
thus increasing vasculature permeability[101].  
After extravasation into the parenchyma of a new organ, tumour cells encounter a 
microenvironment physiologically different compared to the one where they originated. 
Depending on their ability to create favorable conditions for their survival and proliferation, 
tumour cells in metastatic sites can either undergo a quiescent, nonproliferative state 
(dormancy), form small lesions (micrometastases) or develop sites of high proliferation called 
macrometastases[13].    
 
 
1.3            Cytoskeletal remodelling drives cancer cell migration 
and invasion  
1.3.1          Membrane protrusions  
 
 Motile cancer cells are characterised by plasma membrane protrusions that are the 
prerequisite for recognition, binding and degradation of the ECM and the maintenance of cell 
migration modes[32]. Cell protrusions can originate in response of chemoattractive signals that 
cells detect in their microenvironment (chemotaxis) or as guide-sensors in case of random cell 
migration (i.e., 2D cell cultures). They form from local extension of the plasma membrane, a 
process that is driven by spatial and temporal organisation of the actin cytoskeleton. 
Depending on their morphology, molecular structure and function, cell protrusions are 
distinguished in lamellipodia, filopodia, plasma membrane blebs/pseudopodia and 
invadopodia[36].  
Lamellipodia are broad, flat, sheet-like membrane protrusions characterised by high content in 
actin filaments that form a branched dendritic network[102] (Figure 8). They are commonly 
observed at the leading edge of cells migrating on 2D substrates in vitro[79]. Their formation is 
initiated by active actin polymerisation that pushes the plasma membrane forward. Behind 
this highly dynamic region is the lamella, a more stable area with mature FAs where myosin 
II-mediated contractility generate the force to pull the cell body forward[103].   
Filopodia are long, thin protrusions that function as exploratory sensors to help migrating 
cells investigating the surround (Figure 8). They originate from actin polymerisation in long, 
parallel bundles of actin filaments stabilised by the actin-bundling protein fascin[104], whereas 
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their elongation is mediated by members of the formin family, such as mammalian 
Diaphanous-related formins (mDia)[105].  
Plasma membrane blebs or pseudopodia (Figure 8) are considered the functional analogues of 
lamellipodia but they are preferentially observed in 3D contexts in vitro and in vivo[31]. They 
are tiny protrutions formed upon local disruption of the actin filament cortex that allows 
cytoplasmic flow to push outwards the plasma membrane. Polymerisation of the actin cortex 
in the elongated bleb provides then sufficient force for the stabilisation of the resulting 
pseudopod. Actomyosin contractility has a major role in plasma membrane blebbing: it 
induces the rupture of the actin cortex required for generation of the focal hydrostatic pressure 
that initiates the membrane blebbing and also for the retraction of the pseudopodia after 
elongation[106].  
Invadopodia are actin-rich protrusions that form ventrally in cells attached to the substratum 
[107] (Figure 8).  They share most of the molecular scenario that orchestrates actin 
polymerisation in lamellipodia and filopodia, but are distinguished for their high content in 
matrix-degrading proteases. These proteolytic enzymes are actively localised at the plasma 
membrane of the invadopodium through delivery in exocytotic vescicles[108]. Indeed, 
invadopodia constitute proteolytic structures by which migrating cells degrade the basement 
membrane, the underlying stroma and the capillary barriers during metastatic 
intravasation/extravasation[109].  
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globular protein (G-actin) that polymerises in a helical fashion to form a polarised actin 
filament (F-actin) with a fast pointed “barbed” end and a slow growing “pointed” end.  
Polymerised actin appears under different forms, such as highly dynamic, dendritic network 
typical of lamellipodia, long, parallel actin bundles found in lamella and filopodia and thick 
myosin II-conjugated actin bundles called stress fibers, localised in central and rear regions of 
migrating cells[118]. Actin polymerisation is orchestrated by the actin-related protein 2 (ARP2) 
and ARP3 complex (ARP2/3 complex), an actin nucleation factor whose upregulation has 
been shown to enhance cell invasion and metastasis in vitro and in vivo[119]. ARP2/3-mediated 
actin nucleation is promoted by its interaction with both Wiscott-Aldrich syndrome proteins 
(WASPs) and WASP family verprolin homology proteins (WAVE)[120], direct downstream 
effectors of RAC and CDC42 (Figure 9). CDC42 is known to activate the WASP-ARP2/3 
axis and is the main RHO GTPase involved in formation of filopodia and invadopodia[121]; 
whereas actin polymerisation via the WAVE-ARP2/3 nucleation machinery is orchestrated by 
RAC, essential for lamellipodia protrusion[122] (Figure 9). RHO also contributes to actin 
polymerisation with a major role in filopodia elongation[105]. RHO activates mammalian 
Diaphanous homolog (mDia) formins, that promote actin nucleation by barbed-end 
elongation; in addition, RHO phosphorylates and activates LIM kinase (LIMK) which in turn 
inactivates by phosphorylation the actin-binding protein cofilin, responsible for the 
disassembly of actin filaments into monomeric G-actin[123] (Figure 9). LIMK function has 
been shown to be crucial for the maintenance of migratory and invasive phenotypes of BC 
cells[124]. In addition to activation by RHO, LIMK is also activated by p21/RAC1/CDC42-
activated kinases (PAKs), considered major players in cytoskeleton dynamics, cancer motility 
and invasion[125] (Figure 9). In mammals, the PAK kinases family comprehends 6 members, 
PAK1-6 [126]. Among them, PAK1 seems to have a major role in the regulation of actin 
polymerisation by activating LIMK during lamellipodia formation at the front of the cell. 
PAK1 induces LIMK-mediated cofilin phosphorylation that ensures cofilin recycling back to 
the leading edge where it produces free barbed end for the polymerisation of new actin 
filaments at this site. Nevertheless, uncontrolled cofilin activity leads to an accelerated F-actin 
turnover that results in widening of the lamellipodium[127-129]. Thus, PAK1 controls formation 
of lamellipodia and limits their extent through negative regulation of cofilin activity. 
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Finally, extension of plasma membrane blebs is mainly controlled by RHO[130].  RHO and its 
downstream effector, the RHO-associated serine/threonine kinase (ROCK) induce bebbling 
by increasing actomyosin contractility which requires myosin II activity. Myosin II is an 
actin-bundling protein composed of two heavy chains, two regulatory light chains (RLCs) and 
two essential light chains, and its activity is regulated by phosphorylation of the Thr18 and 
Ser19 of its RLC [131]. Myosin II phosphorylation state is regulated by ROCK via two 
mechanisms: direct phosphorylation of the myosin RLC and inhibition of dephosphorylation 
of myosin RLC by phosphorylation and inactivation of the MLC phosphatase (MLCP)[132] 
(Figure 9). ROCK-mediated phosphorylation of the RLC allows actin-bundled myosin II to 
move antiparallel stress fibers past each other. This sliding movement generates the 
contractile force required for tail retraction during the migration cycle and bleb 
protrusion/retraction[130, 133]. After bleb is formed, RAC-driven actin polymerisation leads to 
actin cortex formation that sustains bleb extrusion[134].  
Figure 9. RHO GTPases in actin remodelling and cell protrusion formation. Arp, actin-related 
protein; LIMK, LIM kinase; mDia, mammalian homologue of the Drosophila diaphanous protein; 
MLC, myosin light chain; MLCK, MLC kinase; MLCP, MLC phosphatase; P, phosohorylated; PAK, 
p21 activated kinase; ROCK, RHO kinase; WASP, Wiskott-Aldrich syndrome protein; WAVE, WASP 
family verprolin-homologous protein. Modification from[135] . 
Figure 9: RHO GTPases in actin remodelling and cell protrusion formation 
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1.3.2          Cell adhesion in cell migration 
1.3.2.1         Adherens junctions in collective migration 
 
During collective migration, adhesive cell-cell coupling within multicellular migrating 
strands/clusters is mediated by existing cell-cell contacts, known as adherens junction (AJs). 
Adherens junctions (AJs), as well as TJs and desmosomes, are cell-cell adhesions that are 
established on the lateral surfaces of epithelial cells during morphogenesis of the epithelia[24]. 
AJs anchor cytoskeletal actin elements of two adjacent cells to each other through the 
interplay of a large number of transmembrane adhesion proteins and cytoplasmic molecules 
(Figure 10). Nectins and cadherins, both cell-cell adhesion molecules (CAMs), are the most 
important transmembrane protein families involved in the assembly of AJs. In humans, 
nectins is a group of four members (Nectin1-4) that contain a cytoplasmic tail, a 
transmembrane region and an extracellular (EC) one[136]. During the formation of nascent AJs, 
nectins homo-dimerise on the lateral surface of the cell and then trans-interact with nectin 
clusters on the lateral surface of the adjacent cell through Ca2+-independent heterophilic 
binding of their EC domain (Figure 10). Simultaneously, on the cytoplasmic side, the C-
terminus of the nectin tail binds to afadin, a large cytoplasmic protein that interacts directly 
with actin filaments [137]. These so-formed nectin-based scaffolds serve as structural platforms 
for the following assembly of cadherin adhesive structures. Among the more than 100 
members of the cadherin family, epithelial cadherin (E-cadherin or Cadherin-1) is expressed 
in most epithelial tissues and is commonly used as marker of fully developed AJs[24]. E-
cadherin forms cis and trans-homophilic dimers through its EC domain that are internally 
stabilised by aggregating to nectin-based complexes via catenin molecules such as catenin 
p120, β-catenin and α-catenin (Figure 10). β-catenin binds the intracellular tail of E-cadherin 
and interacts with the adaptor protein α-catenin, which in turn binds to F-actin[138]. Vinculin 
and α-actinin, other two actin-bundling molecules, then associate directly with α-catenin, thus 
connecting E-cadherins to the actin cytoskeleton[139]. Following, two afadin-binding proteins, 
ponsin and afadin DIL domain-interacting protein (ADIP), localise at the nascent AJ and 
connect nectin-afadin clusters to cadherin-based units via binding vinculin and α-actinin, 
respectively[140]-[141]. At the later stage of the AJs assembly, the LIM domain only protein 7 
(LMO7), an afadin and α-actinin interacting protein, localises at the AJ site to connect nectin-
afadin to cadherin-catenin units cluster through α-actinin[142] (Figure 10). The progressive 
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1.3.2.2         Cell-matrix contacts: Focal adhesions 
 
 Migrating cells need to attach to the substratum in order to stabilise membrane 
protrusions and gain traction support over which they pull their bodies forward.  
Cell adhesion to the ECM is predominantly mediated by focal adhesions (FAs), adhesive 
complexes that anchor the actin cytoskeleton inside the cell on the ECM.  FAs are flat, 
elongated structures that usually assemble near the periphery of a spreading or moving cell 
from adhesion precursors. When migration process begins, nascent adhesions are firstly 
established at the leading edge of the cell upon interaction between the ECM and the integrin 
transmembrane receptors. Integrins constitute a large family of heterodimeric receptors, 
consisting of 18 α and 8 β subunits able to assemble in 24 distinct functional variants in 
mammals[148]. They represent the major cellular component found in FA structures and 
mediate physical connection between the cytoskeleton and the ECM (Figure 11)[149]. The 
extracellular domains of both α and β subunits in fact associates with various ECM 
components, depending on different binding affinities, e.g. αvβ3 integrin specifically interacts 
with fibronectin, whereas α1β1 binds collagen and laminin
[150, 151]. Integrin interaction with the 
ECM determines activation of the RHO GTPases which induce a sequential accumulation of 
cytoplasmic proteins at the nascent adhesions. Over 50 different proteins are involved in the 
assembly and maturation of FAs, including integrin-binding proteins, adaptor proteins, and 
enzymes (Figure 11)[152]. Talin and paxillin first interact with the cytoplasmic tail of β-
integrin subunits, followed by the actin-bunding proteins vinculin, α-actinin and tensin 
(Figure 11). Simultaneously, ARP2/3-mediated actin polymerisation takes place in the 
emerging lamellipodium, leading to assembly of an actin dendritic network that is sooner 
recruited at the nascent adhesions. Actin filaments are in fact linked to the integrin-based site 
via talin, vinculin, α-actinin and tensin[143] (Figure 11). Nascent adhesions can either 
disassemble (turnover) or mature in larger adhesion sites, called focal complexes (FXs). 
These result from the involvement of other proteins that function as adaptors for the 
association with actin bundles at the boundary of the lamellum and lamellipodium. For 
example, paxillin, a β integrin-binding protein, serves as scaffold for structural proteins, such 
as vinculin, and different signalling kinases, including SRC, focal adhesion kinases (FAKs) 
and PAKs (Figure 11). FAKs directly associate with β-integrins and paxillin and reinforces 
integrin-actin bundles connection by recruiting additional talin molecules[153, 154]. PAKs co-
localise with paxillin via an adaptor complex, comprehensive of the paxillin kinase linker 
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(PKL) and PAK-interacting exchange factor alpha/cloned out of library (alphaPIX/COOL) 
(Figure 11)[155]. AlphaPIX/COOL, also known as ARHGEF6, is a member of the RHO 
GTPase guanidine exchange factor (GEF) family and along with its function in activating 
RHO small GTPases, is essential for PAK localisation at FA sites [156]. PAKs differentially 
regulate turnover and maturation of the FX (section 1.3.2.2.1). After integrin-actin 
aggregation is achieved, FXs either disassemble or evolve into elongated and more stable 
FAs, a process that requires the association with stress fibers and actomyosin contractility. 
Association of FX complexes with stress fibers is mediated by the activity of α-actinin and 
Enabled/vasodilator-stimulated phosphoprotein (Ena/VASP) proteins: both recruit zyxin 
molecules that directly associate with the termini of stress fibers (Figure 11)[157]. The second 
is conferred by binding of active myosin II between adjacent stress-fibers-integrin clusters 
thus providing contractile force to bring them closer to one another[158]. Persistent focal 
adhesion-associated contractility at the leading edge provides the cell with sufficient force to 
pull its body and slide along the ECM[159]. At the opposite site of the cell, disassembly of FAs 
allows retraction of the trailing edge through actomyosin contraction.  
High heterogeneity in size and dynamics of adhesion complexes has been observed in 
migrating cells, which depends on cell type, composition of the substratum and stimulation by 
external signals. These determine in turn which membrane protrusions, forces and speed rates 
are being generated during migration. For example, FAs are associated with slow migration 
and they are hardly observed in cells migrating in 3D. On the contrary, nascent adhesions and 
FXs are observed in highly motile cells, due to their fast turnover rates[160].  
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Figure 11: Molecular composition of focal adhesions. Heterodimeric (α and β) integrins are the 
primary adhesion receptors (orange cylinders). Additional membrane-associated molecules enriched 
in these sites (red) include syndecan-4 (Syn4), layilin (Lay), the phosphatase leukocyte common 
antigen-related receptor (LAR), SHP-2 substrate-1 (SHPS-1) and the urokinase plasminogen 
activator receptor (uPAR). Proteins that interact with both integrin and actin include -actinin ( -
Act), talin (Tal), tensin (Ten) and filamin (Fil) (golden rods). Integrin-associated molecules in blue 
include: focal adhesion kinase (FAK), paxillin (Pax), integrin-linked kinase (ILK), down-regulated in 
rhabdomyosarcoma LIM-protein (DRAL), 14-3-3  and caveolin (Cav). Actin-associated proteins 
(green) include vasodilator-stimulated phosphoprotein (VASP), fimbrin (Fim), ezrin–radixin–moesin 
proteins (ERM), Abl kinase, nexillin (Nex), parvin/actopaxin (Parv) and vinculin (Vin). Other 
proteins, many of which might serve as adaptor proteins, are coloured purple and include zyxin 
(Zyx), cysteine-rich protein (CRP), palladin (Pall), PINCH, paxillin kinase linker (PKL), PAK-
interacting exchange factor (PIX), vinexin (Vnx), ponsin (Pon), Grb-7, ASAP1, syntenin (Synt), and 
syndesmos (Synd). Adhesion-associated enzymes are presented in light shades: SH2-containing 
phosphatase-2 (SHP-2), SH2-containing inositol 5-phosphotase-2 (SHIP-2), p21-activated kinase 
(PAK), phosphatidyl inositol 3-kinase (PI3K), SRC-family kinases (SRC FK), carboxy-terminal SRC 
kinase (Csk), the protease calpain II (Calp II) and protein kinase C (PKC)[161].  
Figure 11: Molecular composition of focal adhesion 
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1.3.2.2.1       Regulation of actin cytoskeleton in cell-matrix adhesion 
 
RHO, RAC and CDC42 are also involved in the regulation of cytoskeletal dynamics 
during FA formation by directly controlling the balance between actin-mediated protrusion 
and actomyosin contraction. RAC and CDC42 stimulate the formation of nascent adhesion 
and FXs by inducing ARP2/3-mediated actin polymerisation at the initial site of adhesion. On 
the other side, focal adhesion assembly and stabilisation is provided by RHO activation as 
well as myosin II-dependent contractility[162]. Turnover and maturation of FAs is controlled 
by several FAs-associated proteins, such as paxillin, FAK/SRC and PAK. Phosphorylation of 
paxillin by the FAK/SRC complex correlates with the turnover of existing FAs and increased 
motility[163], whereas PAKs differentially regulate both assembly and maturation of FA. PAKs 
exhibit the dual potential to inhibit and promote myosin II activity, necessary for the 
maturation of FAs. PAKs can phosphorylate MLCK, leading to its inhibition and decreased 
MLC phosphorylation[164]. At the same time, they can activate myosin II-mediated 
contractility by direct phosphorylation of the MLC subunit[165-167]. Recent evidences suggest 
that PAKs may contribute to both assembly and maturation of FAs in an isoform-specific 
way. Using siRNAs in breast carcinoma cells, Coniglio et al. demostrated that both PAK1 and 
PAK2 promote BC invasion, by playing opposite roles in the regulation of MLC 
phosphorylation and FAs stabilisation[129]. In particular, they observed that silencing of PAK1 
in BC cells inhibits MLC phosphorylation, suggesting that PAK1 may directly phosphorylate 
MLC; while the depletion of PAK2 enhances MLC phosphorylation, by stimulating the 
RHOA/ROCK axis. Moreover, the observation that FAs do not increase in size in PAK1-
depleted BC cells suggested that PAK1 may play a role in promoting focal adhesion 
maturation, at least in part, by stimulating MLC phosphorylation. The depletion of PAK2, 
instead, led to increased FAs size, likely due to the higher myosin II activation, on one side; 
on the other, loss of PAK2 inhibited the assembly of new FAs that may reflect a direct 
requirement of PAK2 to focal adhesion generation,. Thus, PAK1 and PAK2 cooperate to 
ensure optimal focal adhesion generation and maturation during BC cell migration. 
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1.3.3           Signalling to cytoskeletal remodelling, cell motility and 
metastasis  
1.3.3.1         Regulation of RHO GTPases  
 
Small RHO GTPases are master regulators of spatial and temporal cytoskeletal re-
organisation that is required for various cellular processes including cell-cell interaction, cell 
polarity, cell adhesion, proliferation and chemotaxis[36].  
RHO GTPases function as molecular switches that cycle between an active (GTP-bound) and 
inactive (GDP-bound) conformations[168]. The cyclic switch between GDP and GTP is 
regulated by two classes of cytoplasmic molecules, the guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs). GEFs and GAPs control the cyclic switch of 
RHO GTPases between inactive and active forms. GEFs activate RHO GTPases by promoting 
exchange of GTP for GDP, whereas GAPs inactivate RHO GTPases by enhancing the 
intrinsic GTP-hydrolysis activity. In addition, guanine-nucleotide-dissociation inhibitors 
(GIDs) sequester GDP-bound RHO GTPases, preventing their translocation at plasma 
membrane sites where they are usually  activated[168] (Figure 12). 
Activation of RHO GTPases occurs in response to external stimuli that can be both chemical, 
including growth factors and cytokines and physical, such as adhesion to extracellular matrix 
or other cells and mechanical stresses. External stimuli are detected and captured by plasma 
membrane receptors that consist mainly of three classes: (1) receptor tyrosine kinases (RTK), 
i.e., epithelial growth factor receptor (EGFR), hepatocyte growth factor receptor 
(HGFR/cMet), and transforming growth factor receptor (TGFR), (2) G protein-coupled 
receptors, such as lysophosphatidic acid receptor (LPA-R) and sphingosine-1 phosphate (S1P) 
receptor, and (3) integrins[169] (Figure 12). After stimulation, they initiate intracellular 
transduction of external signals to RHO GTPases through activation of GEFs via different 
mechanisms. As result, GEFs undergo to conformational changes that relieve them from 
autoinhibitory mechanisms, changing their subcellular localisation to increase the chance of 
interaction with RHO GTPase substrates. A common mechanism of GEF regulation used by 
RTKs and GPCRs is the activation of the phosphatidylinositide 3-kinase (PI3K) (Figure 12). 
Activated PI3K leads to production of phosphatiylinhositol 3,4,5-triphosphate (PI[3,4,5]P3) 
which acts as second messenger to activate membrane-associated GEFs, owing to its high 
affinity for the GEF authoinhibitory domain. GEFs activity can also be stimulated by direct 
phosphorylation by membrane RTKs and via heterodimeric G proteins that after activation of 
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GPCR are released in the intracellular space where they interact with GEFs or activate 
PI3K[170, 171] (Figure 12). Moreover, RHO family GEFs are activated downstream signalling 
pathways triggered by integrin-mediated cell adhesion to the ECM. In this respect, after 
paxillin-mediated recruitment at FA sites, FAK is activated by SRC and this results in 
phosphorylation and activation of CAS scaffolding proteins. CAS is a docking protein that 
once activated form a complex with the adaptor protein CRK and together recruit and activate 
RHO family GEFs[135] (Figure 12). 
Over 60 mammalian RHO family GEFs have been identified and their functional 
investigation has revealed a complex regulatory network for these proteins, including 
upstream receptor-specific activation/inactivation pathways and downstream RHO GTPase-
specific regulation[169]. 
Among these, the αPIX (alpha PAK-interacting exchange factor) member of the RHO  family 
GEFs exhibit a particularly complex mode of action in controlling RHO GTPases activity and 
downstream effects. αPIX, also known as COOL2 (Cloned out of library 2) or ARHGEF6 
(RAC/CDC42 guanine nucleotide exchange factor 6), is a GEF member specific for RAC and 
CDC42, because it binds to the RAC/CDC42 target PAK. It can be activated by PI3K 
following upstream stimulation of both RTKs and GCPRs, by G protein subunits derived 
from G protein activation and by integrin-based focal adhesions, where αPIX localises in 
complex with PAK via interaction with GIT-paxillin. Activation of αPIX through all these 
different mechanisms has been shown to be essential for both RAC and CDC42 function[170, 
172, 173]. αPIX activity as GEF highly depends on its cytosolic conformation. It can exist in fact 
as either homodimer and in this state it functions as RAC-specific GEF, or in a monomeric 
form which acts as a GEF for either RAC or CDC42, but the molecular mechanisms that 
mediate the switch between its dimeric and monomeric states and vice versa are still unclear 
[174]. It is known that PAK interaction with αPIX is required for the monomeric form to 
exhibit GEF activity, but it is not sufficient to stimulate the dissociation of dimeric αPIX into 
monomers[175]. In addition, αPIX interaction and localisation of PAK at focal adhesion sites 
induces PAK activation through local stimulation of RAC and CDC42. Moreover, αPIX is 
frequently found in integrin-based adhesion clusters and its overexpression dramatically 
promotes lamellipodia and protrusion formation during integrin-mediated cell spreading, as 
result of αPIX-induced activation of RAC and CDC42[176].  
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1.3.3.2         EGFR and HER2 drive pro-metastatic signalling cascades in 
BC 
 
 Epidermal growth factor receptor (EGFR) and human epithelial growth factor receptor 2 
(HER2) belong to the erythroblastic leukemia viral oncogene homolog (ERBB) family of 
RTKs that play important roles in cell proliferation, survival, motility and development. 
Nevertheless, deregulation of ERBB receptors and their downstream signalling pathways is 
frequently observed in cancer and is critical for  cellular transformation and tumour 
progression[178]. EGFR and HER2 have been implicated in the development of a number of 
cancers, where genetic alterations such as gene amplification result in receptor 
overexpression, or somatic mutations lead to constitutive receptor activation. Particularly, 
overexpression of HER2 is detected in about 20-30% of human breast tumours and correlates 
with increased metastatic aggressiveness such that it is clinically used as prognostic and 
predictive marker for BC, as well as a therapeutic target[179]. 
In mammals, the ERBB family includes ERBB1 (also called EGFR), ERBB2 (also known as 
HER2 or c-NEU), ERBB3 (also named HER3) and ERBB4 (or HER4). As RTKs, they 
comprise an extracellular ligand binding domain, a transmembrane region and a cytoplasmic 
tail with tyrosine kinase activity. Binding of the ligand to the extracellular domain induces 
homo- or heterodimerisation of ERBB receptors which is essential to initiate intracellular 
signal transduction[180]. The ERBB receptors respond to multiple ligands that exhibit a 
receptor-dependent binding specificity. They include: epithelial growth factor (EGF), 
transforming growth factor (TGF)-α, amphiregulin and epigen which bind specifically to 
EGFR; betacellulin (BTC), heparin-binding EGF, and epiregulin which show dual specificity 
by binding both to EGFR and ErbB4; neuregulins (NRGs)/heregulins which bind to ErbB3 
and ErbB4. HER2 lacks ligand binding activity and its function depends on its dimerisation 
with other ligand-bound ErbB receptors. When overexpressed, HER2 is preferentially 
selected for ErbB receptor heterodimerisation and HER2-containing heterodimers exhibit the 
most potent downstream signalling responses[181, 182].  
After binding of the ligand, ErbB dimerisation stimulates the intrinsic receptor tyrosine kinase 
activity which results in autophosphorylation and trans-phophorylation of tyrosine residues in 
the cytoplasmic tail of each dimerised receptor (Figure 13). These phosphotyrosines serve as 
docking sites for the recruitment of various adaptor molecules or enzymes containing specific 
SRC homology 2 (SH2) domains (phosphotyrosines binding domains), such as SRC, SHC, 
growth factor receptor–bound protein 2 (GRB2), PI3K,  non-catalytic region of tyrosine 
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kinase adaptor protein (NCK) and regulatory subunits of the phosphatidyl inositol 3-kinase 
(PI3K), which include p85α, p55α, p50α, p85β, p55γ (Figure 13). These adaptors transduce 
the RTK-captured signal via simultaneous activation of multiple signalling cascades resulting 
in proliferative, survival and migratory outcomes[183].  
EGFR/HER2 heterodimers has been shown to be the favorable dimeric combination for 
induction of BC motogenic and invasive phenotypes[184]. In fact, constitutive expression and 
activation of EGFR and HER2 are responsible for the high transendothelial invasiveness of 
BC cells where tyrosine phosphorylated-EGFR and HER2 are found to be localised in areas 
of high membrane protrusion activity. Moreover, overexpression and increased intrinsic 
tyrosine kinase activity of HER2 is critical for formation of lung metastases from mammary 
gland primary tumours in transgenic mice models[185]. Notably, only EGF stimulation and 
EGFR/HER2 heterodimer formation are able to induce a sufficient HER2 tyrosine 
phosphorylation to recruit SHC, GRB2 and PI3K onto its cytoplasmic tail (Figure 13). 
Activated EGFR/HER2 dimers induce sustained cytoskeletal re-organisation and confer 
motogenic and invasive properties at both cytoplasmic and nuclear levels through several 
downstream pathways[186].  
Firstly, EGFR/HER2-mediated recruitment of PI3K through its SH2-containing p38 subunit 
links RTKs to RHO GTPases regulation. EGF-stimulated lamellipodia formation requires 
PI3K activity which leads to activation of RAC or CDC42 [187].These in turn activates PAK 
which form a complex with LIMK resulting in phosphorylation and activation of the latter. 
Activated LIMK then phosphorylates cofilin leading to inhibition of cofilin-mediated actin 
filament severing[188]. Activation of small RHO GTPases and their downstream signalling 
effectors by EGF stimulation can also occur through EGFR-mediated direct recruitment and 
phosphorylation of RHO GEFs, such as the VAV family which activates RAC and RHO 
leading to cytoskeletal rearrangements[189], and the RAC/CDC42 GEF αPIX which is essential 
for EGFR/HER2-induced activation of PAK function (Figure 13)[190].  
In addition, tyrosil-phosphorylation of HER2 triggers recruitment of SHC and GRB2 adaptor 
proteins, which directly transmit RTK stimulation to the RAS GTPases family and indirectly 
to small RHO GTPases. HER2-activated SHC in fact recruits GRB2 which is constitutively 
associated with Son of Sevenless (SOS), a guanyl nucleotide exchange factor for RAS 
GTPases[188]. Coupling of SOS whith HER2 through GRB2 leads to SOS-mediated GTP-
loading of RAS and subsequent activation of RAS effectors, such as PI3K and rapidly 
accelerated fibrosarcoma (RAF) kinases (Figure 13)[188]. RAF initiates then a cascade of 
phosphorylation events that results in activation of the mitogen-activated protein kinase 
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(MAPK) pathway through the MAPK/ extracellular signal regulated kinase (ERK)-activating 
kinases (MEK). Stimulated MAPKs translocate to the nucleus where their function in the 
phosphorylation of a variety of proteins, including the transcription factors c-MYC, c-JUN 
and c-FOS. The activated c-JUN and c-FOS then interact with each other to form a functional 
transcription complex called activator protein-1 (AP-1) (Figure 13)[191]. EGFR-mediated 
downstream formation of AP-1 transcription factor can also take place through another 
signalling cascade which is initiated via recruitment of the NCK adaptor protein. NCK is able 
to associate with PAKs, thus bringing them in proximity of their EGFR-activated RAC and 
CDC42 regulators on one hand; on the other hand, NCK itself directly activates PAKs, and 
this regulation is essential for PAK1 and PAK2 to induce JNK (c-JUN N-terminal kinase) 
activation, through sequential phosphorylation of MAP/ERK kinase kinase 1 (MEKK1) and 
MAP kinase kinase 4/7 (MKK4/7)[192, 193]. Once activated, JNK enters in the nucleus where it 
specifically phosphorylates c-JUN, thus leading to its dimerisation with c-FOS to form the 
active AP-1 complex (Figure 13).  
AP-1 is a transcription factor complex which forms upon homo- or heterodimerisation of 
FOS- and JUN-family proteins which include c-FOS, FRA1, FRA2, FOS B and c-JUN, JUN 
B, JUN D, respectively, as well as activating transcription factor (ATF) and 
musculoaponeurotic fibrosarcoma (MAF) protein families[191]. These proteins exhibits 
transcriptional gene regulation activity by binding to consensus DNA sequences usually 
present in gene promoter regions. The typical nucleotide sequence recognised by AP-1 factors 
is the 12-O-tetra-decanoylphorbol-13-acetate (TPA)-responsive element (TRE) (fig), which is 
preferentially bound by AP-1 dimers formed by the two main AP-1 proteins, c-JUN and c-
FOS[191]. Growth factor-stimulated AP-1 activity has been largely associated with cytoskeletal 
remodelling, increased invasiveness and metastatic spread of BC[194] [195] [196] [197].  Indeed, 
owing to its activity in transcriptionally regulating gene expression, AP-1 has been shown to 
orchestrate a multigenic invasion program by both up-regulating and down-regulating a large 
number of genes that differentially participate to cytoskeletal dynamics, cell-cell and cell-
ECM adhesion, motility, invasion, angiogenesis and transcriptional regulation of all these 
processes [198]. Amongst the genes strongly up-regulated by AP-1 are several 
metalloproteinases, such as uPA, MMPs and cathepsins and cytoskeletal regulators, such as 
ARP2/3 p16 subunit and the SCAR2 member of the WASP family. Notably, AP-1 is able to 
induce transcriptional expression of its component c-JUN in response to EGF stimulation, by 
interacting with TREs sequences present in its gene promoter (Figure 13)[199]. 
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1.4       Aneuploidy  
Every species is characterised by a distinct karyotype (chromosome complement) that 
is referred as to euploidy. The successful perpetuity of all multicellular organisms relies on 
maintainance of the euploid genomic state during transmission of genetic information to 
daughter cells.  Almost all mammals are diploid, such that they contain two copies (2n) of 
each autosomal chromosome (haploid complement); for instance, in humans the 2n basic 
chromosome number is 46. A balanced ploidy state requires maintanance of an equal number 
of each chromosome, thus ensuring the possession of an equal copy number of genes present 
in different chromosomes[200]. Deviation from the euploid kariotype caused by changes in the 
copy number of specific genes, entire or parts of chromosomes leads to a state of aneuploidy. 
The term aneuploidy refers to any karyotype containing a chromosome number that differs 
from the haploid complement and its multiples (polyploidy). Aneuploidy can arise form either 
gain or loss of entire chromosomes due to chromosome segregation defects, known as 
“whole-chromosome” aneuploidy, or by deletion, amplification or translocation of sub-
chromosomal fragments, so-called “partial” or “segmental” aneuploidy[201]. As aneuploid cells 
are stricken by either an excess or deficit of gene copies located in the affected chromosomes, 
occurring of aneuploidy is generally poorly tolerated in nature, a sweeping consequence of the 
impairment in growth and reproductive fitness caused to the organism. Autosomal aneuploidy 
derived from chromosome mis-segregation during meiosis is indeed responsible for impaired 
fertility, causing 30% of human miscarriages and detrimental embryonic development[202]. 
When aneuploidy is not lethal, it results in severe defects in the progeny, such as mental 
retardation. Indeed a well characterised example of viable aneuploidy is trisomy 21 in 
humans, a genetic condition, responsible for Down syndrome, in which individuals stably 
possess three copies of the chromosome 21[200]. Nevertheless, aneuploidy often encompasses 
chromosomal instability (CIN), a condition in which cells experience ongoing chromosome 
segregation defects, leading to continuous changing of the aneuploid set. Cells affected by 
CIN are always aneuploid due to accumulation of new karyotype alterations[203]. CIN and 
consequently aneuploidy are widely found in many solid tumours and cancer cell lines, and 
are believed to be contributive events during the process of tumourigenesis[204]. 
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1.4.1           Causes of whole-chromosome aneuploidy  
 
1.4.1.1         Chromosome segregation  
Whole-chromosome aneuploidy arises from defects in the processes that orchestrate 
chromosome segregation during different steps of the cell cycle, resulting in gain or loss of an 
individual chromosome (or few of them). Accuracy of these processes is essential for proper 
mitotic spindle assembly, kinetochore-microtubules attachment and dynamics, and 
centrosome number[205].  
To better understand how aberrant chromosome repartition in the two daughter cells can 
occur, we here summarise the main steps of chromosome segregation (Figure 14A). During 
the synthesis phase (S phase) of the cell cycle, the mother cell undergoes DNA replication and 
duplication of the centrosome, a cytoplasmic organelle responsible for the assembly of the 
mitotic spindle. The centrosome is composed by two barrel-shaped structures, the centrioles, 
embedded in a proteinacious substance called the pericentriolar material (PCM), which 
orchestrate microtubule nucleation essential for spindle maturation[203]. Mitosis begins with 
entrance of the cell into prophase, when replicated DNA condensates into sister chromatids 
which are held together each with its own kinetochore linked to the other by cohesin ring 
structures[206]. Almost simultaneously, the duplicated centrosomes migrate to opposite poles 
of the dividing cell, where they form spindle fibers by emanating microtubules that, after 
nuclear membrane breakage, attach to each kinetochore of the sister chromatids. In 
metaphase, the sister chromatids are oriented at the equator of the cell, where they aligned to 
form the so called metaphase plate, due to pulling forces generated by opposite kinetochore 
microtubules. A mitotic checkpoint mechanism, known as spindle-assembly checkpoint 
(SAC) prevents chromosome mis-segregation by halting cell cycle progression until every 
sister chromatid pair is correctly attached to spindle microtubules [207]. Components of the 
SAC machinery senses the presence of incorrectly attached or empty kinetochores and delays 
mitosis in metaphase: they inhibit activity of the anaphase-promoting complex or cyclosome 
bound to its activating subunit CDC20 (APC/C-CDC20), required for metaphase-to-anaphase 
transition. Once all the kinetochores are properly attached, SAC inhibition is disrupted, and 
APC-CDC20 leads to activation of the protease separase: it induces degradation of both 
securin, the separase inhibitory subunit, and Cyclin B, the latter resulting in inhibition of 
cyclin-dependent kinase 1 (CDK1) activity which leads to separase dephosphorylation and 
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activation. Active separase then cleaves cohesion rings, thus promoting detachment of the 
sister chromatids and chromosome segregation[208].   
 
1.4.1.2         Different mechanisms of chromosome mis-segregation lead to 
aneuploidy  
 
Multiple errors occurring during mitosis can give rise to chromosome mis-segregation 
and therefore aneuploidy. Defects in the mitotic checkpoint signalling due to compromised 
SAC functions or APC-CDC20 hyperactivation inevitably lead to formation of aneuploid 
daughter cells lacking or gaining one or few chromosomes, as result of their faulty attachment 
to the spindle (Figure 14B). An impaired mitotic checkpoint due to mutations in the genes of 
the SAC machinery is highly associated to increased CIN and aneuploidy occurrence. 
Nevertheless, mutations that completely inactivate the mitotic checkpoint function are 
accompanied by massive chromosome mis-segregation and are highly detrimental to cell 
fate[204]. 
Production of aneuploid cells can also occur despite functional mitotic checkpoint signalling. 
Aberrant attachments of the spindle microtubules to the chromatid kinetochores represent an 
additional example of mitotic defects with clear aneuploid outcomes. Premature loss of sister 
chromatid cohesion, due to impaired cohesin function or hyperactivation of separase, can 
result in attachment of individual sister chromatids by microtubules from the same spindle 
pole, thus leading to random chromosome segregation (Figure 14C)[206]. Since kinetochore-
microtubule connection occurs, no delay signals are generated by the SAC machinery. This 
principle is valid also when the kinetochore of paired-sister chromatids is anchored by 
microtubules from both spindle poles, a condition known as merotelic attachment (Figure 
14D)[209]. The improper attachment is usually corrected before anaphase entry, but in some 
cases culminates with a median lagging chromosome that is either excluded from both 
daughter cells during cytokinesis or accurately segregated into one of them, where it is 
confined in a micronucleus[210]. Merotely occurrence can be promoted by formation of 
multipolar spindles, which derives from the presence of more than two centrosomes or 
fractured centrosomes within the mitotic cell. In this situation, efficient cytokinetic events can 
generate a progeny of multiple aneuploid cells; on the other hand, aberrant cytokinesis results 
in polyploidisation (Figure 14E)[204, 208]. Supernumerary centrosomes causing multiple 
spindles are generated by several mechanisms, including cytokinesis failure; cell fusion; 
endoreduplication (DNA duplication without following mitosis); and mitotic slippage, a 
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condition in which, after long-term mitotic arrest, a cell exit from mitosis generating one 
tetraploid G1 cell[200]. Acquisition of multiple centrosomes can also occur due to aberrant 
regulation of the protein machinery that control centriole duplication and separation. The 
CDK2 kinase is required to initiate centrosome duplication in S phase and promotes centriole 
maturation and separation together with Polo-like kinase 1 (PLK1), Aurora A kinase and the 
microtubule-molecular motor Kinesin family member 22 (KIF22) at the G2 and M phases[203, 
211]. Constitutive activation of CDK2 promotes aneuploidy by inducing centrososme 
amplification; similarly, mis-regulation of PLK1, Aurora A and KIF22 expression or 
activation is a major cause of chromosome instability and aneuploidy, by promoting 
formation of multiple centrosomes and spindle disorganisation. A crucial regulator that 
maintains homeostasis of these proteins is checkpoint with forkhead and ring finger domains, 
E3 ubiquitin protein (CHFR), a checkpoint protein that delays entry in mitosis in response to 
mitotic stresses, to ensure chromosome stability. CHFR is an E3-ubiquitin ligase that 
promotes degradation of PLK1, Aurora A and KIF22, preventing their excessive 
accumulation and functional activity. Loss of CHFR produces severe CIN, arisen from 
centrosome amplification, spindle mis-organisation and cytokinesis failure[211-213].  
By contrast, failure of centrosome duplication or separation due to mutation, inhibition or 
depletion of central players of these processes is responsible for establishment of monopolar 
spindles (Figure 14F)[214]. Cells containing only one centrosome generally undergo to 
prolonged mitotic checkpoint-dependent arrest, triggered by presence of at least a few 
unattached chromosomes. Although it is not clear what determines the fate of these cells, 
under these conditions cells either die following a sustained mitotic arrest or survive by 
adaptation. This is a poorly understood process that occurs when cells adapt to exit mitosis 
after prolonged mitotic arrest skipping the cytokinesis and karyokinesis (nuclear division) 
steps to generate a tetraploid G1 phase cell that still contains unattached chromosomes 
(Figure 14F). In cases where these abnormalities are accompanied by impaired mitotic 
checkpoint pathway at individual kinetochore, the cells escape from mitotic arrest at earlier 
steps and have more chances to survive[204]. Viable tetraploid cells then can succeed in cell 
division, leading to formation of high grade aneuploid cells, due to abnormal centrosome 
number and increased chromosome instability.  
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cells that after tetraploidisation events (such as failure of cytokinesis) have mis-segregated 
individual chromosomes[204]. Ongoing gain or loss of one or few whole chromosomes during 
mitosis, which determines harbouring of the aneuploid state, is an inevitable consequence of 
chromosomal instability (CIN), another feature shared by many types of cancer. Moreover, 
tumour cells frequently harbor a series of genetic alterations, such as mutations, 
amplifications and deletions, a consequence of the genomic instability that is a hallmark of 
cancer. Targets of genomic instability events commonly found in a variety of solid tumours 
are oncogenes and tumour-suppressor genes such as KRAS, tumour protein p53 (TP53), 
phosphatase and tensin homologue (PTEN), retinoblastoma 1 (RB1), breast cancer 1 
(BRCA1), and others, with inevitable impact on cell proliferation and survival[208]. How CIN 
and therefore aneuploidy causatively contribute to malignant transformation in addition to the 
action of genomic instability, is still unaddressed. The hypothesis is that the property of a cell 
population to rearrange whole chromosome distribution can elicit tumourigenesis, by possibly 
causing loss of heterozygosity (LOH) of a tumour suppressor gene, present in the lost 
chromosome. Conversely, this ability might lead to amplification of an oncogene by 
duplicating the chromosome in which the mutated allele is embedded[216]. 
Mitotic defects causing chromosome mis-segregation and aneuploidy have been shown to 
promote malignant transformation. Evidence for this arises from in vivo and in vitro studies 
where CIN was induced by engineered mutations or deregulation of genes involved in 
different steps of chromosome segregation. For example, transgenic mice that overexpress or 
carry a heterozygotic mutation in individual SAC genes, such as Budding uninhibited by 
benzimidazoles 1 homolog (BUB1), mitotic arrest deficient,yeast, homolog-like 1 (MAD1L1) 
and mitotic arrest deficient,yeast, homolog-like 2 (MAD2L2), exhibit increased tumour 
incidence, as result of impaired mitotic checkpoint signal and consequent increased CIN and 
aneuploidy[217]. Additionally, aberrant cohesion or separation of the two sister chromatids is 
associated with tumourigenic outcomes. Indeed, inactivating deletion or mutations of STAG2 
gene, encoding a cohesin subunit, result in defective chromatid separation and are a cause of 
aneuploidy in different tumour types[218]. In addition to defective mitotic spindle checkpoint 
and chromatid cohesion, abnormal centrosome number has been implicated in 
tumourigenesis. In this respect, amplification and experimental overexpression of Aurora A 
has been reported to yield centrosome amplification, resulting in CIN, aneuploidy and 
malignant transformation in in vivo BC models[219]. Moreover, CHFR deficiency in mice 
greatly increases incidence of spontaneous tumour formation, and promotes CIN through mis-
regulation of Aurora A. CHFR is a tumour suppressor that ensures chromosomal stability by 
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regulating the expression levels of crucial centrosome components, such as Aurora A, PLK1 
and KIF22[211-213]. A tumour suppressive function of CHFR has also been demonstrated in 
BC, where CHFR exhibits low or null expression[220]. Stable downregulation of CHFR in 
immortalised mammary cell lines resulted in the acquisition of multiple malignant 
phenotypes, including increased aneuploidy and anchorage-independent cell growth.  
Finally, primary breast carcinomas display chromosome instability and aneuploidy, associated 
with lack of PTEN expression[221]. The tumour suppressor PTEN controls proliferation and 
survival by inhibiting the proliferative activity of the phosphatydilinositol-3 kinase 
(PI3K)/AKT pathway. Loss of PTEN in BC results in hyperactivation of AKT, which induces 
phosphorylation, degradation and reduced nuclear localisation of CHK1, a DNA damage 
checkpoint kinase that control mitosis entry and prevent chromosome instability.  
 
 
1.4.3          Cytokinesis failure as a precursor of aneuploidy and cancer 
1.4.3.1        General mechanisms of cytokinesis    
Cytokinesis is the final step of cell division responsible for the physical separation of 
two distinct daughter cells, ensuring proper inheritance of the segregated chromosomes, the 
cytoplasmic content, and the plasma membrane. Thus, it is essential for maintenance of 
euploidy during organismal development, adult life and reproduction, and to avoid the 
development of disease, particularly cancers[222].  
In animal cells, cytokinesis is accomplished through a series of key events that include 
formation of the central spindle, assembly and contraction of an actomyosin ring that allows 
cleavage furrow ingression, and abscission via membrane fusion (Figure 15).   
Establishment of the division plane or central spindle (Figure 15) begins at the anaphase 
onset, when a set of microtubules between the segregated chromosomes becomes bundled 
during anaphase in an antiparallel fashion to provide a docking scaffold for key regulators of 
cytokinesis. These include the centralspindlin complex, a heterotetramer consisting of a 
kinesin, MKLP1 and a RHO family small GTPase-activating protein (GAP), CYK-4. After 
release from Cyclin B/CDK1-mediated inhibition, centralspindlin accumulates at the mid-
zone between the nascent daughter nuclei by interacting with bundled microtubules of the 
central spindle[223]. Localisation and clustering of centralspindlin complexes is tightly 
coordinated by Aurora B kinase and 14-3-3 proteins. The latter sequester cytoplasmic MKLP1 
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allowing Aurora B to activate by phosphorylation clustering and stable accumulation of 
centralspindlin at the spindle mid-zone[224]. Active centralspindlin then associates with a RHO 
GTPase guanine exchange factor (GEF), ECT2, which promotes local activation of the small 
RHO GTPase RHOA, critical for the production of the functional actomyosin ring[223]. In its 
active, GTP-bound form, RHOA triggers multiparallel signalling pathways that result in actin 
nucleation and polymerisation via formin activity, and myosin light chain phosphorylation 
(see 1.3.1.1). The resulting actin filaments and active myosin coordinate the arrangement of a 
contractile actomyosin ring that associates with the inner face of the plasma membrane 
(Figure 15). Actomyosin contractility then drives shrinkage of the ring that causes furrowing 
of the plasma membrane, thus progressively reducing the cytoplasmic space that still connects 
the two daughter cells[222, 223]. As ingression of the cleavage furrow proceeds, the microtubule 
bundles in the spindle midzone are compacted in an intercellular bridge, which consists of a 
midbody ring derived from the actomyosin ring and cross-linked midzone proteins (Figure 
15). Final separation, or abscission, is accomplished through coordinated disruption of the 
intercellular bridge and resolution of the two daughter cells‟ plasma membranes[222, 223] 
(Figure 15). The intercellular bridge is disrupted by clearance of microtubule bundles via 
breaking and severing events and by dissociation of the actomyosin ring that requires RHOA 
inactivation. In this respect, 14-3-3 proteins and protein kinase C epsilon (PCKε) are critical 
for completion of cytokinesis. PCKε activation upon binding by 14-3-3 protein dimers is 
required to limit RHOA function at the midbody during late cytokinesis, which in turns allows 
dissociation of the actinomyosin ring during final separation[225]. Ultimately, resolution of an 
independent plasma membrane for each daughter cell is achieved via delivery of membrane 
vescicles at the midzone where they bridge the space remaining after maximal furrow 
ingression via fusion mechanisms. Different cellular machineries are involved in the process 
of membrane separation, including members of the v-SNARE vescicle trafficking and fusion 
machinery, such as Sintaxin 2 (STX2) which mediates membrane fusion for successful 
cytokinesis completion[226]; and RAB family GTPases, such as RAB21, which associates with 
integrins and ensures their proper trafficking/recycling to and from the membrane furrow, 
necessary for a proper abscission[227]. 
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1.4.3.2        Cytokinesis failure as prelude to aneuploidy and tumourigenesis   
 
Accuracy in spatial and temporal coordination of distinct steps of the cytokinesis 
process is necessary for proper inheritance of genetic information and cytoplasmic content of 
the two daughter cells. Misregulation of several cytokinetic proteins can compromise the 
progression of cytokinesis, resulting in generation of binucleated or multinucleated cells, with 
enhanced genomic instability and implications for tumourigenesis. 
For instance, localisation of the centralspindlin complex at the midzone microtubules is 
essential for proper central plane formation and successful cytokinesis. In this respect, 
aberrant regulation of Aurora B, 14-3-3 proteins and CDK1 expression or activity causes 
incorrect accumulation of centralspindlin components at the central spindle and cytokenisis 
defects[224, 229] [230]. Additionally, abnormalities in pathways regulating actinomyosin 
dynamics can slow ring closure making cells incompetent for completion of cytokinesis and 
therefore causing furrow regression and formation of binucleated cells. For example, 
disruption of PCKε-14-3-3 complex is accompanied by RHOA hyperactivation, which leads 
to delay of actinomyosin ring dissociation and consequently to cytokinesis failure[225]. 
Moreover, complete abscission that separates the two daughter cells can be compromised by 
abortive cleavage furrow ingression and impaired membrane fusion. In the first case, 
inhibition of RAB21, a RAS small GTPase that control integrin endo/exocytosis, is known to 
produce binucleated and multinucleated cells, due to reduced trafficking of integrin at the 
cleavage furrow where integrin-mediated adhesion is required for anchoring and furrowing of 
the plasma membrane[227]. In the second case, it has been shown that inhibition of members of 
Figure 15: Main steps of cytokinesis. Cytokenisis begins with assembly of the central spindle via 
microtubule (red) bundling and proceeds with formation of an actinmyosin ring of which contraction 
allows ingression of the cleavage furrow. Maximal membrane furrowing culminates with formation 
of an intercellular bridge containing the midbody, of which disruption enables abscission of the 
plasma membrane that separates the two daughter cells. Modified from[228].   
Figure 15: Main steps of cytokinesis. 
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the SNARE fusion machinery, such as Syntaxin 2, affects later steps of the abscission event, 
impeding complete separation and fusion of the daughter cells‟ membranes[231].  
An inevitable result of a failed cytokinesis process is the production of a tetraploid cell. In 
addition to impaired or unattempted cytokinesis or monopole spindle occurrence as seen 
before, failure of karyokinesis (nuclear division) can also leads to tetraploidisation. 
Karyokinesis failure can occur following defective mitotic spindle formation associated with 
impaired mitotic checkpoint activity with a similar mechanism to that seen in monopolar 
spindle formation (Figure 14F), or in the failed separation of sister chromatids, which is 
usually caused by defects in key regulators of this process, such as APC/C and separase[217]. 
Tetraploidisation, a form of euploidy in which a cell possesses 4 sets of homologous 
chromosomes, has been largely associated with tumourigenesis. Indeed, tetraploid cells exibit 
genomic instability and are believed to elicit a high aneuploidy state, thus contributing to 
malignant transformation. This is consistent with the observation of tetraploid or near-
tetraploid cells in many types of cancer, such as carcinomas of the breast and the cervix[216, 
232]. Moreover, chromosomal abnormalities associated with tetraploidisation, such as 
centrosome amplification, have been observed in cancer. About 80% of invasive breast 
carcinomas display aberrant structure and/or number of centrosomes associated with 
aneuploidy and chromosomal instability[233].  
A critical feature of tetraploid cell is, in fact, the presence of two centrosomes. With the 
entrance in a new cell cycle, these centrosomes likely duplicate and produce multipolar 
spindles with three or four poles, which would lead to generation of aneuploid progeny during 
a subsequent mitosis with successful cytokinesis (Figure 16)[204]. Propagation of tetraploid 
cells can be compromised by the intervention of a “tetraploidy checkpoint”, a mechanism 
believed to sense centrosome amplification and to prevent inheritance of errors of late mitosis 
and enhanced aneuploidy by affecting viability of tetraploid cells[232]. A “tetraploidy 
checkpoint” mechanism was observed upon induction of cytokinesis failure via drug-induced 
inhibition of furrow ingression, when the resulting tetraploid cells undergo to cell cycle arrest 
in G1 phase in a p53-dependent manner[234]. Tetraploid cells generated after transient block of 
cytokinesis are able to promote tumourigenesis in p53-null mice, due to enhanced whole-
chromosome mis-segregation[235]. However, tetraploid cells frequently exhibit the ability to 
succeed cell cycle progression without undergoing to arrest or delay in G1, thus questioning 
the existance of the “tetraploid checkpoint” that monitors centrosome and chromosome 
number. It seems more likely that tetraploids arrest in G1 phase is a consequence of p53 
activation in response to cellular stresses associated with drug treatments or to aberrant 
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1.5       MicroRNAs   
MicroRNAs (miRNAs) are a class of endogenous, non-coding, single stranded RNAs 
ranging in size from 18 to 26 nucleotides. They play an important role in the regulation of 
gene expression, mainly at the post-transcriptional level, thus representing a unique 
mechanism of epigenetic control. 
The first description of miRNAs dates from 1993, when two research groups simultaneously 
identified lin-4, as a gene necessary for the postembryonic development of Caenorhabditis 
elegans[237]. They found that lin-4 gene codifies for a ~22-nts non-coding RNA that 
negatively regulates the protein level of lin-14, creating a temporal gradient of this protein, 
necessary for the developmental transition from the first larval stage (L1) to the second one 
(L2). They also demonstrated that this small RNA is complementary with conserved elements 
located in the 3′ untranslated region (3′UTR) of lin-14 mRNA, suggesting that lin-4 
negatively modulates its translation by base-pairing with these sites in the lin-14 3‟UTR. 
Almost 7 years later, the second miRNA, let-7, was identified also in C. elegans. Let-7 
encodes a temporally modulated 21-nts non-coding RNA that negatively controls the 
expression pattern of a subset of genes, fundamental for the later developmental stages, in a 
similar way as for lin-14 regulation by lin-4[238]. Homologs of let-7 were soon identified 
throughout many metazoans, including flies and humans, thus pinpointing let-7 small RNAs 
as evolutionary conserved regulators of the latest developmental stages [239]. A large number 
of different small, endogenous RNAs were successively found in worms, flies and humans, 
associated with a cell-specific rather than a time-specific pattern of expression[240] [241]. This 
implicated a broader role in the cell physiology for this novel class of RNAs, that was 
commonly referred to as microRNAs.   
To date, over 25,000 mature miRNAs have been sequenced from the genome of a wide 
number of plant and animal species, amongst which Homo sapiens‟ encodes more than 2500 
small RNAs, although some of these need to be authenticated[242, 243]. On the other side, more 
than a half of all human protein-coding genes are evolutionarily selected as miRNA gene 
targets[244], supporting the miRNA potential in the control of the expression of most human 
proteins and their related pathways. Indeed, miRNA functions have been widely described in 
numerous physiological processes, including proliferation, differentiation, development, 
apoptosis and stress response[245]. More importantly, deregulated expression of miRNAs has 
been associated with tumourigenesis and metastasis, and implicated in other common 
diseases[246]. As our understanding of miRNA biology continues to improve, miRNA-based 
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therapy as an effective anti-cancer treatment is becoming a much more tangible 
possibility[247]. 
 
1.5.1           MicroRNA genes 
 Large-scale genomic mapping analysis have identified microRNA-coding 
sequences in all chromosomes, with the exception for the human Y chromosome[248]. 
Genomic organisation of miRNA genes can be distinguished as intergenic or intragenic. 
Intergenic miRNAs are found in genomic regions that do not overlap with annotated genes; 
instead they originate from independent transcription units, carrying their own promoters and 
other regulatory elements. Intergenic miRNAs are generally transcribed by RNA Polymerase 
II (Pol II), thus exhibiting typical features of Pol II transcripts, such as capped 5‟ends and a 
polyadenylated tail (polyA) at the 3‟ends[249]. Intergenic miRNAs can be present as individual 
miRNAs or clustered in polycistronic units that encode a long primary transcript (~3-4kb) 
containing more than one miRNA[250].  
Intragenic miRNAs reside in transcriptional units of host annotated genes as single or 
clustered miRNAs; approximately half of all miRNAs are localised in non-protein-coding 
genes[250], whereas the rest are found within the introns of protein-coding genes. Generally, 
intronic miRNA genes share the same promoter regulation as their host genes and 
consequently exhibit similar expression profiling as their host transcripts[251]. Nevertheless, it 
has been reported that intronic miRNAs can be under transcriptional control of their own 
promoters, such as the miR-17-92 cluster, which is localised in intron 3 of the chromosome 13 
open reading frame 25 (C13orf25) gene [252]. Intronic miRNAs are transcribed within the 
intron of their host messenger transcripts, from which they are processed following the 
classical pathway of miRNA biogenesis. In special cases, intronic miRNAs constitute the 
entire intron of a protein-coding gene and are therefore released upon splicing of the host gene 
mRNAs. These are known as mirtrons and typically bypass the first processing event during 
their maturation [253].  
Very rarely, intragenic miRNA are found in regions that overlap an exon and an intron of 
non-protein-coding genes. These are known as exonic miRNAs and their expression is 
coordinated by their host gene promoters[254].    
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1.5.2           MicroRNAs biogenesis 
 
The majority of mirRNAs go through a biogenesis model demarked by maturation 
events necessary for their ultimate function (Figure 17). MiRNA-coding sequences are 
generally transcribed by RNA polymerase II (Pol II), or less frequently by Pol III, yielding a 
long, primary miRNA transcript, called pri-miRNA[249] [255]. After transcription, pri-miRNA 
are capped and polyadenylated at the 5‟ and 3‟ end, respectively and fold in their 
characteristic conformation containing one or more stem-loop structures (hairpins) (Figure 
17). Typically the pri-miRNA hairpin contains a ~33 base-pairs (bp) double-stranded stem 
formed by regions of imperfect complementarity, with flanking single stranded 5‟ and 3‟ 
ends[256]. One of the two strands of the pri-miRNA stem includes the mature miRNA 
sequence, which needs to be excised (Figure 17). Two processing events lead to the 
formation of the mature miRNA. The first takes place in the nucleus and is mediated by the 
so-called Microprocessor complex, which consists of the RNase III endonuclease DROSHA 
and the RNA-binding protein DiGeorge syndrome critical region 8 (DGCR8) (Figure 17)[257] 
After recognition and binding of the stem-loop structure of the pri-miRNA by the 
Microprocessor complex, DROSHA cleaves both strands of the pri-miRNA stem near the 
base of the hairpin, thus releasing a ~60-70-nt stem-loop intermediate, known as miRNA 
precursor (pre-miRNA) (Figure 17)[258]. However, a sub-class of miRNAs (such as intronic 
miRNAs called “mirtrons”) undergo a non-canonical maturation pathway that does not 
require a DROSHA/DGCR8-mediated cleavage event, but instead uses the cellular splicing 
machinery for the formation of the pre-miRNA[253, 259]. Pre-miRNAs consist of a >14 base 
pairs (bp) stem-loop region along with a 5‟phosphate and a 2-nt overhang at the 3‟end. This 
structure is essential for recognition by the nuclear transport receptor Exportin 5 (EXP5)[260], 
that, in complex with a RAN-GTP, exports the pre-miRNA to the cytoplasm via the nuclear 
pore complex (NPC) (Figure 17)[261]. 
The second processing event (maturation) occurs in the cytoplasm by the RNase III 
endonuclease DICER (Figure 17). DICER, first found to be implicated in the process of RNA 
interference (RNAi) by mediating the formation of the small interfering RNAs (siRNAs)[262], 
has also been shown to mediate miRNA maturation[263-265] . DICER recognises the 3‟end of 
the pre-miRNA and cleaves off the loop, generating a ~22-nt dsRNA duplex (miRNA-
miRNA*) with 2-nt overhangs at both 3‟ends (Figure 17). This duplex is formed by a 
functional strand called the guide strand (miRNA) and a complementary strand, known as the 
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passenger strand (miRNA*). In the cytoplasm, DICER is part of a multiprotein complex, 
called the RNA-induced silencing complex (RISC) loading complex (RLC)[248]. This is 
assembled upon interaction of DICER with the dsRNA-binding proteins, TAR RNA-binding 
protein (TRBP)[266] and protein activator of protein kinase R (PACT) in mammals, and 
subsequently with a member of the Argonaute (AGO) protein family. TRBP and PACT 
facilitates DICER-mediated cleavage and the recruitment of AGO protein (Figure 17)[266, 267].  
Following DICER-mediated cleavage, the RLC is disbanded through dissociation from the 
miRNA duplex of DICER and its partners, TRBP and PACT. The double-stranded duplex is 
then unwound by helicase activity (which may not be universal), into the passenger strand that 
undergoes degradation, and the guide strand which forms the active RISC complex (Figure 
17)[268]. The mechanism that controls sorting of the two miRNA strands remains still unclear; 
although some evidences suggest that the thermodynamic stability of the base pairs at the two 
ends of the duplex may be determinant, so that the strand with less base pair stability at its 
5‟end will become the guide strand[269]. This represents the mature miRNA that is loaded onto 
the RISC complex upon interaction of the RISC component AGO with both ends of the 
miRNA strand[270]. The mature miRNA then guides the RISC to a target messenger RNA 
(mRNA) by a mechanism of imperfect base pair complementarity (Figure 17)[271]. The 
mature miRNA interacts with specific sites commonly present in the 3‟untraslated region 
(3‟UTR) of the target mRNA through the so-called “seed” region[272]. This consists of 
nucleotides comprised between positions 2 to 8 from the 5‟end of the miRNA sequence and 
forms a perfect match with the site in the mRNA 3‟UTR. This interaction may be stabilised 
by base pairing of a less stringent degree of the 3‟end of the miRNA, whereas central bulges 
are commonly formed due to the presence of mismatches predominantly in the centre of the 
miRNA sequence. In rare cases, near-perfect complementarity is observed between the 
miRNA sequence and its target site[273], resembling the complete base-pairing occurring 
between the siRNA and its mRNA target during the process of RNA interference (RNAi) 
(Figure 17)[274, 275]. Depending on the degree of complementarity established after interaction 
between the miRNA and its target mRNA, a distinctive AGO composition of the RISC 
complex will be observed. In mammals, the AGO protein family consists of 4 members 
(AGO1-4), which all function in miRNA-mediated post-transcriptional repression of target 
mRNAs, whereas only AGO2 exhibits additional RNAse III endonuclease activity. In the 
majority of the cases, imperfectly matched miRNA-mRNA duplexes are formed upon 
interaction of the miRNA with its mRNA target, and any of the four AGO members can 
associates with these heteroduplexes. On the other hand, when a perfect miRNA-mRNA 
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1.5.3           MicroRNAs functions 
 MiRNAs are important physiological regulators of gene expression in plants and 
animals, thus their function has been demonstrated in a wide range of cellular processes[276].   
Generally, miRNAs inhibit gene expression at the post-transcriptional level, by inducing 
either translational repression or degradation of their mRNA targets. The degree of 
complementarity in the miRNA-mRNA interaction determines one or other mechanism of 
inhibition. In the vast majority of the cases, poor base pair alignment is sufficient for the 
translational repression of miRNA targets. For this reason, it is not surprising that each 
miRNA is able to inhibit multiple genes, and one single mRNA can be targeted by several 
miRNAs[277]. On the other hand and in very few cases, highly matched mRNA targets 
preferentially undergo degradation induced by AGO2-mediated endonucleolytic cleavage. 
MiRNA-mediated translational repression can occur through different mechanisms, which 
include: (1) inhibition of translation at the initiation stage; (2) block of translation at post-
initiation stages; and (3) repression of translation by deadenylation and/or degradation of the 
target mRNA. 
Translational inhibition at the initiation step was first observed after identification of a cap-
binding-protein-like motif in human AGO2 proteins; AGO2 was found able to bind to the 
m7G cap on a target mRNA, thus competing with the cap-binding protein eukaryotic 
translation initiation factor 4E (eIF4E) and subsequently inhibiting the initiation of translation 
of specifically capped mRNAs (Figure 18)[278]. Alternatively, translation initiation could be 
inhibited by the miRNA silencing machinery that impedes recruitment of the ribosomal 
subunits or formation of mature ribosomal complex at the 5‟end of the mRNA (Figure 
18)[279].  
Additionally, miRNAs have been found able to repress translation of their mRNA targets at 
post-initiation steps; a mechanism that was firstly suggested by the evidence that several 
mature miRNAs and AGO proteins co-localise with polysomal fractions both in mammals[280] 
and plants [281]. Various mechanisms of translational inhibition at post-initiation steps have 
been described. MiRNAs may impede elongation by either “dropping-off” translating 
ribosomes from the target mRNA, thus promoting premature termination[282], or inducing co-
translational degradation of the nascent polypeptides (Figure 18)[283].  
Finally, translational inhibition has been also shown to be achieved by miRNA-mediated 
mRNA degradation. By doing so, miRNAs affect target mRNA levels, thus decreasing their 
availability to the translational machinery. MiRNAs induce removal of the poly(A) tail at the 
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3‟end of the mRNA sequence by recruiting the deadenylation complex C-C chemokine 
receptor 4 (CCR4)-NOT1 (Figure 18)[284]. Deadenylase recruitment to the miRNA-silencing 
machinery is orchestrated by the AGO-interacting glycine-tryptophan [GW] repeat-containing 
protein of 182 kDa (GW182) which directly interacts with the complex NOT1[285]. Via 
GW182 interaction, the functional RISC is localised to specific foci within the cytoplasm, 
called processing bodies (P-bodies), where mRNA turnover occurs. In P-bodies, mRNA 
targets are in fact, decapped by decapping enzyme 1 and 2 (DCP1/DCP2) complexes[286], and 
therefore exposed to exonucleolytic digestion by the cytoplasmic 5‟-to-3‟exonuclease 
XRN1[248]. In cases of high-grade complementarity between the miRNA and the target 
sequence, AGO2 complexes within the RISC and directly induce mRNA degradation by 
endonucleolytic cleavage (Figure 18). Indeed, AGO2, also known as “slicer”, cleaves the 
phosphodiester bond at the mRNA sequence corresponding to the tenth and eleventh 
nucleotides of the miRNA guide strand. AGO2-interacting GW182 brings the active AGO2-
RISC to the P-bodies, where the cleaved mRNA is completely degraded (Figure 18): the 3' 
fragment of the mRNA is destroyed by the exonuclease XRN1, while the 5' fragment is 
degraded by the exosome, a complex composed by different exonucleases involved in 3'-5' 
RNA degradation[287]. 
Although miRNAs are universally recognised for their negative post-transcriptional regulation 
of gene expression, recent findings have raised the possibility of alternative functions of 
miRNAs, also at additional levels of gene expression. Indeed miRNAs can exhibit the ability 
to promote post-transcriptional translation, in the presence of certain conditions. An example 
of miRNA-mediated translational activity is given by miR-369-3: under serum starvation 
conditions, this miRNA interacts with the 3‟UTR of the tumour necrosis factor α (TNFα) 
mRNA via AGO2-RISC complex, which recruits the fragile X-related protein 1 (FXR1) and 
stimulates mRNA translation[288].  
Moreover, recent evidence indicates a role for miRNAs in the nucleus at the transcriptional 
level, by either inhibiting or activating gene expression. For example, miR-320 has been 
shown to silence transcriptional expression of the cell cycle gene DNA-directed RNA 
polymerase III subunit RPC4 (POLR3D), by inducing recruitment of epigenetic mediators at 
the promoter of this gene in mammalian cells[289]. On the contrary, miR-373 is able to interact 
with complementary sites present in the promoter of the E-Cadherin and cold-shock domain-
containing protein C2 (CSDC2) gene; this interaction is associated with Pol II enrichment at 
the transcription starting sites of these genes, which initiates their transcriptional 
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1.5.4           Regulation of miRNA biogenesis 
The process of miRNA biosynthesis is subject to several control mechanisms that can 
be time-dependent, as seen for the temporal regulation of both lin-4 and let-7 expression, as 
well as organism/tissue-specific. Nonetheless, differential regulative control may apply only 
for a subset of miRNAs; more importantly, aberrant regulation of miRNA expression may 
contribute to pathogenesis, such as diseases and cancer. 
There are three levels of regulation of miRNA biogenesis: pre-transcriptional, transcriptional, 
and post-transcriptional[292].  
Many factors can affect miRNA expression at the pre-transcriptional level. Amongst them, 
genomic instability can lead to gain or loss of miRNA gene copy number; this has been 
widely observed in different types of cancers, as result of events of amplification, 
translocation or deletion of loci containing miRNA genes[293]. Additionally, miRNA gene 
expression is controlled by epigenetic mechanisms, such as DNA methylation and histone 
modification[292]. In fact, many miRNA genes are located in CpG islands, such as miR-127 
which is silenced upon promoter hypermethylation in bladder cancer, and let7a-3, found to be 
highly methylated in normal lung tissues, but hypomethylated and up-regulated in lung 
cancer[294, 295]. 
MiRNA transcription is the most highly regulated step of the miRNA biogenesis process. 
Most of the miRNA genes are controlled by their own promoters which are transcribed by Pol 
II; this suggests that miRNA genes share the same transcription factors and other regulatory 
elements as the protein-coding genes. In fact, it has been shown for example that the 
transcription factor c-MYC directly induces expression of the miR-17-92 cluster during both 
B-cell proliferation and estrogen receptor (ER) activation in normal breast cells[296, 297]. On the 
other side, miRNA regulation by transcription factors has been amply associated to 
tumourigenesis. C-MYC-mediated activation of the miR-17-92 cluster or repression of several 
miRNAs, such as miR-15a, -29, -34, -23 and let-7 families leads to lymphoma initiation and 
progression[298] [299]. Another master-gene regulator, p53, controls the expression of many 
miRNAs[300], including miR-23, miR-26 and miR-34 families, the latter described as a key 
effector of the p53 tumour suppressor function[301, 302]. Furthermore, androgen receptor (AR) 
increases the abundance of miR-125b at the transcriptional level in prostate cancer cells[303] 
and the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) regulates miR-
155 transcriptional regulation during lymphomagenesis[304].  
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In a similar way as for tumour suppressors and oncogenes, negative or positive regulation of 
miRNA expression by transcription factors can imply a state of cellular transformation that 
likely results in malignancy potential. Therefore, identification of putative miRNA regulators 
is of critical importance for the development of therapeutic strategies aimed to either restore 
silenced miRNAs or inhibit excessive miRNA expression. For this purpose, characterisation 
of miRNA promoters facilitates prediction of potential transcription factors that control the 
expression of specific miRNAs. Detailed information about promotor regions found in the 
entire human genome are provided by the ENCyclopedia of DNA Elements (ENCODE) 
Project and are available on the University of California, Santa Cruz (UCSC) Genome 
Browser[305]. Started in 2003, the ENCODE Project collects data from research groups 
worldwide about all functional elements in the human genome sequence. These include: 
histone modifications, transcriptional regulatory elements, Pol II and Pol III transcription 
starting sites (TSS) and binding positions for many transcription factors, such as c-MYC, c-
FOS, c-JUN, E2F1, STAT1 and NF-κB identified in the whole genome by chromatin 
immunoprecipitation-sequencing (ChIP-seq) analysis in 27 human cell lines. From this tool, 
researchers can obtain preliminary information about possible regulatory mechanisms of a 
given miRNA that need to be experimentally validated [306]. 
After transcription, several steps of the miRNA maturation pathway can be exposed to 
external regulation. One example is given by miRNA-specific mechanisms that control 
DROSHA-mediated processing of the pri-miRNA. Although the DROSHA-DGCR8 
Microprocessor complex processes many pri-miRNAs; a subset of miRNAs are maturated by 
a larger complex, which contains along with DROSHA and DGCR8, several additional 
factors[307]. Among these the RNA helicases p68 and p72 have been shown to be essential for 
the processing of specific pri-miRNAs[308]. Furthermore, the heterogeneous nuclear 
ribonucleoprotein A1 (hnRNP A1) binds specifically to pri-miR-18a increasing DROSHA 
processing rate[309].  
Secondly, miRNAs are regulated at the DICER processing step. For example, pre-miR-138 is 
expressed ubiquitously but its mature form is restricted just to certain cell types, indicating 
tissue-specific DICER processing of this miRNA[310]. Additional regulatory mechanisms of 
miRNA formation were identified after observation that LIN-28 is a stem-cell-specific 
regulator of let-7 post-transcriptional maturation at both DROSHA and DICER level. In the 
nucleus, LIN-28 inhibits Microprocessor-mediated cleavage of pri-let-7[311], by competing 
with DROSHA[312, 313]. In the cytoplasm, LIN-28 is able to inhibit DICER-mediated cleavage 
of the pre-let-7 family member [314] by recruiting a terminal uridylyl transferase (TUTase) to 
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the precursor. The uridylated pre-let-7 (up-let-7) cannot be processed by DICER and is 
degraded by an unidentified nuclease[315]. Furthermore, Trabucchi et al. linked the KH-type 
splicing regulatory protein (KSRP) to the machinery regulating miRNAs maturation. They 
showed that KSRP is part of both DROSHA and DICER complexes and regulates the 
biogenesis of a subset of miRNAs in mammalian cells. KSRP binds with high affinity to the 
terminal loop of the target miRNA precursors and promotes their maturation. This mechanism 
of regulation provides differential expression patterns of target mRNAs that affect specific 
biological programs, including proliferation, apoptosis and differentiation [316]. 
 
 
1.5.5           Bioinformatic prediction and experimental validation of 
miRNA targets 
 
MiRNA function is mediated by repressing translation of target mRNAs, thus 
identification of the targets is of crucial importance in understanding the biological role(s) of 
a miRNA. Target recognition by a miRNA is determined predominantly by the degree of 
complementarity between the miRNA-binding site contained in the target 3‟UTR and the 
miRNA “seed” region, with less contribution from the 3' region of the miRNA[272, 317]. Based 
on the complementarity prerequisite and other determinants of miRNA-mRNA interactions, 
several research groups have elaborated various computational algorithms for the prediction 
of miRNA targets. These in silico systems base their predictions on the following three 
criteria: (1) perfect alignment between the miRNA seed and the 3'UTR of the target mRNA; 
(2) structural and thermodynamic stability of miRNA-target duplex, and (3) degree of 
evolutionary conservation of miRNA target sites. Examples of algorithm search for miRNA 
target prediction are TargetScan, PicTar, RNAhybrid, DIANA-MicroT miRanda, and miRbase, 
which are freely accessible on the web and are widely used to identify putative miRNA 
targets[318-320]. Despite being based on the same parameters, these methods use different 
approaches in elaborating computational predictions based on sequence alignments; for this 
reason, different algorithms give variable outputs of putative target sites for a specific 
miRNA, with plausible false positive production[321]. Therefore, predicted targets need to be 
experimentally validated in order to identify the true mRNA target(s) and elucidate miRNA 
functional roles[322]. 
Experimental validation of putative miRNA targets can be assessed in several different ways. 
Firstly, reporter systems are widely used in assessing for interaction of a given miRNA with 
its cognate mRNA. They consist of cloning the entire 3‟UTR of the predicted target in a 
Introduction 
81 
 
plasmid vector downstream of the open reading frame of a reporter gene, such as a luciferase, 
and co-expressing the reporter vector and the miRNA of interest into a cellular system. 
Assayed reduction of reporter activity/expression is evidence of interaction between the 
miRNA and its predicted binding site[318]. Concomitant use of appropriate controls, such as 
vectors with mutated miRNA-binding sites, proves direct interaction and also eliminate any 
non-functional miRNA binding site that have been predicted for one or more target mRNAs.  
For this interaction to happen in physiological conditions, it is necessary that both miRNA 
and its putative target(s) are co-expressed in the same cell models or tissue samples. 
Expression profiles of miRNAs and relative gene targets are usually obtained by quantitative 
real-time polymerase chain reaction (qPCR), Northern blotting and in situ hybridization 
assays. 
Further, experimental validation of true miRNA targets is achieved by using both miRNA 
gain and loss of function approaches. In the first case, increase in miRNA levels is obtained 
by transient overexpression of a synthetic miRNA mimic in a cell model expressing the target 
mRNA. Consistent with miRNA-induced repression of target translation, decrease in the 
amount of protein encoded by the target mRNA is expected and can be quantified by Western 
blot analysis. Nevertheless, it has been demonstrated that reduction of target protein levels by 
miRNAs is variable and relatively mild, probably depending on the intracellular abundance of 
the target product and on the fact that a single miRNA can simultaneously target several 
genes[323]. Since miRNAs are also able to promote destabilisation and turnover of target 
mRNAs[284], predictable changes in the abundance of target messengers can be quantified 
(i.e., by real-time qPCR).  
Nevertheless, gain of function experiments alone for the validation of miRNA targets are not 
an ideal approach, since the robust intracellular increase of a given miRNA induced by 
ectopic overexpression of a miRNA mimic could result in regulation of a subset of genes that 
are normally not targeted by this miRNA, when it is expressed at physiological levels. 
Therefore, experimental miRNA inhibition would increase the chance of identifying true 
target mRNAs. In fact, silence of the activity of a given miRNA leads to the up-regulation of 
specific genes that represent its physiological targets, because their up-regulation is the direct 
result of the impaired miRNA-mediated repression, caused by the experimental inhibition of 
the endogenous miRNA activity. Nevertheless, it has been shown that the distinct gene targets 
found repressed after engineered overexpression of a given miRNA are found with high 
similarity also after inhibition of the same miRNA[323], indicating that miRNA over-
expression experiments may be still reliable. Therefore, combination of these two 
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experimental approaches would allow identification of the true physiological miRNA targets 
with a higher probability than each approach would do alone.  
MiRNA loss of function (inhibition) is achieved by using miRNA inhibitors, such as synthetic 
oligonucleotides (anti-miRNAs) and miRNA-sponges. Both methods silence miRNA function 
by preventing assembly of functional miRISC, which is reflected in an increase of miRNA 
targets levels. Anti-miRNAs are oligonucleotides with miRNA-specific reverse complement 
sequence and anneal to the mature miRNA, thus competing with target mRNAs for 
binding[324]. MiRNA-sponge vectors encode transcripts expressed from strong promoters (Pol 
II promoters) containing multiple, tandem miRNA binding sites in their 3‟UTR, that sequester 
intracellular mature miRNA from interaction with its target mRNAs. MiRNA-sponge systems 
have been shown to induce equal or higher degree of miRNA silencing compared to anti-
miRNA activity[325]. Moreover, miRNA-sponge vectors expressing miRNA inhibitors in 
conjunction with reporter genes (i.e. luciferase or green fluorescent protein [GFP]) allow 
sorting of sponge-treated cells, as well as prolonged miRNA silencing from stable 
chromosomal integration of these sponge-transgenes. This represents a great advantage since 
maximal effect of miRNA-mediated target repression is usually observed after prolonged 
miRNA inhibition[326]. Therefore, miRNA-sponges constitute a reliable method for 
investigation of tissue-specific miRNA function in vivo[327]. 
Following validation of predicted miRNA targets, it is necessary to determine the impact of 
this regulation on biological processes in which the validated targets are involved. Commonly 
used experimental approaches are assays of cell proliferation/apoptosis, cell differentiation, 
cell migration/invasion, signalling pathways and in vivo experimental procedures, depending 
on the target protein involved. However, large-scale miRNA target predictions may 
complicate investigation of the biological function of a given miRNA, as an excessive number 
of predicted targets imply a potential role for a given miRNA in numerous cellular processes. 
Web-based bioinformatics resources, such as the Database for Annotation, Visualisation and 
Integrated Discovery (DAVID)[328] and the Gene Ontology (GO)[329] databases, are able to 
process large lists of genes giving outputs of biological meanings, such as cellular pathways 
enriched for a subset of genes. Use of these resources provides a more stringent approach in 
large-scale analysis of the physiological function of a specific miRNA.     
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1.5.6           MicroRNAs and cancer 
Under normal physiological conditions, miRNAs take their part in the complex 
regulatory machinery that maintains the cell “in shape”. MiRNAs are present when a cell 
proliferates, tries to survive or must die; they help the cell fight against external enemies or 
evolve and differentiate; they work for a cell to find its place in the environment and 
communicate with other cells.   
As for protein-coding genes, alterations in the normal expression pattern of miRNAs disrupt 
the intracellular equilibrium, thus establishing favorable conditions for diseases and cancer.  
Dysregulation of miRNAs is a very common feature in cancer. As mentioned before, miRNA 
genes are under the control of genetic and epigenetic mechanisms, such as transcription 
factors, promoter modifications and events of genomic instability, that link miRNA 
deregulation to a state of malignancy[293, 294, 298]. Different types of cancer exhibit 
characteristic miRNA expression profiles, so much so, that miRNAs have been elected good 
markers for cancer classification, diagnosis and prognosis[330]. Although some miRNAs are 
overexpressed in cancer cells, such as the oncogenic cluster miR-21[331], an overall down-
regulation is commonly observed[332]. This phenomenon is usually attributed either to 
overexpression or hyperactivation of oncogenic transcription factors, such as c-MYC, known 
to repress a plethora of miRNAs in different cancers[298], or to deregulation of the miRNA 
biogenesis machinery[333], both commonly observed in cancer. For example, in vivo studies 
have demonstrated that depletion of DICER1 and DROSHA impairs miRNA processing, 
resulting in cellular transformation and tumourigenesis[334]; accordingly, reduced DICER1 and 
DROSHA expression have been associated with poor prognosis of cancer patients[335].    
Deregulation of individual or clustered miRNAs has a direct impact on cancer phenotypes, 
depending on their specific target repertoire and, therefore, on the cancer networks that 
miRNAs interact with.  Indeed, oncogenic miRNAs negatively regulate tumour suppressors, 
whereas tumour suppressor miRNAs often target protein-coding oncogenes. 
Generally, oncogenic miRNAs, known as oncomiRs, are positively regulated in order to 
repress pro-apoptotic, anti-growth and reprogramming signals, typically controlled by tumour 
suppressors. One such miRNA with a defined oncogenic function is miR-21, which shows 
aberrant expression in different types of cancer[336]. Mir-21 promotes tumourigenesis at 
different levels: by accelerating cell cycle and growth through repression of the tumour 
suppressor phosphatase and tensin homolog (PTEN)[337]; and by inducing neoplastic 
transformation and anchorage-independent growth of BC cells via repression of the program 
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cell death 4 (PDCD4) and the tumour suppressor Tropomyosin 1 (TMP1), respectively[338, 339]. 
Additionally, oncomiRs negatively regulate critical modulators of the cell cycle, including 
inhibitors of cell division kinases (CDK) or transcriptional repressors of the retinoblastoma 
(RB) family. By doing so, oncomiRs facilitate cell cycle entry and phase transition, thus 
contributing to tumour development[340].  
On the other hand, inhibition of miRNA expression determines general up-regulation of 
protein-coding oncogenes, commonly associated with anti-apoptotic and pro-survival 
phenotypes. One of the best characterised oncosuppressor miRNA is the miR-34 family, 
which has been shown to mimic major functions of its positive regulator p53, including 
induction of growth arrest and apoptosis (reviewed in[341]). MiR-34 members regulate these 
processes by targeting several genes, such as the anti-apoptotic protein BCL2 and numerous 
cell cycle regulators, including the cell division kinases 4 and 6 (CDK4 and 6), cyclin E2 and 
the eukaryotic transcription factor E2F3[301]. It is clear how depletion of the miR-34 family, 
which occurs in a number of cancers, is critical for tumour initiation and progression[342].  
Moreover, miRNAs exhibit tumourigenic potential by targeting components of the epigenetic 
machinery, such as DNA methyltransferases 3A and B (DNMT3A and B), repressed by miR-
29 in lung cancer[343], and the histone methyltransferase EZH2, inhibited by miR-101 and 
miR-26a in prostate and BC, respectively[344]. This epigenetic regulation by miRNAs implies 
genome-wide changes that affect gene expression in a hereditable way; thus miRNAs 
indirectly contribute to cancer cell reprogramming[345].    
Classification of miRNAs in view of their potential role during cancer pathogenesis is very 
often complicated by the observation that miRNAs can act as both oncogenes and tumour 
suppressors[245]. This discordance mainly depends on the cellular context in which miRNAs 
are expressed and the expression pattern of target mRNAs. This implies that miRNAs can 
participate in distinct pathways, thus differentially affecting cell proliferation, growth and 
survival pathways. An example of this controversial situation is offered by the miR-17~92 
polycistron: in human B-cells, which overexpress c-MYC, this cluster functions as a tumour 
suppressor by inhibiting c-MYC-mediated cell proliferation via repression of E2F1; 
contrarily, miR-17~92 exhibits oncogenic activity in B-cell lymphoma where it cooperates 
with c-MYC to impede apoptosis[346]. Moreover, evidence demonstrates that individual 
members of the miR-17~92 polycistron (consisting in miR-17, -18, -19a, -20, -19b1, -92a1) 
have opposite roles in the tumourigenesis of the same type. In fact, in BC miR-17 impairs 
anchorage-independent cell growth by targeting the oncogenic nuclear receptor coactivator 3 
amplified in breast 1 (AIB1), which cooperates with nuclear estrogen receptor in modulating 
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gene expression[347]. MiR-19, instead, repress expression of PTEN and function as an 
oncomiR in breast tumours[348]. This evidence suggests that despite their similarity in 
sequence, related miRNAs can differently contribute to cancer development by repressing 
distinctive pattern of gene targets.  
MiR-23b and miR-26a represent another two examples of miRNAs with opposite roles in 
tumour initation and progression and they are further discussed in detail in 1.4.6.1 and 1.4.6.2, 
respectively.   
 
1.5.6.1         MiR-23b in cancer 
Mammalian miR-23b is a 21-nt microRNA, ubiquitously expressed, that belongs to 
the miR-23 family. This consists of two cluster paralogs that originated by ancient gene 
duplications: miR-23a~27a~24-2 cluster and its paralogous miR-23b~27b~24-1 cluster. The 
first is an intergenic cluster localised on chromosome 19p13 (C19p13), while the second is 
located on C9q22 and is intronic[349]. 
The expression of the miR-23b~27b~24-1 cluster is controlled by a complex transcription unit 
(TU), Chromosome 9 open reading frame 3 (C9orf3). The product of this gene is a unique 
primary transcript which is processed in three mature miRNAs: miR-23b, miR-27b and miR-
24-1. Mature sequences of miR-23b and miR-27b differ by just one nucleotide from their 
paralogs miR-23a and miR-27a: the third nucleotide from the 3‟end in both cases; whereas 
mature miR-24-2 and miR-24-1 have the same sequence[350]. The high degree in sequence 
similarity, predominantly in the 5‟end where the seed region resides, suggests that miR-23b 
and miR-23a, as well as the other two couples of paralogs, can interact with the same patterns 
of target mRNAs. In fact, target prediction programs, such as TargetScan[351] extrapolate 
common targets of miR-23a and miR-23b and miR-27a and miR-27b.  
The role of miR-23b in cancer initiation and progression has been largely investigated, but a 
clear function for miR-23b as either onco-miR or tumour suppressor has not yet been defined. 
The first evidence of a miR-23b involvement in cancer indicated that the overexpression of 
miR-23b mimics in human colorectal cancer cells leads to inhibition of their proliferative and 
migratory capabilities. MiR-23b was found to induce these phenotypes by direct repression of 
the urokinase-type plasminogen activator (uPA) and the proto-oncogene c-MET[352]. uPA was 
subsequently confirmed to be a direct target of miR-23b in an additional two studies. In an 
elegant work based on high-throughput screens of miRNAs with a role in cell migration, miR-
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23b was shown to negatively regulate tumour growth, invasion and angiogenesis in in vivo 
experimental human colon cancer metastasis, by inhibiting a cohort of pro-metastatic genes, 
including, FZD7, MAP3K1, uPA and PAK2[353]. This evidence confirmed a tumour 
suppressive role of miR-23b in human colorectal cancer. The third report validating uPA as 
miR-23b target revealed that experimental miR-23b overexpression reduces uPA levels, thus 
leading to reduced migration of human cervical cancer cells[354]. In the same study, it was also 
observed that loss of miR-23b expression correlates with HPV (human papilloma virus)-
associated cervical cancer development: HPV reduces miR-23b synthesis via inactivation of 
p53, which was found to bind p53-specific binding sites in the promoter of miR-23b, thus 
resulting in its transcriptional activation. This work demonstrated that HPV-mediated 
inhibition of the p53/miR-23b/uPA pathway contributes to HPV-associated cervical cancer 
development.   
Additional studies have reported a tumour suppressor activity for miR-23b also in prostate 
cancer. Dahiya et al.[355] showed that methylation-induced silencing of miR-23b in prostate 
cancer confers proliferative and invasive advantages, as miR-23b reconstitution inhibited 
proliferation, apoptosis, colony formation, EMT and migration/invasion of prostate cancer 
cells in vitro and in vivo. The functional effect of miR-23b was found to be mediated by 
coordinated repression of proto-oncogene SRC kinase and AKT, reduction of the 
mesenchymal markers Vimentin and Snail and increase of E-Cadherin. Moreover, miR-23b 
was reported to cooperate with miR-27b in suppressing migration, invasion and anoikis in 
highly metastatic prostate cells that manifested impaired activation of RAC1 and up-
regulation of E-Cadherin following reconstituted miR-23b expression[356].  Further, as 
mentioned before, the oncogenic transcription factor c-MYC is able to transcriptionally 
repress miR-23b and miR-23a in human P-493 B lymphoma cells and PC3 prostate cancer 
cell line. c-MYC-mediated reduction of the two paralogs results in release from repression of 
their target protein, mitochondrial glutaminase (GLS), which enhances glutamine metabolism, 
a physiological process that provides energy to sustain tumour growth[299]. 
Finally, in a recent study Lin et al. described an oncogenic role for both miR-23b and miR-
27b in the development and progression of BC[357]. They firstly observed that both miRNAs 
were up-regulated in BC patient samples compared to normal specimens. Then, they found 
that expression of miR-23b/27b is positively regulated by HER2/NEU, EGF, and TNFA 
through the AKT/NF-κB signalling pathway. Additionally, by using miRNA loss-of-function 
approaches, they demonstrated that suppression of miR-23b/27b activity in a highly 
metastatic BC cell line (MDA-MB-231-4175) impaired tumour growth and metastasis in vivo. 
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This effect was attributed to release from miR-23b/27b-mediated repression of Nischarin, a 
novel intracellular protein that shows preliminary functions in inhibiting migration. This role 
for miR-23b in BC is in contrast with observations that experimental suppression of miR-23b 
function was associated with increased migratory abilities of BC MCF-7 cells[353] and that 
expression of miR-23b/27b was down-regulated in HER2/NEU-transformed mammary 
epithelial cells[358]. Finally, we performed a detailed analyses of expression levels of three 
miR-23 family members (miR-23b, miR-27b and miR-23a) obtained from published data 
using the GEO2R software in Gene Expression Omnibus (GEO)[359]. This has revealed that 
none of these miRNAs is differentially expressed in metastatic versus primary tumour versus 
normal tissue/cell lines of breast origin; whereas they are significantly deregulated during 
colon and prostate cancer initiation/progression (Table 1).  
 
Table 1. MiR-23b/27b/23a expression in tissutal or cellular samples of different tumour types 
from 8 Genome Expression Omnibus (GEO) datasets. P values and fold changes were calculated 
by using unpaired, two-tailed t tests by using Graph Prism software. 
Tumour 
type 
Dataset 
(GEO) 
n Samples miR-23b miR-27b miR-23a 
 
Breast 
 
 
GSE26659 94 PT vs. normal tissues NS NS NS 
 
Breast 
 
GSE39543 
 
51 
 
PT vs. normal tissues 
 
NS 
 
NS 
 
NS 
       
 
Breast 
 
 
GSE32922 37 PT vs. normal tissues NS NS NS 
 
Breast 
 
 
GSE45666 116 PT vs. normal tissues NS NS NS 
 
 
Breast 
 
 
 
GSE37407 
 
22 
29 
19 
19 
29 
 
PT vs. normal tissues 
BM vs. PT tissues 
LM vs PT tissues 
SM vs. PT tissues 
LN vs.PT tissues 
 
NS 
NS 
NS 
NS 
NS 
 
NS 
NS 
NS 
NS 
NS 
 
NS 
NS 
NS 
NS 
NS 
 
Breast 
 
GSE40056 
 
10 
8 
 
A vs. LA cell lines 
LA. vs. I cell lines 
 
NS 
NS 
 
NS 
NS 
 
NS 
NS 
 
 
Colon 
 
GSE35834 
 
53 
 
52 
LM vs. PT tissues 
PT vs. normal 
tissues 
NS 
Down, P=0.0003 
fc:-0.5280 
NS 
Down, P<0.0001 
fc:-0.64313 
NS 
Up, P<0.0001 
fc:0.4113 
 
 
Prostate 
 
 
GSE35834 
 
113 
 
126 
 
Met vs. PT tissues 
 
PT vs. normal tissues 
 
Down, P<0.0001 
fc:-1.909 
Down, P<0.0001 
fc:-0.6348 
 
Down, P<0.0001 
fc:-1.749 
Down, P<0.0001 
fc:-0.6793 
 
Down, P<0.0001 
fc:-0.8689 
Down, P=0.0004 
fc:-0.4139 
Key: PT, primary tumour; BM, brain metastasis; LM, liver metastasis; SM, skin metastasis;  Met, metastasis; fc, 
fold change; NS, non-significant; A, aggressive (MDA-MB-231, HS578T, BT549, SUM159); LA, less 
aggressive (BT474, MDA-MB-468, T47D, ZR75-1, MCF-7, SK-BR3); I, immortalised (MCF-10A, MCF-12A).  
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1.5.6.2         MiR-26a in cancer 
Mir-26a is a ubiquitous 22-nt miRNA, and, along with miR 26b, is a member of the 
miR-26 family. Evolutionary events have determined localisation of the genomic loci of miR-
26a and miR-26b within the introns of genes that encode for three members of the carboxy-
terminal domain RNA polymerase II polypeptide A small phosphatase (CTDSPs) family: 
CTDSPL (CTDS phosphatase-like), CTDSP1 and CTDSP2. Mature miR-26a derives from 
two miRNA precursor paralogs, pre-miR-26a-1 and pre-miR-26a-2, of which sequence 
resides in the fifth intron of CTDSPL and CTDSP2 gene, respectively. The fourth intron of 
CTDSP1 contains the pre-miR-26b, which is then processed to release mature miR-26b[360] 
[361]. The nucleotide region between nucleotides at position 1 and 9 is the same in both miR-
26a and miR-26b mature sequences; therefore prediction of common targets is valid also for 
these two miRNA paralogs. 
MiR-26a has been implicated in a large variety of cancers, exhibiting different roles 
depending on the tissue-context.  
Two independent studies reported that miR-26a expression is reduced in hepatocellular 
carcinoma (HCC)[362] [363]. In a first report, recovered miR-26a expression in HCC cell lines 
was able to induce cell cycle arrest and apoptosis through repression of cyclins D1 and E2[362]. 
Similar phenotypes were observed in a second report, where miR-26a works synergistically 
with miR-26b, as well as their host genes CTDSP1/2/L, to block G1/S phase progression in 
HCC cells. Moreover, miR-26a/26b, concomitantly expressed with their host genes, were 
negatively regulated by c-MYC, accelerating HCC cell cycle[363]. Decreased levels of miR-
26a in HCC compared to normal tissues were also confirmed by another clinical dataset as 
shown in Table 2.  
C-MYC-mediated repression of miR-26a was also depicted in lymphoma cells and associated 
with lymphomagenesis. Accordingly, miR-26a was found to be down-regulated in primary 
human Burkitt lymphoma and its ectopic expression impairs cell proliferation of c-MYC-
dependent cells, through down-regulation of the histone methyltransferase EZH2[364]. Further, 
decreased expression of miR-26a correlates with increased levels of EZH2 in 
rhabdomyosarcoma[365]. The same correlation was also observed in BC. Indeed, experimental 
overexpression of miR-26a in MCF-7 BC cells inhibits oncogenic EZH2 and methaderin 
(MTDH), resulting in cell cycle arrest, apoptosis and inhibition of colony formation in vitro 
and impaired tumourigenicity of these cells in vivo[366]. Accordingly, trastuzumab treatment of 
BC cell lines induces miR-26a expression, an event that induces cell cycle arrest in G1 phase 
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and apoptosis[367]. In addition, tumour suppressive function of miR-26a in BC is shown also 
by regulating proliferation, apoptosis, migration and colony formation via miR-26a-induced 
depletion of the anti-apoptotic myeloid cell leukemia sequence 1 (MCL1)[368]. Nevertheless, 
analyses of further clinical datasets available on GEO database reveals that miR-26a/26b are 
not found consistenly down-regulated in BC tissue samples and that miR-26a expression is 
higher in BC cell lines compared to immortalized normal cells (Table 2).  
On the contrary, miR-26a has been shown to have oncogenic activity in other types of cancer. 
For example, it induces cholangiocarcinoma growth by targeting glycogen synthase kinase 
(GSK)-3β; miR-26a-mediated intracellular reduction of GSK-3β leads to activation of β-
catenin, which in turn induces expression of oncogenic, proliferative genes, such c-MYC, 
Cyclin D1 and peroxisome proliferator-activated receptor δ (PPARδ)[369]. Furthermore, miR-
26a is amplified in high grade glioma and enhances in vivo glioma initiation by inhibiting 
PTEN[370]. 
 
Table 2. MiR-26a/26b expression in tissutal or cellular samples of different tumour types from 8 
Genome Expression Omnibus (GEO) datasets. P values and fold changes were calculated by using 
unpaired, two-tailed t tests by using Graph Prism software. 
 
 
Tumour 
type 
Dataset 
(GEO) 
n Samples miR-26a miR-26b 
 
Breast 
 
GSE26659 94 PT vs. normal tissues 
 
Down P<0.0001 
fc: -1.408 
 
Up, P<0.0001 
fc: 0.6561 
 
Breast 
 
GSE39543 51 
 
PT vs. normal tissues 
 
NS NS 
 
Breast 
 
GSE32922 37 PT vs. normal tissues 
 
Down, P=0.0180 
Fc: -0.9863 
 
Down, P=0.0047 
Fc: -2.171 
 
 
Breast 
 
 
GSE45666 
 
116 
 
PT vs. normal tissues 
 
Down, P<0.0001 
fc: -2.907 
 
Down, P<0.0001 
fc: -5.109 
 
 
 
Breast 
 
 
GSE40056 
10 
 
8 
A vs. LA cell lines 
 
LA. vs. I cell lines 
 
Down, P=0.0108 
fc:-1.163 
Up, P=0.0396 
fc:1.394 
 
 
Down, P=0.0024 
fc:-2.747 
 
NS 
 
 
 
Colon 
 
GSE35834 52 PT vs. normal tissues 
 
Down, P=0.0094 
fc:-0.3821 
NS 
 
Prostate 
 
GSE35834 123 PT vs. normal tissues 
 
Down, P=0.0094 
fc:-0.3423 
NS 
Key: PT, primary tumour; fc, fold change; NS, non-significant; A, aggressive (MDA-MB-231, 
HS578T, BT549, SUM159); LA, less aggressive (BT474, MDA-MB-468, T47D, ZR75-1, 
MCF-7, SK-BR3); I, immortalised (MCF-10A, MCF-12A).  
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1.5.6.3         MicroRNAs and metastasis 
 
Along with their role in cancer initiation, miRNAs have been unraveled as important 
regulators of metastatic progression, insomuch as they are commonly referred as metastamirs 
[371]. MiRNAs are able to affect expression and function of genes involved in cell adhesion, 
cytoskeletal remodelling, and cell signalling pathways, known to direct multiple steps of the 
metastatic process[372].  
Recent reports have shown that miRNAs can modulate formation and maintenance of cell-cell 
and cell-matrix adhesions, leading to outcomes of increased or reduced aggressiveness. For 
example, miR-9 abolishes the expression of the cell-cell adhesion mediator E-cadherin, thus 
promoting cell motility, invasion and metastatic potential of BC cells in vitro and in vivo[373]. 
Contrarily, members of the miR-200 family and miR-205 have been shown to restore 
epithelial phenotypes by targeting ZEB transcription factors, known transcriptional repressors 
of E-cadherin, thus impairing BC cell migration and invasiveness[374, 375]. Cell-matrix 
adhesion molecules, such as integrins, can be also amongst miRNA targets. For example, 
integrin α5 and integrin β3 are negatively regulated by miR-31 and let-7a, respectively, 
resulting in impaired cell invasion of BC[376] and melanoma[377].  
Additionally, miRNAs widely modulate the complex machinery that drives cytoskeletal 
dynamics, from central leaders, such as RHO GTPases, to their regulators and downstream 
effectors. For example, mir-224 and miR-31 suppress BC cell invasion and metastasis by 
targeting CDC42 and RHOA, respectively[376, 378]. Furthermore, induced by the transcription 
factor Twist, miR-10b inhibits the homeobox D10 (HOXD10), resulting in increased RHOC 
expression and consequently inducing BC cell invasion and metastasis[379]. MiR-10b is able 
also to impair RAC1 activation, by targeting the RAC-specific GEF T lymphoma invasion 
and metastasis 1 (TIAM1), thus contributing to decreased BC migration and invasion[380]. On 
the contrary, miR-155 synergistically activates RHO, RAC and CDC42, by targeting 
ARHGDIA, a GDP dissociation inhibitor that inhibits ARHGEFs, resulting in hepatocellular 
carcinoma (HCC) metastatic spread[381].Furthermore, miR-139 can directly regulate the 
expression of the RHO-associated kinase ROCK2, leading to suppression of HCC cell 
migration and invasion[382]; whereas miR-7 down-regulates PAK1 protein translation in BC 
cells and, consequently, suppresses their motility, invasiveness and metastatic potential[383]. In 
addition, overexpression of miR-200 was shown to inhibit the invasive capabilities of prostate 
and BC cells, mediating the suppression of WAVE3, a member of the WASF family[384]. 
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Numerous evidences implicate miRNAs function in direct or indirect regulation of metastatic 
signalling processes. A clear example is the hepatocyte growth factor (HGF)/c-MET 
signalling cascade which regulates cell growth, cell motility and morphogenesis. c-MET has 
been shown to be directly regulated by miR-1, miR-206, miR34a and miR-23b. MiR-1 and 
miR-206, can directly suppress c-MET expression and inhibit cell proliferation and migration 
of rhabdomyosarcoma[385]. MiR-34a decreases c-MET-induced phosphorylation of 
extracellular signal-regulated kinases 1 and 2 (ERK1/2) and inhibits HCC cells migration and 
invasion[386]. MiR-23b reduces proliferative and migratory abilities of HCC cells by inhibiting 
c-MET and urokinase-type plasminogen activator (uPA)[352]. Both epithermal growth factor 
receptor (EGFR) and phosphatidylinositol 3-kinase (PI3K) signalling cascades are also 
regulated by different metastamirs. EGFR expression is inhibited by BC metastasis suppressor 
1 (BRMS1)-mediated up-regulation of miR-146a[387]; and miR-125a/miR-125b 
overexpression reduces ERBB2 and ERBB3 levels, leading to reduced migration and invasion 
capacities of BC cells[388]. The PI3K signalling cascade is controlled by the tumour suppressor 
lipid phosphatase PTEN, a direct target of miR-21[389], miR-221 and miR-222[390] which 
cooperate to induce HCC cell migration and invasion.  
Amongst the miRNAs with a well-defined role in metastatic progression, very few stand out 
for their ability to control multiple metastatic genes, so that they are considered true 
metastamirs. 
In a study aimed to discover BC metastasis-related miRNAs, Tavazoie et al. identified miR-
355 as the first miRNA with a role in metastasis suppression[391]. MiR-355 was found to be 
selectively lost during BC cell dissemination to the lung and bones, and more importantly, its 
reintroduction suppressed metastasis of BC cells to different organs. Further analysis showed 
that miR-355 mediated its suppressive function by altering migration and morphology of BC 
cells, through synergistic repression of a cohort of pro-metastatic genes, namely SRY-box 
containing transcription factor (SOX4), receptor type tyrosine protein phosphatase (PTPRN2), 
c-MER tyrosine kinase (MERTK) and the ECM glycoprotein Tenascin C (TNC) [391]. MiR-
335-mediated suppression of SOX4 and TNC was found to be critical for metastatic abolition 
induced by miR-355.  
Additionally, in an elegant report, Valastyan et al. demonstrated that miR-31 plays a 
pleiotropic role in the regulation of different steps of BC metastasis[376]. They observed, in 
fact, that miR-31 supervises different malignant phenotypes, such as motility, invasion, 
resistance to anoikis, and metastatic colonisation at distant sites of BC cells. MiR-31 
coordinates inhibition of a set of pro-invasive/metastatic genes, including the already 
Introduction 
92 
 
mentioned RHOA and integrin-α5 (ITGA5), and the cytoskeletal protein radixin (RDX), 
Frizzled-3 (FZD3), the metalloproteinase 16 (MMP16) and the myosin phosphatase RHO-
interacting protein (M-RIP). MiR-31-induced suppression of metastasis was found to be 
mediated by repression of at least FZD3, RHOA, ITGA5 and RDX, as their knockdown 
abolished migration and invasion of BC cells.   
Finally, miR-200 participates in metastatic progression by controlling two different regulatory 
networks associated with opposite metastatic roles. The miR-200 family was firstly described 
as a suppressor cluster of BC invasion and metastasis by targeting ZEB1/2, which results in 
de-repression of E-Cadherin that maintains the epithelial tumour phenotype. A contradictory 
role for miR-200 reveales that this miRNA family functions as an enhancer cluster of BC 
metastatic colonisation, through silencing of the S. cerevisiae 23 homolog A (SEC23A). 
SEC23A is a vesicles-associated protein, that mediates secretion of metastasis-suppressive 
proteins including insulin-like growth factor binding protein 4 (IGFBP4) and tubulointerstitial 
nephritis antigen-like 1 (TINAGL1), which were found to mediate suppression of BC 
metastasis to the lung[392].  
MiR-355, miR-31 and miR-200 family are major examples of how miRNAs can act 
pleiotropically to regulate distinct molecular pathways that dictate the progression of cancer. 
 
1.5.6.4         MicroRNAs in anticancer therapy 
Increasing understanding of miRNA biology and their implication in cancer initiation 
and progression raises the possibility to use miRNA-based strategies in cancer therapy. 
MiRNAs exhibit several key qualities that make them suitable candidates for the development 
of drug delivery-based anti-cancer therapies. Firstly, owing to their small size and low 
molecular weight, miRNAs are ideal for systemic dissemination and uptake by target cells. 
Secondly, they are biological antisense interactors, and hence their intracellular uptake is less 
likely to induce an immune response, thus limiting toxic effects[393]. Moreover, owing to the 
ability of miRNAs to simultaneously regulate multiple genes involved in the same biological 
process, the use of a single miRNA as therapeutic target or drug can function as a 
combinatorial therapy, resulting in a cumulative effect on a subset of targets at multiple level 
in the same pathway[247]. Once more, because miRNAs frequently show altered expression in 
cancer, it is likely that agents developed to either inhibit oncomiRs or restore tumour 
suppressor miRNAs could result in  cancer-specific effects[294, 394]. Oncogenic miRNAs can be 
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inhibited by using anti-miRs and virus-associated sponge constructs[395]. Anti-miR-based 
strategies comprehend locked nucleic acids (LNAs) and antagomiRs, which are synthetic 
oligonucleotides complementary to the mature miRNA sequence, carrying chemical 
modifications that increase their stability in vivo, their specificity for the miRNA target and 
their uptake from cells[393]. For example, antagomirs are usually conjugated to cholesterol 
molecules that increase their affinity with the plasma membrane, thus facilitating their entry 
in the cell. Application of LNA-based oligonucleotides and antagomiRs has successfully 
resulted in inhibiting miRNA activity in experimental mouse tumour models[396]; in addition, 
the use of LNA against miR-122 in non-human primates is showing exciting promise in the 
treatment of the hepatitis C virus (HCV), and consequent reduction in HCV-related 
hepatocellular carcinoma[397]. Miravirsen, a 15-nt LNA complementary to miR-122 has been 
recently introduced in a clinical trial in patients with chronic HCV infection and it showed to 
induce dose-dependent reduction of the HCV RNA levels due to miR-122 repression[398].  
By contrast, restoration of miRNA expression with evident tumour suppressor functions can 
be achieved by delivery of miRNA mimics or viral vectors[395]. Both of these strategies have 
produced positive results in experimental animal models of cancer[399] [362].  
Delivery of miRNAs or miRNA inhibitors (sponge) via viral strategies, such as adeno-
associated viruses (AAV) is highly promising for several reasons: it is efficient as it ensures 
continual miRNA expression or inhibition; it is relatively safe, because the virus does not 
integrate into the genome, thus it is non-mutagenic; and finally it can be achieved with a high 
degree of tissue-specificity, due to availability of a number of different AAV serotypes that 
show natural tropism for different organs[393].   
Delivery of miRNA mimics or antagonists represents a major challenge. First, the use of 
chemically modified mimics or anti-miRs (cholesterol-conjugated) does not exclude a 
possible uptake of these agents by tissues that normally do not express the miRNA of interest 
or where its inhibition can cause unwanted phenotypes, resulting in potential indirect 
effects[400]. Moreover, only systemic administration into the circulation system allows 
miRNA-based agents to reach many pathological tissues that are not directly accessible, but 
“naked” RNA-compounds injected in the blood are rapidly excreted via renal infiltration due 
to their small size[401]. For these major reasons, systemic delivery of miRNA 
mimics/inhibitors can be achieved via incorporation into larger vehicles, such as lipid-based 
nanoparticles and other different carriers. Various pharmaceutical and engineering companies 
have been challenged by the development of miRNA formulations with the properties to (1) 
overcome the numerous physical barriers encountered in vivo (enzymatic degradation, 
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entrapment in the capillary system, crossing of the plasma membrane), and (2) access  target 
cells with high tissue-specificity[401]. 
In April of this year, for the first time, use of miRNA mimics as anticancer therapeutics has 
reached clinical trial in humans[402]. Mirna Therapeutics (Texas) has launched a phase 1 trial 
recruiting patients with liver cancer and liver-associated metastatic cancer and treating with 
MRX34, a synthetic miRNA mimic of the endogenous miR-34, a known master tumour 
suppressor miRNA. MRX34 is a double-stranded oligonucleotide delivered using a liposome-
formulation, called Smarticles, patented by Marina Biotech, Washington. The Smarticles 
technology has been formulated in order to prevent unwanted interactions with normal cells, 
and achieve maximal accumulation of the miRNA mimic into the tumour, using the tendency 
for liposomal accumulation within the liver. 
Despite the numerous clinical tests that MXR34 needs to overcome on its way to become an 
effective and licensed drug agent, it represents an exciting start point for the development and 
the improvement of RNA-based therapeutic strategies with realistic clinical relevance.  
     
1.6         Aims 
At the time of starting this project there was little published research  that described 
miRNAs as crucial regulators of cellular pathways relevant for the acquisition of metastatic 
potential. Therefore the initial aim of this study was to identify miRNAs with possible roles in 
the regulation of malignant traits leading to initiation and development of the metastatic 
process, with particular focus on BC progression. We aimed to:  
 investigate the impact of miRNAs on cellular phenotypes that mark aggressiveness of 
tumour cells, such as cytoskeletal remodelling, migratory and invasive capabilities and 
their metastatic potential; 
 gain insight into the molecular mechanism(s) that underlie the miRNA function in 
regulating gene targets involved in intracellular pathways relevant to these 
phenotypes; 
 and evaluate the effect and therapeutic potential that manipulation of these miRNAs 
may entail on the progression of BC. 
 
In order to identify candidate miRNAs and establish their functional regulatory networks, we 
aimed to: 
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i. adopt a bioinformatic approach by combining use of algorithms of miRNA target 
prediction and web-based resources for large-scale analysis of biological gene functions, 
to gain a preliminary understanding of the miRNA physiological role(s);  
ii. use both miRNA gain- and loss-of-function strategies to experimentally investigate the 
potential miRNA roles predicted in aim (i); this is achieved by performing a variety of 
techniques that assess for cell proliferation/ apoptosis, cytoskeletal dynamics, such as 
cell-cell and cell-matrix adhesion, cell migration/ invasion, intracellular signalling 
pathways and transcriptional regulation in a number of BC cell models; 
iii. identify putative miRNA gene targets by using available prediction tools and RNA-
sequencing-based genome-wide screening strategies, and validate them by performing 
western blot and luciferase reporter assays; 
iv. investigate the impact of miRNA perturbation on tumourigenic and metastatic potential 
of BC cell models in vivo; 
v. establish the clinical relevance of the miRNAs of interest by examining their expression 
levels in a cohort of primary and metastatic samples derived from patients affected by 
invasive BCs. 
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2.1            Materials  
2.1.1          Buffers and Solutions 
Table 3. Lists of buffers and reagents 
Reagent Recipe Storage 
 
1M Dithiothreitol  
(DTT) 
 
1M Tris-HCl 
 
 
Laemmli’s buffer 
 
 
NP-40 lysis buffer 
 
 
SDS loading 
buffer (2x) 
 
10x SDS-PAGE  
Running buffer 
 
10x Transfer buffer 
 
TBS 10x 
(Tris-Buffered Saline) 
 
TBST buffer 
(TBS/ Tween® 20) 
 
Blocking buffer  
 
pp-MLC 2 Ab Buffer 
 
 
IFF 
 
Solution 1 
 
 
 
Solution 2 
 
 
ChIP buffer 
 
 
0.075M KCL  
Hypotonic solution  
 
Fixative solution 
 
Gurr’s buffer 
 
1.54g of DTT in total of 10ml of double distilled 
MilliQ water (ddH20) 
 
60.5g Tris in total of 500ml ddH20 and adjusted to 
desired pH with pure HCl 
 
50mM Tris-HCl pH 6.8, 15% glycerol, 0.1% (w/v) 
bromophenol blue, 4% SDS  
 
30ml of 5 M NaCl, 100 ml of 10% NP-40, 50 ml of 
1M Tris (pH 8.0), and 820 ml of ddH2O 
 
125mM Tris-Cl pH 6.8, 20% glycerol, 4% SDS, 
100mM DTT, 0.04% (w/v) bromophenol blue 
 
10g SDS, 30.3g Tris, 144.1g glycine dissolved in  
1l of ddH20 
 
30.3g Tris, 144,1g glycine dissolved in 1l of ddH20 
 
24.23g Trizma HCl, 80.06 g NaCl dissolved in 1l of 
ddH20 and adjusted pH to 7.6 with pure HCl 
 
100ml of TBS 10x, 900ml ddH20,  
1ml Tween® 20 (BDH) 
 
5% dried skimmed milk powder in TBST 
 
5% bovine serum albumin (BSA, Sigma-Aldrich, 
Dorset, UK) in TBST 
 
1% BSA, 2% FCS in PBS 
 
0.25% Triton-X-100, 10mM EDTA, 0.5mM EGTA, 
10mM Tris-HCl ph8, 300µl Protease Inhibitors 
(Roche, Diagnostic Ltd, West Sussex, UK)  
 
0.2M NaCl, 1mM EDTA, 0.5mM EGTA, 10mM 
Tris-HCl ph8, 300µl Protease Inhibitors (Roche) 
 
0.01% SDS, 1.1% Triton-X100, 1.2mM EDTA, 
16.7mM Tris-HCl, pH 8.1, 167mM NaCl 
 
559mg of KCl in 100 ml of ddH20 
 
 
3:1 Methanol:Acetic acid 
 
0.469g NaH2PO4, 0.937g Na2HPO4 in 1l of  dH20 
 
 
100μl aliquots at -20°C 
 
 
RT 
 
 
RT 
 
 
4 °C 
 
 
500μl aliquots at 4°C 
 
 
RT 
 
 
RT 
 
RT 
 
 
RT 
 
 
Prepared as required 
 
10ml aliquots at -20°C 
 
 
50ml aliquots at -20°C 
 
4 °C 
 
 
 
4 °C 
 
 
4 °C 
 
 
RT 
 
 
Prepared as required 
 
RT 
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2.1.2          Mammalian cell lines 
Table 4. Lists of mammalian cell lines 
Cell Type        Tissue Morphology Tumourigenicity 
 
HCT116 
 
Colon  
 
Mesenchymal 
 
Human colorectal carcinoma cell line  
 
HeLa 
 
Cervix 
 
Epitheloid 
 
Human cervical carcinoma cell line 
 
MCF-7 
 
 
MDA-MB-468 
 
 
MDA-MB-231 
 
 
 
pEGFP- MDA-MB-231 
 
 
miR-23b-Sponge-EGFP- 
MDA-MB-231 
 
 
miR-26a- Sponge -EGFP- 
MDA-MB-231 
 
 
Breast 
 
 
Breast 
 
 
Breast 
 
 
 
Breast 
 
 
Breast 
 
 
 
Breast 
 
Epithelial 
 
 
Epithelial 
 
 
Mesenchymal  
 
 
 
Mesenchymal 
 
 
Mesenchymal 
 
 
 
Mesenchymal 
 
Human cell line derived from a pleural 
effusion of adenocarcinoma 
 
Human tumorigenic cell line derived from a 
pleural effusions of adenocarcinoma 
 
Human Metastatic and high invasive cell line 
derived from pleural effusions of ductal 
carcinoma 
 
MDA-MB-231 cell line stably expressing 
pEGFP-C1 plasmid 
 
MDA-MB-231 cell line stably expressing 
pEGFP-C1 plasmid containing the miR-23b-
sponge construct 
 
MDA-MB-231 cell line stably expressing 
pEGFP-C1 plasmid containing the miR-26a-
sponge construct 
 
T-MDA-MB-231 Breast 
 
Mesenchymal Tumour cell line derived from tumour 
developed after MDA-MB-231(p) injection 
into mice 
 
AD-MDA-MB-231 
 
Breast 
 
Mesenchymal Metastatic cell line derived from T-MDA-
MB- 231 cells metastasised to murine adrenal 
gland 
 
B-MDA-MB-231 
 
Breast 
 
Mesenchymal Metastatic cell line derived from T-MDA-
MB- 231 cells metastasised to murine bone 
 
L-MDA-MB-231 Breast 
 
Mesenchymal Metastatic cell line derived from T-MDA-
MB- 231 cells metastasised to murine lungs 
 
 
Table 5. Normal growth media 
Cell Type   Media Additives  Storage 
 
HCT116 
 
McCoy‟s 5A medium 
(modified) (Gibco®, 
Life Technologies 
Ltd, Paisley, UK) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% fetal calf serum (FCS) 
 
 
4°C, used within one 
month 
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Cell Type   Media Additives  Storage 
 
MCF-7 
MDA-MB-468 
MDA-MB-231 
HeLa 
 
DMEM (Dulbecco‟s 
Modified Eagle‟s 
Medium)(Sigma-
Aldrich, Dorset, UK) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS 
 
4°C, used within 
one month 
 
pEGFP-MDA-MB-231 
miR-23b- Sponge -EGFP- 
MDA-MB-231 
miR-26a- Sponge -EGFP- 
MDA-MB-231 
 
 
DMEM (Dulbecco‟s 
Modified Eagle‟s 
Medium)(Sigma-
Aldrich) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS 
500μg/ml G-418 (Roche Diagnostic 
Ltd, West Sussex, UK) 
 
4°C, used within 
one month 
 
T-MDA-MB-231 
AD-MDA-MB-231 
B-MDA-MB-231 
L-MDA-MB-231 
 
Advanced MEM 
(Minimum Essential 
Medium) (Gibco®) 
 
2mM Glutamine 
50 units/ml Penicillin 
50μg/ml Streptomycin 
10% FCS 
10 nM insulin (Sigma-Alderich) 
 
4°C, used within 
one month 
 
Table 6. Transfection media and reagents 
Transfection Media Additives Transfection reagent   Storage 
 
Normal growth medium 
 
 
Opti-MEM® I Reduced Serum 
Medium(Gibco®) 
 
 
No 
 
 
No 
 
HiPerFect Transfection Reagent (Qiagen, West 
Sussex, UK) 
 
Lipofectamine® 2000 Reagent (Invitrogen, Life 
Technologies Ltd, Paisley, UK) 
 
 
4°C 
 
 
4°C 
    
 
2.1.3          Primers 
All the primers were synthesised by Sigma-Aldrich (Dorset, UK). 
 
Table 7. Primer sequences for plasmid constructs 
Gene Primer sequence (5’ to 3’) 
 
 
 
 
Sponge-miR-23b 
  
 
S1-AGCTCATAAGGTAATCCCCCGAATGTGATCGATGGTAATCCCCCGAATGTGATC 
AS1-ACGCGTGATCACATTCGGGGGATTACCATCGATCACATTCGGGGGATTACCTTAT 
S2-ACGCGTCATAAGGTAATCCCCCGAATGTGATCGATGGTAATCCCCCGAATGTGATC 
AS2-ACTAGTGATCACATTCGGGGGATTACCATCGATCACATTCGGGGGATTACCTTATG 
S3-ACTAGTCATAAGGTAATCCCCCGAATGTGATCGATGGTAATCCCCCGAATGTGATC 
AS3-GATCGATCACATTCGGGGGATTACCATCGATCACATTCGGGGGATTACCTTATG 
 
 
 
Sponge-miR-26a 
S1-AGCTCTATAAGCCTATCCTCTATACTTGAACGATAGCCTATCCTCT 
AS1-ACGCGTCTTCAAGTATAGAGGATAGGCTATCGTTCAAGTATAGAG 
S2-ACGCGTCATAAAGCCTATCCTCTATACTTGAACGATAGCCTATCC 
AS2-ACTAGTCTTCAAGTATAGAGGATAGGCTATCGTTCAAGTATAGAG 
S3-ACTAGTCATAAAGCCTATCCTCTATACTTGAACGATAGCCTATCC 
AS3-GATCCTTCAAGTATAGAGGATAGGCTATCGTTCAAGTATAGAGGA 
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Gene Primer sequence (5’ to 3’) 
 
 
 
Sensor-miR-23b 
 
S1-CTAGTCGGAGGTAATCCCTGGCAATGTGATCGATGGTAATCCCTGGCAATGTGAT 
AS1-ACGCGTATCACATTGCCAGGGATTACCATCGATCACATTGCCAGGGATTACCTCCGA 
S2-ACGCGTACGGAGGTAATCCCTGGCAATGTGATCGATGGTAATCCCTGGCAATGTGAT 
AS2-ACTAGTATCACATTGCCAGGGATTACCATCGATCACATTGCCAGGGATTACCTCCGT 
S3-ACTAGTACGGAGGTAATCCCTGGCAATGTGATCGATGGTAATCCCTGGCAATGTGAT 
AS3-AGCTATCACATTGCCAGGGATTACCATCGATCACATTGCCAGGGATTACCTCCGT 
 
 
 
Sensor-miR-26a 
 
S1-CTAGTCGGAGCCTATCCTGGATTACTTGAACGATGCCTATCCTGGATTACTTGAA 
AS1-ACGCGTTTCAAGTAATCCAGGATAGGCATCGTTCAAGTAATCCAGGATAGGCTCCGA 
S2-ACGCGTACGGAGCCTATCCTGGATTACTTGAACGATGCCTATCCTGGATTACTTGAA 
AS2-ACTAGTTTCAAGTAATCCAGGATAGGCATCGTTCAAGTAATCCAGGATAGGCTCCGT 
S3-ACTAGTACGGAGCCTATCCTGGATTACTTGAACGATGCCTATCCTGGATTACTTGAA 
AS3-AGCTTTCAAGTAATCCAGGATAGGCATCGTTCAAGTAATCCAGGATAGGCTCCGT 
 
PAK1-3’UTR 
S-CGCACTAGTATCACTAACTCTCCAGCC 
AS-CGCACGCGTAATTTGTGCTGCAGAGGC 
 
PAK2-3’UTR 
S-CGCACTAGTATGGTCTGCATAACCTGAATGA 
AS-CGCACGCGTGAACTCAGGTGGCACTGCAGCT 
 
PAK2-3’UTR-23b mut 
S-GGAAGAAAAGTATTTGATTTTTACCTTTTTTAACAAAGAAAAAGT 
AS-CAAAATTTCTAAAACTGACTTTTTCTTTGTTAAAAAAGGTAAAAA 
 
PAK2-3’UTR-26a mut 
S-CTTTGGGGTATTTCCAATACTACTATGGCAGATTGGAGTTTTTC 
AS-GAAAAACTCCAATCTGCCATAGTAGTATTGGAATACCCCAAAG 
 
ANXA2-3’UTR-
23bmut 
S-GTTGGAAGTGAAGTCTATGATGACTAACACTTTGCCTCCTGTGTACT  
AS-AGTACACAGGAGGCAAAGTGTTAGTCATCATAGACTTCACTTCCAAC  
 
ARHGEF6-3’UTR-
23bmut 
S-AGCTGGCCAAGGCTTATTAAATGACTACCCAACTTTTCCCCAGG  
AS-CCTGGGGAAAAGTTGGGTAGTCATTTAATAAGCCTTGGCCAGCT  
 
CFL2-3’UTR-23bmut 
S-GCACTACAATGTATGTGATCGTCAATGACTATAGCTTAGAATACTGCAAAGGATAAG  
AS-CTTATCCTTTGCAGTATTCTAAGCTATAGTCATTGACGATCACATACATTGTAGTGC  
 
LIMK2-3’UTR-
23bmut 
S-CAGGGACCACATCAATGACTGAGGAAGCCTCCACCTC  
AS-GAGGTGGAGGCTTCCTCAGTCATTGATGTGGTCCCTG  
 
PIK3R3-3’UTR-
23bmut 
S-CACAAGAAGTGATTTTGTGAATGACTAGTGGAGAGGCCGAGCAG  
AS-CTGCTCGGCCTCTCCACTAGTCATTCACAAAATCACTTCTTGTG  
 
CHFR-3’UTR-26adel 
S-GCTAGCTTTGCCATGTCATCTGGAATAATTTTGATTTTTGGAAAAAAAAGTTTTTTA 
AS-TAAAAAACTTTTTTTTCCAAAAATCAAAATTATTCCAGATGACATGGCAAAGCTAGC 
 
MCL1-3’UTR-26adel 
S-ACTTTATTAGCCTAGTTTATCACCAATAACGGAAGGCTCAGTAA 
AS-TTACTGAGCCTTCCGTTATTGGTGATAAACTAGGCTAATAAAGT 
 
1LARP1-3’UTR-
26amut 
S-ACATCTTCACTTTCTGAAGACACTACTATTTAGGACCGATGTATCTGTGAC 
AS-GTCACAGATACATCGGTCCTAAATAGTAGTGTCTTCAGAAAGTGAAGATGT 
 
2LARP1-3’UTR-
26adel 
S-ATGTGCTAGGATATCATATTTAAAAGGACAAAAAAATGTAAAATGAGCTTGTATTATAACATTAA 
AS-TTAATGTTATAATACAAGCTCATTTTACATTTTTTTGTCCTTTTAAATATGATATCCTAGCACAT 
 
3LARP1-3’UTR-
26amut 
S-ACAAAAAAATGTATAAAAATAAACACTACTAAAGGCAATCGAGGGCCGGCCG 
AS-CGGCCGGCCCTCGATTGCCTTTAGTAGTGTTTATTTTTATACATTTTTTTGT 
 
YWHAE-3’UTR-
26amut 
S-GCTCGCTCAACCTCTTTTGTTCAGTATGTGTAACTACTAGCTAATTTGTACTACTG 
AS-CAGTAGTACAAATTAGCTAGTAGTTACACATACTGAACAAAAGAGGTTGAGCGAGC 
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Table 8. ChIP primer sequences 
Gene Primer sequence (5’ to 3’) 
 
IL6 promoter 
  
forward -CGTGCATGACTTCAGCTTTAC 
reverse TGCAGCTTAGGTCGTCATTG 
 
miR-23b(1) promoter 
 
forward GGAATACTAGGGTACCAGGGCA 
reverse GCAGCTTGGCTGGCTAGG 
 
miR-23b(2) promoter 
forward ACCATCTGCCTGCTCTTTCT 
reverse GGGACAGCAGCTTACATT 
 
miR-23b(3) promoter 
forward GCTCCTCGTTGAGTCATCAG 
reverse GAAGCCCGTTTTGAACACCA 
 
miR-nc promoter 
forward GAGGCTGTGCTTGGAGTAGG 
reverse CGTTTCCCCTGTGAAAGGTA 
 
Table 9. RT-PCR primer sequences 
Gene Primer sequence (5’ to 3’) Gene Primer sequence (5’ to 3’) 
 
ABL2 
forward GCTCAGCAGTCTAATCAATGG 
reverse CACATACACCTTGCCATCTG 
 
PAK2 
forward GCATGGATGAAGCACAGA 
reverse AACCAAAGTCAGTGAGCTTA 
 
ANXA2 
forward CCTGAACCTGGTTCAGTGC 
reverse CCCTTCATGGAGTCATACAGC 
 
PIK3R3 
forward ATCCTCCAGCTCTTCCACC 
reverse GGCATATCCCGCAATTTGTC 
 
ARHGEF6 
forward ATTTCAACAGACACTCTGCCA 
reverse GTTCCAACTCATCACTGTGCT 
 
PLAU 
forward GGGAGATGAAGTTTGAGGTGG 
reverse TTCAGCAAGGCAATGTCGT 
 
CFL2 
forward AGGGCACTATGGCTTCTGG 
reverse ACCAAGATCTGCTTTGCTTCC 
 
PPP1R12A 
forward AAGATCAACACAGGGAGTGAC 
reverse TTTCTTGTTCTCTGGTTCGGG 
 
c-JUN 
 
forward CTCCAAGTGCCGAAAAAGGAAG 
reverse CACCTGTTCCCTGAGCATGTTG 
  
pri-miR-23a 
  
forward TCTCATATGCAGGAGCCACCA 
reverse GCAAGTTGCTGTAGCCTCCTTG 
 
CHFR 
 
forward CTCCAAGTGCCGAAAAAGGAAG 
reverse CACCTGTTCCCTGAGCATGTTG 
 
pri-miR-23b 
 
forward GTGTGTGCAGACAGCACG 
reverse AATCTGCAGTGAGCGCGA 
 
ENAH 
forward GCTACACAGACCTTCCACC 
reverse ATGTTGGCCCTGTTTCCTG 
 
pri-miR-26a-1 
forward GCCCAATGGCATAGCAAGA 
reverse GGCCAGTCATGCTTACAGTGAC 
 
FN1 
forward TCAGATAAATCAACAGTGGGAG 
reverse AGTCTCTTCAGCTTCAGGT    
 
pri-miR-26a-2 
 
forward AGGCATCCCTGTGATGAAGGT 
reverse TTGAGAGCTCCTTGCTGCTGT 
 
GSK3B 
forward ACGCTCCCTGTGATTTATGTC 
reverse GCTTTGCACTTCCAAAGTCAC 
 
RAP1A 
forward CGTTGGGAAGTCTGCTCTG 
reverse TTCCGTGTCCTTAACCCGT 
 
ITGA1 
forward CTTCTGGTCCCGAGATGTG 
reverse GCATACTGTTTCCTTTCCCTC 
 
RAP1B 
forward TCGTTCTTGGCTCAGGAGG 
reverse TGCTGTAAATTGCTCCGTTCC 
 
LARP1 
forward AGTTTGAACCTGAGTATTCCCA 
reverse CATCCGTAGGAACTTGCTG 
 
RAP2C 
forward GATTTCTACCGCAAAGAGATC 
reverse CTCATTGGCTTGATATCCTGAA 
 
LIMK2 
forward CCCTGAGATGCTGAACGGA  
reverse CCTGCCCAATGATCTCACAG 
 
SSH2 
forward GTTCCTGGGCTCAGAATGG 
reverse TAAGTGTCATTCCAGTACGCC 
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Gene Primer sequence (5’ to 3’) Gene Primer sequence (5’ to 3’) 
 
MACF1 
forward CAGGAAGAACTCAATTCCCGA 
reverse CCAGCACTCCCATCATCAG 
 
STX2 
forward CGGAGTACAATGAGGCACAG 
reverse GGTGGTTCTCCCAGTTATCTC 
 
MCL1 
forward CCTTCCAAGGCATGCTTCG 
reverse GTTTAGCCACAAAGGCACCA 
 
U6 snRNA 
forward CTCGCTTCGGCAGCACA 
reverse AACGCTTCACGAATTTGCGT 
 
NRAS 
forward AAGACTCGGATGATGTACCT 
reverse GCATCTTCAACACCCTGTC 
 
YWHAE 
forward ACAGTTGAAGAAAGAAACCTCC 
reverse AGTCTCAACCATTTGCCGA 
 
2.1.4          Plasmid vectors 
Table 10. List of plasmid vectors 
Plasmid ID Gene Company 
 
pEGFP-C1 Vector 
 
 
 
 
miR-23b-sponge-pEGFP-C1 Vector 
 
miR-26a-sponge-pEGFP-C1 Vector 
 
pMIR-REPORTTM miRNA 
Expression Vector 
 
PAK1-3’UTR pMIR-REPORTTM 
 
PAK2-3’UTR pMIR-REPORTTM 
 
PAK2-3’UTR-23b mut pMIR-
REPORTTM 
 
PAK2-3’UTR-26a mut pMIR-
REPORTTM 
 
pRL-TK Vector 
 
ANXA2-pLightSwitch_3’UTR Go 
Clone vector 
 
ANXA2-3’UTR -23bmut 
pLightSwitch_Go Clone vector  
 
ARHGEF6-pLightSwitch_3’UTR 
Go Clone vector 
 
ARHGEF6-3’UTR -23bmut 
pLightSwitch_Go Clone vector  
 
CFL2-pLightSwitch_3’UTR Go 
Clone vector 
 
CFL2-3’UTR -23bmut 
pLightSwitch_Go Clone vector  
 
CHFR-pLightSwitch_3’UTR Go 
Clone vector 
 
CHFR-3’UTR-26adel 
pLightSwitch_Go Clone vector  
 
LARP1-pLightSwitch_3’UTR Go 
Clone vector 
1LARP1-3’UTR-26amut 
pLightSwitch_Go Clone vector  
 
2LARP1-3’UTR-26adel 
pLightSwitch_Go Clone vector  
 
3LARP1-3’UTR-26amut 
pLightSwitch_Go Clone vector  
 
LIMK2-pLightSwitch_3’UTR Go 
Clone vector 
 
6084-1 
 
 
 
 
 
 
 
 
AM5795 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E2241 
 
S804350 
 
 
 
 
 
 
 
S813665 
 
 
 
 
 
S812911 
 
 
 
 
 
 
 
 
 
S812599 
 
 
 
 
 
 
 
 
 
 
 
S814042 
 
 
 
 
 
 
 
 
 
 
S810231 
 
Enhanced Green Fluorescent 
Protein (EGFP) 
 
EGFP-hsa-miR-23b-sponge 
 
EGFP-hsa-miR-26a-sponge 
 
Firefly Luciferase (Luc) 
 
 
 
 
Firefly Luc-hsa-PAK1-3‟UTR 
 
Firefly Luc-hsa-PAK2-3‟UTR 
 
Firefly Luc-hsa-PAK2-3‟UTR 
mutated for miR-23b-binding site 
 
Firefly Luc-hsa-PAK2-3‟UTR 
mutated for miR-26a-binding site 
 
Renilla Luciferase 
 
Synthetic Renilla Luc (RenSp)-hsa-
ANXA2-3‟UTR  
 
RenSp Luc-hsa-ANXA2-3‟UTR 
mutated for miR-23b-binding site  
 
RenSp Luc-hsa-ARHGEF6-3‟UTR  
 
 
RenSp Luc-hsa-ARHGEF6-3‟UTR 
mutated for miR-23b-binding site  
 
RenSp Luc-hsa-CFL2-3‟UTR  
 
 
RenSp Luc-hsa-CFL2-3‟UTR 
mutated for miR-23b-binding site 
 
RenSp Luc-hsa-CHFR-3‟UTR  
 
 
RenSp Luc-hsa-CHFR-3‟UTR  
deleted for miR-26a-binding site 
 
RenSp Luc- hsa-LARP1-3‟UTR  
 
RenSp Luc- hsa-LARP1-3‟UTR  
mutated for miR-26a-binding site 1 
 
RenSp Luc- hsa-LARP1-3‟UTR  
deleted for miR-26a-binding site 2 
 
RenSp Luc- hsa-LARP1-3‟UTR  
mutated for miR-26a-binding site 3 
 
RenSp Luc- hsa-LIMK2-3‟UTR  
 
Clontech Laboratories Inc., 
CA, USA 
 
 
 
 
 
 
 
Invitrogen, Life Technologies 
Ltd, Paisley, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Promega,  Madison, WI, USA 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
Materials and Methods 
 
104 
 
Plasmid ID Gene Company 
 
LIMK2-3’UTR-23bmut 
pLightSwitch_Go Clone vector 
 
MCL1-pLightSwitch_3’UTR Go 
Clone vector 
 
MCL1-3’UTR-26adel 
pLightSwitch_Go Clone vector 
 
NRAS-pLightSwitch_3’UTR Go 
Clone vector 
PAK2-pCMV6-XL5 
 
pCMV6-XL5 
 
 
 
 
PIK3R3-pLightSwitch_3’UTR Go 
Clone vector 
 
PIK3R3-3’UTR-23bmut 
pLightSwitch_Go Clone vector 
 
PLAU-pLightSwitch_3’UTR Go 
Clone vector 
 
TLN2-pLightSwitch_3’UTR Go 
Clone vector 
 
YwhAE-pLightSwitch_3’UTR Go 
Clone vector 
 
YWHAE-3’UTR-26amut 
pLightSwitch_Go Clone vector 
 
 
 
 
 
 
 
 
S811815 
 
 
 
 
 
 
 
 
 
S808568 
 
SC315439 
 
 
 
 
S814084 
 
 
 
 
 
S807136 
 
 
S806580 
 
 
 
 
S806563 
 
RenSp Luc- hsa-LIMK2-3‟UTR 
mutated for miR-23b-binding site  
 
RenSp Luc- hsa-MCL1-3‟UTR  
 
 
RenSp Luc- hsa-MCL1-3‟UTR  
deleted for miR-26a-binding site  
 
RenSp Luc- hsa-NRAS-3‟UTR  
 
Untagged, full length hsa-PAK2- 
coding sequence (TruClone) 
Cloning vector 
 
 
RenSp Luc- hsa-PIK3R3-3‟UTR  
 
 
RenSp Luc- hsa-PIK3R3-3‟UTR 
mutated for miR-23b-binding site  
 
RenSp Luc- hsa-PLAU-3‟UTR  
 
 
RenSp Luc- hsa-TNL2-3‟UTR  
 
 
RenSp Luc- hsa-YWHAE-3‟UTR  
 
 
RenSp Luc-hsa-YWHAE-3‟UTR  
mutated for miR-26a-binding site 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
OriGene Technologies, Inc., 
Rockville, MD 
OriGene Technologies, Inc., 
Rockville, MD 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
SwitchGear Genomics, Menlo 
Park, CA 
 
 
 
2.1.5          Antibodies and probes 
Table 11. Primary antibodies 
Antibody Dilution Company Dilution buffer 
 
Polyclonal rabbit PAK1 
 
Polyclonal rabbit PAK2 
 
Monoclonal mouse MLC  
 
Polyclonal rabbit (Thr18/Ser19) pp-
MLC2  
 
Monoclonal mouse β-actin 
 
Monoclonal mouse E-cadherin (HECD-1) 
 
Monoclonal mouse Vinculin (V9264) 
 
Policlonal rabbit c-JUN (H-79) 
 
Policlonal rabbit c-FOS 
 
Monoclonal rabbit CD31 
 
1/5000 
 
1/1000 
 
1/2500 
 
1/1000 
 
 
1/100000 
 
1/1000 
 
1/400 
 
1/500 
 
1/1000 
 
1/75 
 
abcam® , Cambridge, UK 
 
abcam® , Cambridge, UK 
 
abcam®, Cambridge, UK 
 
Cell Signalling, Danvers, USA 
 
 
abcam®, Cambridge, UK 
 
Takara Bio Inc., Shiga, Japan 
 
Sigma-Aldrich, Dorset, UK 
 
Santa Cruz, California, USA 
 
abcam®, Cambridge, UK 
 
Millipore, Walford, UK 
 
Blocking buffer 
 
Blocking buffer 
 
Blocking buffer 
 
pp-MLC 2 antibody 
buffer 
 
Blocking buffer 
 
Blocking buffer (WB), 
IFF (IF)  
IFF 
 
ChIP buffer/blocking 
buffer 
Blockin buffer 
 
1% BSA in TBST 
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Table 12. Secondary antibodies 
Antibody Dilution Company Dilution buffer 
 
Polyclonal goat anti-rabbit IgG/HRP 
 
Polyclonal goat anti-mouse IgG/HRP 
 
Alexa Fluor® 555 goat anti-mouse 
IgG 
 
Biotinylated goat anti-rabbit IgG 
 
 
1/2500 
 
1/2500 
 
1/1000 
 
1/250 
 
Dako, Cambridge, UK 
 
Dako, Cambridge, UK 
 
Invitrogen, Life Technologies Ltd, 
Paisley, UK 
abcam®, Cambridge, UK 
 
 
Blocking buffer 
 
Blocking buffer 
 
IFF 
 
1% BSA in TBST 
 
 
 
Table 13. Probes 
Probe Dilution Company Dilution buffer 
 
Phalloidin-Alexa Fluor® 488 
 
TO-PRO-3 
 
Streptavidin-HRP complex 
 
Cole’s haematoxylin 
 
1/500 
 
1/1000 
 
1/500 
 
 
Invitrogen, Life Technologies Ltd, Paisley, UK 
 
Invitrogen, Life Technologies Ltd, Paisley, UK 
 
Amersham Pharmacia Biotech, Bucks, UK 
 
Pioneer Research Chemicals, Colchester, UK 
 
IFF/PBS 
 
PBS 
 
PBS 
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2.1.6          Patient samples 
Table 14: Patient characteristics data  
Patient characteristics 
Age 
<35 Yr 
35-49 Yr 
50-59 Yr 
>60 Yr 
Median age, years [403] 
 
Nodal Status 
1-3 
 4 
 
Tumour Size 
0-20 mm 
>20-50 mm 
>50 mm 
 
Tumour Grade 
Grade I 
Grade II 
Grade III 
 
ER Status 
ER positive 
ER negative 
 
HER2 Status 
Positive 
Negative 
 
Histological Type 
Invasive Ductal Carcinoma 
Invasive lobular Carcinoma 
Number of patients (%) 
 
2 (3%) 
13 (19.7%) 
18 (27.3%) 
33 (50%) 
59.5 (33-84) 
 
 
44 (66.7%) 
22 (33.3%) 
 
 
 
 
31 (46.9%) 
27 (40.9%) 
8 (9.2%) 
 
 
9 (13.6%) 
44 (66.7%) 
13 (19.7%) 
 
 
56 (84.8%) 
10 (15.2%) 
 
 
 
 
9 (13.7%) 
57 (86.3%) 
 
 
59 (89.4%) 
7 (10.6%) 
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2.2            Methods 
2.2.1          Mammalian cell culture 
2.2.1.1        Growing and passaging cells 
 Cells were cultured in 150 cm2 flask or 100 mm dishes or 6-well plates unless 
otherwise specified and maintained at 37°C in a humidified 5% CO2 incubator. Cells were 
routinely passaged when a confluence of ~90% was reached, depending on the growth curve 
of each cell line. To passage cells, medium was aspirated, cells were washed once with PBS 
and then trypsinised with EDTA-trypsin at 37°C for 3 to 10 minutes to allow them to detach. 
FCS was added to inactivate the trypsin (1:1 ratio) and cell clumps were disrupted through 
gentle pipetting. Suspension of cells was pipetted out of flask, and transferred in 15 mL sterile 
centrifuge tube. The cell suspension was centrifuged for 4 min at 1300 rpm. After 
centrifugation, the supernatant was aspirated and cell pellet was resuspended in the 
appropriate volume of medium. The resulting suspension was split to the desired dilution into 
new flasks and fresh media was added. Cells were used between passages 4 and 20 in all 
experiments. 
 
2.2.1.2        Transient cell transfections 
 For miRNAs overexpression, indicated cell lines were plated in 6-well tissue 
culture plates at 50% of confluence suspended in 1.5 ml of medium. Cells were allowed to 
adhere and grow at 37°C with 5% CO2. After 24 h, the proper amount of each miRNA 
precursor (5nM) or siRNA (40nM) oligonucleotides was added to 0.5 ml of medium without 
additives. 12µl/well of Hiperfect Transfection Reagent (Qiagen) were added to each solution 
and gently mixed. The oligonucleotides suspensions were then incubated for 9 minutes at RT 
to allow the formation of transfection complexes. After incubation, the complexes were added 
drop-wise onto the cells, and the plates were gently swirled to ensure uniform distribution of 
the transfection complexes in each well. The cells with the transfection complexes were then 
incubated under normal growth conditions for 48 h. The transfection of each oligonucleotide 
was performed in triplicate for both protein and RNA extractions and each assay.  
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For prolonged overexpression of miRNA precursors, cell were plated in 6-well plates at 30% 
confluence, and transfected with the miRNA precurors as described above; after 72h, cells 
were split and re-transfected with additional miRNA oligonucleotides; this protocol was 
repeated every 3 days for up to 9 days. The transfection for 9 days with each miRNA 
precursor was performed in triplicate. 
For 3‟UTR reporter assays, HCT116 cells were plated in 24-well tissue culture plates at a 
density of 5 x 104 cells/well in 0.5ml of medium without antibiotics. Cells were allowed to 
adhere and grown at 37°C with 5% CO2 for 24h. Transfection complexes were prepared as 
follows: 200ng of pMIR-REPORT firefly luciferase vectors (Applied Biosystems, Life 
Technologies Ltd, Paisley, UK), including miRNA-sensor, PAK2, PAK1 or their relative 
mutant 3‟UTRs (Table 7), 100ng of Renilla luciferase vector (pRL-TK) and the indicated 
miRNA precursors (100nM) or the miRNA-sponge-EGFP vectors (100ng), were added in 
50µl Opti-MEM® I Medium, gently mixed and incubated for 5 minutes at RT. After 
incubation, the oligonucleotide solutions were combined with the appropriate volume 
(0.5µl/well) of Lipofectamine® 2000, gently mixed and incubated for 20 minutes at RT to 
allow complex formation to occur. The complexes were then added drop-wise to each well 
containing cells and medium, and then incubated under normal growth conditions for 48 h. 
Each transfection was performed in triplicate in three independent experiments. MCF-7 cells 
were plated in 24-well tissue culture plates at a density of 1.5 x 105 cells/well in 0.5ml of 
medium without antibiotics. Cells were allowed to adhere and grow under normal cell growth 
conditions for 24 h. Transfection complexes were prepared by mixing 50ng of 
pLightSwitch_3UTR GoClone vectors (Table 7) with 100nM of the indicated miRNA 
precursors or 150ng of miRNA-sponge-EGFP vectors or the parental plasmid and processed 
as previously described. The cells with the transfection complexes were then incubate under 
normal growth conditions for 24h. Each transfection was performed in triplicate in three 
independent experiments. 
 
2.2.1.3        Cell treatments 
 For EGF treatment, MDA-MB-468 cells were plated in 100 mm dishes at a 50% 
confluence and incubated under normal growth condition to adhere. EGF (Invitrogen, Life 
Technologies Ltd, Paisley, UK) or its vehicle DMSO (for the time point 0) was added at a 
final concentration of 25ng/ml for the indicated time points in three independent biological 
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replicates. After each treatment time point, dishes were placed on ice and medium was 
aspirated. Cells were washed twice with cold PBS, scraped and centrifuged for 5 minutes at 
1300rpm. The supernatant was removed and the cell pellet was processed for RNA extraction. 
For nocodazole treatment, MCF-7 and MDA-MB-231 cells after 9d of transfection with the 
indicated miRNA precursors were exposed to 200ng/ml of nocodazole (solubilised in absolute 
DMSO) for 12h and then processed for chromosome metaphase spread assay. 
 
2.2.1.4        Generation and maintenance of plasmid-stable-transfected cell 
lines 
 
MDA-MB-231 cells were used to generate cell lines stably expressing the pEGFP-C1 
vector and its derivatives, the miR-23b-sponge-EGFP and the miR-26a-sponge-EGFP plasmid 
vectors (Table 10). The parental pEGFP-C1 plasmid carries along with the gene encoding for 
an enhanced variant of the wild-type green fluorescent protein (EGFP), a neomycin resistance 
cassette which allows stably transfected eukaryotic cells to be selected using the antibiotic G-
418 solution. The first step was to determine the working concentration of G-418 so as to 
ensure selection and maintenance of the neomycin-resistant cells by eliminating untrasfected 
cells. A titration experiment was performed by exposing untrasfected MDA-MB-231 cells 
seeded at different densities to different doses of G-418 (0.0, 0.1, 0.3, 0.5, 0.8, 1mg/ml) for 
10d, and 0.5mg/ml showed to be the minimum amount of G-418 which induced cell death of 
99% at all densities. Secondly, 2 x 106 cells were seeded in 100mm dishes in medium without 
antibiotics and allowed to adhere at 37°C with 5% CO2 ON; 10µl of Lipofectamine
® 2000 
Reagent were incubated with 0.5ml of Opti-MEM® I Serum Reduced Medium for 5min at RT 
and then mixed with 2µg of each plasmid or ddH2O (for the negative control) previously 
diluted in 0.5ml of the same transfection medium; the mixture was incubated for 20min at RT 
and then added drop-wise onto the cells. After 48h of transfection, stably transfected cells 
were selected with normal growth media supplemented with 0.5mg/ml of G-418. Untrasfected 
cells died within 7-10d from the addiction of the antibiotic. Stably transfected cells were 
seeded at a low density so as that each single cell formed a monoclonal colony in presence of 
G-418. When colonigenic foci were visible to the naked eye, 24 colonies for each transfection 
condition were transferred into 24-well plates: cloning discs were immersed in trypsin-EDTA 
for 2-3min, then dropped on top of a single cell colony and incubated for 5min at 37 ºC to 
allow cells to detach. Each cloning disc carrying monoclonal cells was then transferred to 
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each well of a 24-well plate in presence of G-418-cointaining medium. Cells derived from 
monoclonal colonies were maintained by refreshing medium twice a week, and expanded to 
high confluence before to be transferred to 6-well plates. After cells were passaged for 2-3 
times in 100mm dishes, they were assessed for EGFP expression by fluorescence activated 
cell sorter (FACS) analysis. Only the clones that showed an EGFP-expressing cell population 
higher than 80% were selected for further analysis. RT-PCR, western blotting, luciferase and 
proliferation assays indicated that clone n.10, n.2 and n.22 were the best representatives for 
miR-23b-sponge-EGFP, miR-26a-sponge-EGFP and pEGFP-C1 expression, respectively.  
 
2.2.2          3’UTR-Luciferase reporter assays 
 Forty hours after transfection, cells were lysed with 50µl/well of the Cell Culture 
Passive Lysis Buffer (5x) (Promega, Madison, WI, USA) fivefold diluted in dH2O and placed 
on agitator at constant speed for 30 minutes. For HCT116 cells, luciferase assays were 
performed by using the Dual-Glo Luciferase assay system (Promega, Madison, WI, USA). 
The lysates were transferred in an Opti-plate 96-well and mixed with 50µl/well of Dual-
GloTM Luciferase Reagent. After 10 minutes, the 96-well plate was sealed and the firefly 
luciferase activity was measured by using a luminometer. The measure of renilla luciferase 
luminescence was carried out by adding 50µl/well of Dual-GloTM Stop & Glo® Reagent, 
prepared according to the manufacturer‟s instructions. After 10 minutes, the reading of 
Renilla luminescence was taken by a luminometer. The ratio between firefly and renilla 
luminescence measurements was then calculated, and averages of triplicates were determined. 
For MCF-7 cells, the LightSwitch Luciferase Assay System (Switchgear Genomics Menlo 
Park CA, USA) was used: lysates were transferred in an Opti-plate 96-well, mixed with 
50µl/well of Assay Solution and incubated for 30 min out of the light. Luminescence signals 
were read by a luminometer and averages of triplicates were calculated. 
 
2.2.3          Plasmid constructions 
 MiR-23b- or miR-26a-sponge-EGFP vectors were constructed by annealing, 
purifying and cloning oligonucleotides (Table 7) containing six adjacent bulged binding 
motifs for the relevant human miRNA into the HindIII and BamHI sites of the multiple 
cloning site (MCS) of the pEGFP-C1 plasmid. Sensor constructs for miR-26a and miR-23b 
were produced using a similar strategy but they were cloned as 3‟UTRs into the SpeI and 
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HindIII sites of the MCS of p-MIR REPORT Firefly Luciferase vector. Amplification of 
PAK1 and PAK2 3‟UTRs from genomic DNA was performed by PCR by using the GoTaq 
Flexi DNA Polymerase kit (Promega Madison, WI, USA) and a specific primer set (Table 7). 
To check if the amplification reaction was succeed the PCR products were tested on 
electrophoresis running agarose gel. The amplicons were then purified by using the QIAquick 
PCR Purification Kit (Qiagen, West Sussex, UK) according to the manufacturer‟s 
instructions. Double digestion of the blunt-ends of the amplicons was performed by using 
SpeI and MluI restriction enzymes (New England BioLabs, Beverly, MA, USA) at 37°C ON. 
All the primers used for the amplification of 3‟UTRs were designed by adding a SpeI-specific 
restriction site on the 5‟end, and a MluI-specific restriction site on the 3‟end, so as to allow 
amplicons to be cloned in the MCS of the pMIR-REPORT firefly luciferase vector. The 
ligation reaction was carried out by incubating each amplicon with the linearized pMIR-
REPORT firefly luciferase vector (ratio 3:1) and 1µl of T4 DNA Ligase (New England 
BioLabs, Beverly, MA, USA) at 16°C ON. Site-directed mutagenesis of the miRNA-binding 
motif within the 3‟UTR of the analysed genes was performed by using the QuikChange Site-
Directed Mutagenesis II or XL Kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer‟s instructions, and the specific primer sets (Table 7). All the plasmids were 
confirmed by sequencing. 
 
  
 
2.2.4          Quantitative real-time Reverse Transcription-PCR 
2.2.4.1         RNA preparation 
 
 Cells were lysed with 1ml of Trizol reagent (Invitrogen, Life Technologies Ltd, 
Paisley, UK) through vigorous pipetting and lysates collected in Eppendorf tubes. By working 
under hood, 200µl of chloroform per 1ml of Trizol reagent were added to the lysates. The 
samples were vortexed vigorously for 15 seconds, incubated at RT for 2 to 3 minutes, and 
then centrifuged at 12,000 x g for 15 minutes at 2 to 8°C. Following centrifugation, each 
mixture separates into a lower phenol-red, chloroform phase, an interphase, and a colorless 
upper aqueous phase. RNA remains exclusively in the aqueous phase. Each aqueous phase 
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was transferred carefully into fresh Eppendorf tubes. The total RNA was precipitated from the 
aqueous phases by mixing with 500µl of isopropyl alcohol and incubating for 10 minutes at 
RT. The mixtures were then incubated ON at -80°C to enhance small RNA precipitation. 
After incubation, the RNA precipitates were centrifuged at 12,000 x g for 10 minutes at 2 to 
4°C to form a pellet on the side-bottom of the tube. The supernatants were removed, and the 
RNA pellets were washed by adding 1ml of 75% ethanol and mixing by vortexing. The 
samples were centrifuged at 7,500 x g for 5 minutes at 2 to 8°C. The supernatants were 
removed and any residues of ethanol were air-dried. Finally the RNA pellets were 
resuspended in an appropriate volume of RNAse-free water. Subsequently, RNA 
concentration was measured at 260nm and 280nm wavelengths, using a NanoDrop ND-100-
Spectrophotometer (Labtech international, East Sussex, UK). The RNA quality was 
determined on non-denaturing agarose electrophoresis gel: for each RNA sample isolated, two 
intensive bands at approximately 4.5 and 1.9 kb were observed at the transilluminator. These 
bands represent 28S and 18S rRNA and indicate successful RNA preparation. RNA extraction 
from 5 to 8 10µm FFPE sections of each tumour tissue sample was performed using the 
RNeasy FFPE kit (Qiagen, West Sussex, UK), in accordance to manufacturer‟s instructions. 
 
2.2.4.2         cDNA synthesis 
 The reverse transcription of mature miRNAs was performed using the TaqMan 
MicroRNA Reverse Trascription Kit (Applied Biosystems, Life Technologies Ltd, Paisley, 
UK). 10ng of total RNA were mixed with 7µl of master mix and 3µl of miRNA-specific RT 
TaqMan Probes (Applied Biosystems) in a 48-well PCR plate (Thermo Schientific, Abgene®, 
Leicestershire, UK) according to manufacturer‟s instructions. The samples were incubated in 
a 7900Ht Thermal Cycler (Applied Biosystems) at 16°C for 30 min to allow primers 
annealing, following by 30 minutes at 42°C for the elongation step, and 5 minutes at 85°C to 
inactivate the reverse transcriptase. For gene expression, cDNA was synthetised by using the 
Superscript III First Strand cDNA synthesis system (Invitrogen, Life Technologies Ltd, 
Paisley, UK): 1 µg of purified Dnase-treated RNA was mixed with 50nM of the reverse 
primer of each primer set (Table 9) and incubated in a 7900Ht Thermal Cycler at 70°C for 10 
min to allow RNA denaturation, and then place on ice to allow primer annealing. The proper 
amount of reverse transcriptase and dNTPs were then added to the RNA and incubated at 
50ºC for 50 min, and at 85ºC for 10 min in a 7900Ht Thermal Cycler. After RT cycles, the 
cDNAs samples were placed on ice and then prepared for quantitative real-time PCR. 
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2.2.4.3         Quantitative real-time PCR 
 
 To amplify mature miRNAs, for a single reaction, 1 ng of relative cDNA template 
was distributed in a Fast Optical 96-well reaction plate (Applied Biosystems, Life 
Technologies Ltd, Paisley, UK), followed by the appropriate volume of TaqMan® Universal 
PCR Master Mix, No Amperase® UNG (Applied Biosystems) and the relative 20x Real Time 
TaqMan probe (Applied Biosystems). Each reaction was done in triplicate. The plate was then 
sealed using the Optical Adhesive Cover Starter Kit (Applied Biosystems) and centrifuged 
(2,000 x g) for 30 seconds at 4°C. Quantitative real-time PCR (qPCR) was performed with an 
ABI Prism 7900HT sequence detection system (Applied Biosystems) with a thermal cycling 
program as follow: a first stage of 10 min at 95°C was followed by a step of 15 sec at 95°C 
for 40 cycles and one last step of 1 min at 60°C. For both gene-specific expression and ChIP 
enrichment, 10 ng of cDNA per reaction were amplified using the Power SYBR green PCR 
master mix (Applied Biosystems) and the specific gene primer set. Quantitative real-time 
PCR (qPCR) was performed with an ABI Prism 7900HT sequence detection system) with a 
thermal cycling program as follow: a first stage of 10 min at 95°C was followed by 40 cycles 
20 sec at 60°C and 20 sec at 72ºC. Finally, data were analysed using qBasePlus software 
(biogazelle). All the used primer set sequences in the qRT real-time PCR are reported in the 
table 9. 
 
2.2.5          SDS-polyacrylamide gel electrophoresis and western blot 
2.2.5.1         Protein extraction 
 Cell pellets were lysed in 30 to 60 μl of NP-40 lysis buffer + protease inhibitors 
cocktail solution (Roche, Diagnostic Ltd, West Sussex, UK). Eppendorf tubes containing cell 
lysates were placed on a rotator for 15 minutes at 4°C. A microcentrifugation of the lysates at 
maximum speed (13,000 rpm) for 15 minutes at 4°C allowed the separation of protein from 
insoluble elements. The supernatants containing proteins were transferred in new Eppendorf 
tubes and subsequently subjected to protein quantification. 
To preserve protein phosphorylation, cells were washed twice with cold PBS and lysed 
directly in the well of the 6-well plate by adding 50 µl of Laemmli‟s buffer (Table 3) . Each 
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lysate, forming a viscous gel-like solution, was gently scraped with an end-cut tip, transferred 
in an Eppendorf tube, and immediately incubated at 95 °C in a pre-heated water-bath for 5 
minutes to allow protein denaturation to occur. In order to reduce the viscosity, an index of 
the chromatin presence in the solutions, the lysates were sonicated twice for 2 seconds at 
constant power, and then frozen in an ethanol-dry ice bath (-80 to -70°C) to avoid the 
formation of crystal particles. The protein concentration in these lysate samples was not 
determined due to their composition. 
 
2.2.5.2         Protein quantification  
 
 Protein concentration was determined using the Bradford Reagent Kit (Bio-Rad, 
Berkeley, CA, USA). Absorbance readings were measured at 595 nm using a Beckman DU® 
530 Life Science UV/Visible spectrophotometer (Harlow Scientific, Arlington, MA). Upon 
collection of the data, the concentration of the unknown samples was determined based on 
standard absorbance value. The protein samples were then prepared for the SDS-
polyacrilamide gel electrophoresis: 3µg/µl of protein samples were mixed with SDS Loading 
Buffer (5x) and boiled at 95°C for 5 minutes. 
 
 
2.2.5.3        SDS-polyacrylamide gel electrophoresis 
 
 Both acrilamide (8-20%) resolving and 4% stacking gels were prepared manually 
as required. Once rainbow marker (Fermentas, Thermo Scientific, Leicestershire, UK)) and 
the protein samples (10µl) were loaded, electrophoresis was carried out for 2 to 3 h at 80V. 
Proteins were separated by SDS-polyacrilamide gel electrophoresis (SDS-PAGE) and run in 
1x SDS-PAGE running buffer.  
 
2.2.5.4        Western blots 
 
 The proteins were transferred to a Hybond C super nitrocellulose membrane (GE 
Healthcare, UK) for 1 h at 100V in transfer buffer using a Mini-PROTEAN® Tetra Cell (Bio-
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Rad, Berkeley, CA, USA). The membrane was stained with Ponceau S solution (Fluka, 
Sigma-Alderich, Dorset, UK) to check if the transfer was successful. The membrane was 
washed once for 10 minutes with blocking buffer in order to remove the staining and then 
blocked with blocking buffer at RT for 1 hour. The membrane was then transferred in the 
primary antibody solution and left at 4°C ON (Table 11). TBST was used to wash the 
membrane for three times, 15 minutes each. An IgG/HRP secondary antibody (Table 12) 
diluited in blocking solution was then added, and the membrane was incubated at RT for 1 
hour. The membrane was washed 3 times with TBST and Enhanced Chemiluminescence 
(ECL) detection system (GE Healthcare) was used for visualisation. The emitted fluorescence 
was detected using Hyperfilm ECL (GE Healthcare) on SRX-101A x-ray developer.  
 
2.2.5          Chromatin Immunoprecipitation (ChIP) 
 MDA-MB-231 cells were seeded in 150 cm2 dishes at a density of 9 x 106 cells and 
allowed to adhere ON. Cross-linking of proteins to DNA was performed by adding 0.75% 
formaldehyde drop-wise directly to the media for 10 min at RT. 125 mM glycine was added 
for 5 min at RT in order to stop the cross-linking reaction. Cells were then rinsed twice with 
cold PBS containing protease inhibitors (Roche, Diagnostic Ltd, West Sussex, UK), scraped 
and collected into 50 ml tube. After centrifugation at 2,000 rpm for 10 min, the resulted cell 
pellet was resuspended in solution 1 to lyse plasma membranes and incubate in rotation for 10 
min at 4 °C. After centrifugation, lysates were washed with solution 2 in rotation for 10 min 
at 4 °C and then centrifuged to separate the nuclei from cytoplasmic lysates. Nuclei were then 
lysed in 1 ml of Sonication buffer (Millipore, Walford, UK) and processed to sonication four 
times for 20 seconds each. The sonicated DNA-sample was splitted in 3 equal aliquots (for 
mock, IgG and anti c-JUN antibody incubation) that were then incubated with salmon sperm 
DNA-Protein A agarose (Millipore, Walford, UK) and centrifuged at the highest speed for 10 
min. The three supernatants obtained were then diluited in ChIP buffer, centrifuged to pellet 
the agarose away, and incubated in rotation with 1 µg of c-JUN antibody at 4 °C ON (Table 
11). The day after c-JUN antibody/histone complex were collected by adding agarose beads to 
the samples for 1h. After several washes in law/high salt washing buffer, agarose beads were 
removed from samples by adding elution buffer (Millipore, Walford, UK) and histone-DNA 
crosslinking reversion was carried out by incubating the samples with 5M NaCl ON at 65 °C. 
On the third day, 0.25 µl of RNase (100 mg/ml, Qiagen, West Sussex, UK) were added to the 
samples to degrade RNA for 30 min at 37 °C. Finally, DNA was purified in chloroform 
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(50%)-phenol (49%)-isoamyl alcohol (1%) mix washed in 100% ethanol, and then 
resuspended in 100 µl of TE buffer (Qiagen). 
 
2.2.6          Cell adhesion assay 
 The day before running the assay, 24-well plates were coated with 250 µl/well of 
50 µM type I collagen (BD Biosciences, Oxford, UK) in sterile PBS and incubated ON at 4 
°C. As control, a number of wells were coated with 5% heat-denaturated BSA. The day of the 
assay, pre-coated wells were washed once with PBS and blocked with 1% heat-denaturated 
BSA for 1 hour at 37 °C. MDA-MB-231 cells transfected for 48 h with the indicated 
oligonucleotides were then seeded in serum-free medium on pre-coated wells (n=3 per 
transfection) at a density of 1 x 105 cells per well and allowed to adhere for 30 minutes. Cells 
were then labelled with 1M Calcein/AM (Invitrogen, Life Technologies Ltd, Paisley, UK) for 
15 minutes at 37 °C and carefully washed three times with PBS containing 1mM CaCl2 and 
1mM MgCl2. The fluorescence signal was measured by using an Infinite
TM 200 quad-4 
spectrophotometer (Tecan UK Ltd, Reading, UK at an excitation wavelength of 485 nm and 
an emission wavelength of 520 nm. The differences in fluorescence measurements from three 
independent experiments were depicted as percentages of adherent cells. 
 
2.2.7          Cell spreading assay 
 The collagen-coating procedure was performed as described for adhesion assay 
after inserting a rounded cover slip in each well. In this case 0.55 x 105 MDA-MB-231 cells 
were plated in triplicate on pre-coated cover slips 48 h after transfection. After 30, 60 or 90 
min of incubation at 37 °C, culture medium was removed from wells and cells were fixed 
with pre-warm 4% (w/v) paraformaldehyde (PFA) in PBS for 10 min at RT. Cells were then 
gently washed twice with PBS and incubated with 0.5 M glycine in PBS for 20 min at RT in 
order to quench aldehyde-induced autofluorescence. Two washes with PBS were performed 
before to permeabilize the cells with 0.3% v/v Triton-X-100 for 10 min and block them for 30 
min with IFF + 5% goat serum. Incubation of the cells with anti-vinculin primary antibody for 
1 h at RT was followed by two washes with IFF. By this point all the next steps were carried 
out under dark conditions. Cells were incubated for 2 h with Alxa Fluor® 555 goat anti-mouse 
secondary antibody and phalloidin-Alexa Fluor® 488, then washed twice with IFF and nuclei 
staining was performed adding TO-PRO-3 in PBS for 5 min. After a last wash with PBS, 
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cover slips carrying the stained cells were mounted on microscopy glass slides and then 
processed for confocal microscopy. 
 
2.2.8          Cell-cell junction, focal adhesion and lamellipodia 
visualisation 
 
To highlight cell-cell junction formation, MCF-7 and MDA-MB-231 cells transfected 
with the indicated miRNA precursors for 9 days were plated at high density in 24-well plates 
(2 wells per condition) on top of a rounded cover slip and allowed to adhere ON at normal 
cell growth conditions. Cells were then fixed and processed for immunofluorescent staining as 
described for the spreading assay, but in this case an anti-E-cadherin primary antibody was 
used in order to visualise cell-cell junctions.  
For focal adhesion visualisation, 0.55 x 105 MDA-MB-231 cells were plated in 24-well plate 
(in triplicate) on collagen-coated cover slips 48 h after transfection (coating was performed as 
described for adhesion assays). After 1h of incubation at 37 °C, culture medium was removed 
from wells and cells were fixed and processed for immunostaining as already described, but in 
this case cells were stained only with anti-vinculin primary antibody for 1 h at RT to visualise 
focal adhesion areas.  
To detect lamellipodial structures, 0.5 x 105 MDA-MB-231 cells were plated on a rounded 
cover slip in 24-well plates 48 h after transfection. Cells were allowed to adhere ON under 
normal cell growth conditions and then fixed and processed for actin cytoskeleton staining as 
already described. For each assay, three independent experiments were performed.  
 
2.2.9          Annexin V-apoptotic assay 
 To assay the apoptotic properties of miR-26a and miR-23b, MDA-MB-231 were 
transfected with the indicated microRNA precursor mimics and the cell death control siRNA 
(20nM) (Qiagen, West Sussex, UK) that was used as positive control. After 48 h, detached 
cells were combined with adherent cells after lifting with trypsin-EDTA, stained with 
Annexin V/PE apoptosis detection kit (BD Biosciences, Oxford, UK) according to 
manufacturer‟s protocol and analysed using a FACSCanto II flow citometer (BD Biosciences, 
Oxford, UK). Apoptotic cells were represented by high PE-Annexin V fluorescence signals. 
The assay was performed in three independent replicates. 
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2.2.10        Cell growth assay 
 Cell growth was analysed by performing a sulfoRHOdamine B colorimetric (SRB) 
assay. MCF-7 and MDA-MB-231 cells were seeded at a density of 0.3 x 104 cells/ well in 96-
well plates and transfected for 48 h with the indicated molecules in quintuplicates. To assess 
the effect of miRNA inhibition on cell growth, the indicated miR-23b-, miR-26a-sponge-
EGFP-MDA-MB-231 clones along with the pEGFP-MDA-MB-231 and normal MDA-MB-
231 cells were seeded at a density of 0.3 x 104 cells/ well in 96-well plates in quintuplicates 
and allowed to adhere ON under normal cell growth condition. SRB assay was performed by 
processing the plates on a timeline of 7 days (one plate every two days) as follow: cells were 
fixed by adding 100 µl/well of ice-cold trichloroacetic acid (TCA) to each culture for 1h at 4 
°C. Cells were then washed five times in running tap water and stained with 100 µl/well of 
0.4% (w/v) of SRB buffer (Sigma-Aldrich, Dorset, UK) in 1% acetic acid for 30 min. After 
five washes with 1% acetic acid, plates were allowed to air dry ON. On the day of plate 
reading, SRB stain was solubilised by adding 100 µl/well of 10mM Tris-base to each well. 
Plates were placed on rotating platform for 10 min and absorbance was read with an 
InfiniteTM 200 quad-4 spectrophotometer (Tecan UK Ltd, Reading, UK) at a wavelength of 
492 nm.  
2.2.11        Cell migration assays 
2.2.11.1      Transwell migration assay 
 MDA-MB-231 cells transfected with the indicated oligonucleotides for 48 h or stably 
expressing the miR-23b-sponge-EGFP construct or the parental control, were seeded (5 x 104 
cells/insert) in triplicate in Tranwell® Polycarbonate Membrane inserts 24-well plates atop 
uncoated membranes with 8.0 μm pores (BD Biosciences, Oxford, UK). Cells were plated in 
serum free-medium and allowed to migrate from the upper chamber of the transwell insert 
toward a complete growth medium in the lower chamber. After for 9 h of migration, culture 
medium was removed from both the chambers, and insert membranes were fixed with 4% 
(w/v) PFA for 30 min at 37 °C. Cells attached on both sides of the membrane were then 
stained with 0.2% crystal violet in 20% methanol for 30 min at 37 °C and washed five times 
in PBS. Further, non-migrated cells were removed by scraping the upper side of the porous 
membranes with a cotton swab. Membranes carrying migrated cells (bottom side) were cut 
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out from the insert with a scalpel and sealed on microscope glass slides for microscope 
imaging. 
 
2.2.11.2      Cell tracking assay 
 MDA-MB-231 cells were seeded in 24-well tissue culture plates at a final density of 
1 x 104. After 48 h of transfection, time-lapse sequences were digitally recorded at intervals of 
20 minutes for 24 h using ImageXpress Micro® microscope (Molecular Devices, Sunnyvale, 
CA, USA) fitted with a humidified 37 °C incubation chamber and 10x objective. Cell 
trajectories were determined by following the centroid of the nuclei using the NHI ImageJ 
plugin "MTrackJ" (http://www.imagescience.org/meijering/software/mtrackj/) and speed of 
cell body movement was calculated for mean cell migratory speed.  A 50-100 cells per each 
condition were analysed and three independent experiments were performed. 
 
2.2.12        Type I collagen 3-dimensional invasion assay 
 MDA-MB-231 cells transfected for 48 h with the indicated miRNA precursors or 
stably expressing the indicated vectors were plated in black-walled 96-well plates at a final 
density of 7 x 104 and allowed to adhere ON under normal cell growth conditions. Type I 
collagen mixture  was prepared by working on ice as follow: 20% 5x serum-free cell culture 
medium, 2% 1M Hepes pH 7.5 and type 1 collagen (BD Biosciences, Oxford, UK) at a final 
concentration of 2.3 mg/ml. Type I collagen mixture (100 µl/well) was laid over the cells and 
allow to polymerize for 1 hour at 37 °C and 5% CO2. 100 µl of cell culture medium 
supplemented with 10% FCS as chemoattractant were added on top of the polymerized 
matrices and cells were allowed to invade upward through them for 16 h under normal cell 
growth conditions. The plates were then fixed in 100 µl of 4% (w/v) PFA for 30 min, washed 
twice with PBS and permeabilized with 0.2% v/v Triton-X-100 for 30 min After washing 
each plate well with PBS twice, staining of the actin cytoskeleton and the nuclei was achieved 
by incubating for 2 h the matrix-invading cells with phalloidin-Alexa Fluor® 488 and TO-
PRO-3 in PBS, respectively. Plates were washed again twice with PBS and then processed for 
confocal microscopy. Three independent experiments per conditions were performed. 
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2.2.14        Metaphase chromosome spread preparations 
After nocodazole treatment, MCF-7 and MDA-MB-231 cells transfected for 9 d with 
the indicated precursors were processed for metaphase chromosome spreads as follow: cell 
culture media and PBS used for rinsing cells were collected in 15 ml centrifuge tubes and 
spun down at 1000 rpm for 7 min in order not to lose dislodged, mitotic cells. Adherent cells 
were harvested by trypsinisation, collected with normal cell growth medium, added to the 
previously pelletted cells and spun down at 1000 rpm for 7 min. Supernatant was aspirated, 
leaving a small volume of medium (~300 µl) in which cells were resuspended by gently 
pipetting bubbles. Cells were induced to swell by adding 10 ml of hypotonic solution and 
incubating for 15 min at 37°C. Then few drops of fixative solution were added and cells were 
collected by centrifugation at 800 rpm for 8 min. After aspirating the supernatant, cells were 
resuspended thoroughly by gently flicking the tube. One ml of fixative solution was added 
drop-wise in constant agitation and cells were incubated for 1 h on ice. Cells were then spun 
down at 500 rpm for 5 min, the supernatant was removed and 1 ml of fixative solution was 
added. After repeating the last three steps three times, 20 µl of fixed swollen cells were slowly 
dropped onto a glass microscope slide, which was immediately run through the flame of a 
burner (bottom side of the slide toward the flame) in order to cause the rupture of the cell 
membranes and release of the chromosomes. The microscope slides were then incubated at 
37°C for 1 h and then processed for chromosome staining: slides were stained with 5 ml of 
Giemsa stain (Sigma-Aldrich, Dorset UK) diluted 1:20 in dH20 for 15 min, then rinsed in 
Gurr‟s buffer for 5 min and in dH20 for few seconds. After air-drying, few drops of Permount 
oil were added to the slide surface and covered with a cover slip. After drying at 37°C ON, 
slides were processed for microscope imaging. Tree independent experiments were 
performed. 
 
2.2.13        Soft agar colony formation assay 
 Stocks of 3% low melting point agarose (Invitrogen, Life Technologies Ltd, Paisley, 
UK) in PBS (20 ml aliquots) were prepared, autoclaved and stored at 4°C before use. On the 
day of the assay, one 3% agarose aliquot was melted and maintained in liquid phase in a water 
bath at 85°C. A 6-well plate was coated with 2 ml/well of a 0.6% agarose mixture (3% 
agarose diluited with warm normal cell growth medium) and allowed to polymerize for 5-10 
min at RT. MCF-7 cells transfected with the indicated oligonucleotides for 9 d were harvested 
Materials and Methods 
 
121 
 
by trypsinisation, spun down and resuspended in warm medium at a final concentration of 1.5 
x 104 cells/100 µl. A 0.3% agarose mixture was prepared by diluting the 3% agarose with 
warm medium and mixed with the transfected cell suspension (1.5 x 104 cells in 2 ml of 0.3% 
agarose). 2 ml of cell/agarose mixture was added in each well on top of the 0.6% agarose 
layer in triplicate per condition. The plate was then incubated under normal cell growth 
conditions for 3-4 weeks, to allow anchorage-independent cell growth. When formation of 
colonies more than 75 nm in diameter was observed, they were imaged by light microscopy. 
Colonies were then stained with 0.5 mg/ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT, Invitrogen, Life Technologies Ltd, Paisley, UK) in 
ddH2O after incubation at normal cell growth conditions ON. Each well was then 
photographed to visualise MTT-stained colony formation. The assay was performed in 
triplicate per condition in two independent experiments. 
 
2.2.14        Confocal microscopy and cell imaging 
2.2.14.1      Confocal microscopy 
For spreading assay and visualisation of cell-cell junctions, focal adhesions and 
lamellipodial structures, images were captured with a Plan-Apochromat 63x/1.40 oil objective 
using a Zeiss LSM 510 META confocal microscope fitted with an LSM 510 META scanhead 
and driven by Zeiss LSM 510 confocal software. 20-50 images were taken for each condition 
in each assay. For invasion assays, serial 5 µm-z sections of collagen gels containing invading 
cells were taken using the same confocal microscope. 5 fields per well were imaged and 
analysed using the Zeiss LSM 5 Image Browser (Carl Zeiss MicroImaging, Inc., Cambridge, 
UK). Invasion indexes were calculated as the number of cells at 40 μm divided by the number 
of cells at 0 μm.  
 
2.2.14.2      Cell imaging 
 To determine cell-cell junction linearity, images taken by confocal microscopy 
were false-coloured in a black-and-white fashion and processed using the Zeiss LSM 5 Image 
Browser: junction lengths and distances between vertices were manually traced and their 
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measurements were used to calculate a linearity index. 150-250 junctions per condition in two 
independent experiments were counted. 
To highlight the area of FAs, the images taken by confocal microscopy were false-coloured in 
a black-and-white fashion and 50-80 cells per condition were analysed using NHI ImageJ 
software. Quantification of FA area is represented as the average of FA area per cell.  
Cells imaged in the time-lapse tracking assays were analysed for lamellipodial formation. 
Lamellipodial structures were manually counted in a blind fashion and 100 cells per each 
condition in the three independent experiments were considered.  
For transwell migration assays, porous membranes carrying the migrated cells were imaged 
with 10x objective lens with an ACIS ChromaVision microscope (ChromaVision Medical 
Systems Inc. CA, USA). Images of five fields per triplicate per each experiment were taken. 
Quantification of number of migrated cells was determined by manually counting total cells 
per each field and transwell cell migration is expressed as percentage of the mean of the 
averages of three independent experiments.  
Metaphase chromosome spreads were examined by 100x oil immersion lens with a Zeiss 
Axiovert 100 (deconvolution) microscope.  About 100 chromosome spreads per condition per 
experiment were imaged and the percentage of chromosome spreads was determined as 
average of number of chromosomes per spread.    
To visualise soft agar colony formation, colonies were photographed and subsequently 
counted by using Image, number of colonies is expressed as mean of the averages of two 
independent experiments performed in triplicated per condition. To analyse colony size, 
colonies were imaged using an ImageXpress Micro® microscope (Molecular Devices, CA, 
USA) fitted with humidified 37 °C incubation chamber and a 20x objective; colony size was 
measured by using NHI ImageJ software and percentages to control derived from mean of the 
average size in two independent experiments performed in triplicate per condition. 
Paraffin-embedded sections from mammary gland primary tumours, lymph nodes and lungs 
were imaged with a 10x lens with a Zeiss Axiovert 100 microscope. Microvessels were 
counted per 5 high power fields per section in three different primary tumours per treatment. 
Metastatic areas within the lymph nodes (n=7 per treatment) and necrotic areas within the 
primary tumours (n=3 per treatment) were measured using the NHI ImageJ software. 
Quantification of metastatic areas and normal tissue was expressed as percentage of tissue 
type in the lymph nodes, whereas percentage of necrotic areas within the primary tumours 
was measured to quantify necrosis. 
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2.2.15        In vivo studies 
All procedures involving animals were performed in accordance with the UK Home 
Office Project licence PPL70/7256. Mir-23b-sponge-EGFP-MDA-MB-231 or pEGFP-MDA-
MB-231 cells were harvested by trypsinisation, spun down at 1300 rpm for 5 min and 
resuspended in warm normal growth medium supplemented with 0.5 mg/ml of G-418 solution 
at a final concentration of 1x106 cells/25 µl. Working quickly on ice, cell suspension was 
mixed with matrigel (BD Biosciences, Oxford, UK) with a ratio 1:1. Cell/matrigel 
suspensions were kept on ice during preparation of animals for cell implantation. BALB/c 
nude female mice (n=7 per treatment) were anaesthetised with 4% isofluorane and their body 
temperature was maintained by laying them on a thermal pad. Forceps were used to test rear 
foot reflexes in order to ensure that mice were deeply asleep before to proceed.  By using 
surgical scissors, a small incision was made to reveal the mammary gland of the left caudal-
most inguinal nipple. Cell/matrigel suspension was loaded into a 1 ml syringe fitted with a 27-
gauge hypodermic needle and 1x106 cells/50 µl were injected into the fat pad of the exposed 
mammary gland. The incision was then closed with a single suture and mice were recovered 
from anesthesia in a 37°C warm chamber. After recovery, a dose of 0.1 mg of the analgesic 
Rimadyl (Pfizer, New York, NY) was administered to the mice orally (diluted in drinking 
water) every day until wound healing was completed. Mice were kept under continuous sterile 
conditions (individually-vented cages) and had constant food and water access throughout the 
whole experiment period. Once orthotopic tumour formation in the injected mammary gland 
was observed, tumours were monitored and measured once a week. After about 2 months, 
when the maximal tumour volume of 300 mm2 was reached, mice were sacrificed. Primary 
tumours, the left inguinal lymph nodes and lungs were removed and fixed with 10% neutral 
formalin for paraffin-embedded sections and immunohystochemistry staining. 
 
2.2.14        Immunohistochemistry for histopathological analysis 
Immunohistochemistry was performed using the streptavin-biotin complex indirect 
immunoperoxidase method. Sections of 4 µm thickness from paraffin-embedded mammary 
gland primary tumours, lymph nodes and lungs were dewaxed, rehydrated and incubated with 
0.3% hydrogen peroxide for 30 min to block endogenous peroxidase activity. Antigen 
retrieval was performed by microwaving the sections for 20 minutes in 0.01 M citrate buffer 
(pH 6.0) at 750W. The sections were incubated with the primary antibody to cluster of 
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differentiation 31 (CD31, Millipore, Walford, UK) for 3 hour at RT. After washing with PBS, 
the sections were then incubated with a biotinylated IgG secondary antibody (Abcam, 
Cambridge, UK) for 30 minutes, washed with PBS, then incubated with streptavidin-
peroxidase complex (1:500, Amersham Pharmacia Biotech, Bucks, UK) for 30 minutes. The 
sections were developed with activated 3,3-diaminobenzidine-tetrahydrochloride solution 
(Sigma-Aldrich, Dorset, UK) and 0.1% H2O2 and counterstained with Cole‟s hematoxylin. 
Sections were then dehydrated, mounted on glass microscopy slides using Pertex mountant 
(CellPath, Hemel Hempstead, UK) and processed by microscopy.  
 
2.2.15        Illumina RNA-seq and analysis 
Total RNA from MCF-7 cells transfected with miR-23b, miR-26a or miR-n.c. 
precursors for 9 d and from miR-23b-, miR-26a-sponge-EGFP-MDA-MB-231 and pEGFP-
MDA-MB-231 cells was isolated as described in the RNA preparation section. Two 
micrograms of total RNA from each sample was used to produce cDNA libraries from polyA 
enriched RNA using the True-seq RNA preparation kit (Illumina, San Diego, USA) according 
to the manufacturer‟s instructions. Paired-end sequences (reads) of 100 nt in length were then 
generated using a HiSeq 2000 instrument (Illumina). Fastq files containing the sequenced 
reads, obtained at the end of the sequencing, were mapped to the University of California at 
Santa Cruz (UCSC) human genome (hg19 assembly) with TopHat version 1.4.1 
(http://tophat.cbcb.umd.edu), using default settings. A total of 29,437,797, 26,630,458, 
29,106,929, 29,977,877, 25,385,055 and 32,764,706 mapped reads for miR-23b-
overexpressing MCF-7, miR-26a-overexpressing MCF-7, miR-n.c-overexpressing MCF-7, 
miR-23b-sponge-EGFP-MDA-MB-231, miR-26a-sponge-EGFP-MDA-MB-231 and pEGFP-
MDA-MB-231 cells, were attained, respectively. The mapped bam files obtained at the end of 
the runs were loaded on the Partek Genomic Suite (Partek Incorporated, USA) for RNA 
quantification and analysis. This software is able to transform mapped bam files in kilobases 
per million of mapped reads (RPKM) as output for any gene, that represent the gold standard 
for RNA-seq normalisation. RPKMs represent the computed values. Significant change in 
gene expression was selected applying a Chi-square test. 
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2.2.16        Clinico-pathological characteristics of the patients 
 MiRNA expression profiling was performed on primary breast cancers and 
corresponding lymph node metastases from 66 patients with lymph node positive breast 
cancer, eligible for chemotherapy at Imperial College Healthcare NHS Trust, London, UK. 
All one-hundred and thirty-two samples were formalin-fixed and paraffin-embedded and 
prepared for miRNA processing. The clinico-pathologic characteristics are listed in table 14. 
Prospective written consent was obtained in accordance with ethical guidelines. 
 
2.2.17        Statistical analysis 
 Data are presented as mean ± SEM calculated using Graph Prism software. Student‟s 
t-test and Chi-Square test were used for comparison, with P < 0.05 considered significant. 
Sequence data were submitted to Gene Expression Omnibus database, accession number 
GSE37918. 
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3.1            MiR-23b regulates cytoskeletal dynamics, migration, 
invasion and metastasis in BC cells 
After establishment of the primary tumour, the acquisition of aggressive traits allows 
cancer cells to detach from their origin site through migratory and invasive events that mark 
the first step of the metastatic process[30]. This generally requires the disruption of existing 
cell-cell contacts, the establishment of cell-matrix adhesions, the degradation or 
rearrangement of the ECM, and finally the movement of the tumour cell. The actin 
cytoskeleton constitutes the structural support to cell morphology, polarity, adhesion and 
migration. Primary regulators of cytoskeletal dynamics are three members of the Rho family 
of small GTPases, RHO, RAC and cell cycle division 42 (CDC42), that, in response to 
external stimuli, coordinate actin-based structures via a plethora of cytoplasmic effector 
proteins[404]. Nevertheless, aberrant activity of Rho small GTPases results in deregulation of 
cytoskeletal modulators and consequent mis-organisation of the actin cytoskeleton, leading to 
increased migration and invasiveness[37]. Owing to their ability in regulating gene expression 
post-transcriptionally, microRNAs (miRNAs) are able to affect cellular pathways relevant to 
cell adhesion, cytoskeletal remodelling, migration and invasion thus contributing to regulation 
of the metastatic process[372]. In this respect, we wished to identify interesting candidate 
miRNAs with potential roles in metastatic progression, with particular focus on BC. We 
adopted a bioinformatic approach based on an extensive literature review and use of web-
based resources for the prediction of miRNA putative targets and the analysis of their 
biological functions. Firstly, our literature research pinpointed miR-23b as a suitable 
candidate to fulfill the main purposes of our project. At that time, in fact, only one published 
research linked miR-23b function with the regulation of metastatic phenotypes, as it was 
found to reduce hepatocellular carcinoma cell motility through regulation of uPA and c-
MET[405]. However, the role of miR-23b in BC and its relative regulatory pathways remained 
largely unknown. 
 
 
3.1.1           Bioinformatic analysis indicates a potential role for miR-
23b in cytoskeletal remodelling and cell adhesion 
 
To gain a preliminary understanding of the biological functions of miR-23b, we 
obtained a list of the 938 genes predicted as putative targets for miR-23b by TargetScan web-
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EDVHG WRRO> @:H WKHQ DQDO\VHG WKLV JHQH OLVW XVLQJ'$9,' RQOLQH GDWDEDVH IRU JHQH
RQWRORJ\*2DQQRWDWLRQDQGSDWKZD\HQULFKPHQWDQDO\VLV>@,QSDUDOOHOZHSHUIRUPHG
DQ LGHQWLFDO DQDO\VLV RI D OLVW FRPSRVHG E\  UDQGRPO\ FKRVHQ JHQHV XVHG DV QHJDWLYH
FRQWURO1RWDEO\ WKLVDQDO\VLV VSHFLILFDOO\ LPSOLFDWHGPLUE LQ WKHUHJXODWLRQRISDWKZD\V
LQYROYHG F\WRVNHOHWRQ RUJDQLVDWLRQ FHOOFHOO MXQFWLRQV DQG DFWLQ ILODPHQWEDVHG SURFHVV
)LJXUH $ 7KHVH FHOOXODU SDWKZD\VZHUH QRW SUHGLFWHG IRU WKH VDPH QXPEHU RI FRQWURO
JHQHVDQDO\VHG)LJXUH%
)LJXUH  $ ELRLQIRUPDWLF DSSURDFK UHYHDOV SRWHQWLDO UROHV RI PL5E LQ F\WRVNHOHWDO
G\QDPLFV DQG FDQFHUUHODWHG SDWKZD\V $%/LVW RI SDWKZD\V 7HUPV UHWULHYHG XVLQJ '$9,'
IXQFWLRQDO DQQRWDWLRQGDWDEDVH IRU WKHSRWHQWLDOPL5EJHQH WDUJHWVSUHGLFWHGE\7DUJHW6FDQ
VRIWZDUH$DQGUDQGRPO\FKRVHQJHQHV%(DFKDQQRWDWHG7HUPLVDVVRFLDWHGZLWKDVSHFLILF
3YDOXH6LJQLILFDQWSDWKZD\VHQULFKHGRIPL5ESRWHQWLDOWDUJHWVDUHKLJKOLJKWHGLQJUHHQ 
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As miRNAs typically target multiple genes within a specific regulatory pathway[406], we 
considered those implicated in an interaction network as high confidence candidates for mir-
23b targeting, and evaluated which putative target genes were part of specific interaction 
networks using Cytoscape software[407]. Cytoscape is a free program developed for the 
analysis, integration and visualisation of molecular and genetic interaction networks. It 
processes large amounts of data derived from gene expression profiling, and other functional 
genomics and proteomics analysis, and integrates them on the base of an interaction network 
retrieved for the analysed genes. Data are then visualised in a network graph where biological 
entities, such as genes or proteins, are represented by nodes, connected with links or edges, 
which define intermolecular interactions. As shown in figure 20A we found that 176 (18%) 
out of 938 putative miR-23b target genes were components of such networks. Next, we 
analysed this smaller gene portion using DAVID and overlapped the enriched pathways 
retrieved for network-interacting genes with those of the original analysis (Figure 19A). 
Accordingly, we observed that the shared pathways were those involved in cytoskeletal 
remodelling, cellular junctions, cell adhesion and cancer (Figure 20B). Moreover, a total of 
60% of the putative miR-23b target genes implicated in cytoskeletal remodelling by our 
DAVID analysis were implicated in the interaction network identified by Cytoscape (Figure 
20C). This cross-validated bioinformatic analysis suggested a preliminary role for miR-23b in 
regulating cytoskeletal dynamics.  
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)LJXUH %LRLQIRUPDWLF DQDO\VLV LPSOLFDWHV DPL5E IXQFWLRQ LQ F\WRVNHOHWDO UHPRGHOOLQJ
SDWKZD\V$&\WRVFDSH DQDO\VLV LQGLFDWHV WKDW D JURXS RIPL5ESRWHQWLDO JHQH WDUJHWV
UHGQRGHVIRUPVLQWHUDFWLRQQHWZRUNVHGJHVDQGWKHUHIRUHFRXOGEHFRQVLGHUHGDVKLJKFRQILGHQFH
WDUJHWV % 9HQQ GLDJUDPV VKRZ VLJQDOOLQJ SDWKZD\V GHULYHG IURP WKH '$9,' DQDO\VLV RI 
SRWHQWLDOPL5EJHQHWDUJHWVVKRZHGLQILJDQGWKHVDPHDQDO\VLVRQPL5ESXWDWLYHWDUJHWV
WKDW IRUP DQ LQWHUDFWLRQ QHWZRUN VKRZHG LQ$&*HQH FRXQW OHIW JUDSK DQGJHQH SHUFHQWDJH
ULJKWJUDSKRIERWKPL5ESUHGLFWHGWDUJHWVDQGPL5EKLJKFRQILGHQFHWDUJHWVLQYROYHGLQWKH
LQGLFDWHGVLJQDOOLQJSDWKZD\V
5HVXOWV

131 
 
,QYLWURH[SHULPHQWDOHYDOXDWLRQRIPL5EIXQFWLRQLQ
F\WRVNHOHWDOUHPRGHOOLQJSDWKZD\V
7UDQVLHQWPL5ERYHUH[SUHVVLRQHQKDQFHVHSLWKHOLDO
SKHQRW\SHVRI%&FHOOV

:HILUVWO\DGRSWHGDJDLQRIIXQFWLRQDSSURDFK WR LQYHVWLJDWH WKHUROHRIPL5E LQ
WKH UHJXODWLRQ RI F\WRVNHOHWDO G\QDPLFV SUHGLFWHG E\ RXU ELRLQIRUPDWLF VWXG\:H LQGXFHG
RYHUH[SUHVVLRQ RI PL5E E\ WUDQVIHFWLQJ ERWK HSLWKHOLDO DQG PHVHQFK\PDOOLNH %& FHOO
OLQHV0&)DQG0'$0%FHOOVUHVSHFWLYHO\ZLWKDV\QWKHWLFPL5ESUHFXUVRUSUH
PL5 PLPLF D QHJDWLYH FRQWURO PLPLF PL5QF DQG PL5D SUHPL5 PLPLF XVHG DV D
IXUWKHUQHJDWLYHFRQWURO)LJXUH$IWHUWUDQVIHFWLRQXVLQJOLJKWPLFURVFRS\YLVXDOLVDWLRQ
ZHLQYHVWLJDWHGWKHHIIHFWRIPL5EXSUHJXODWLRQRQLQYLWUR'FXOWXUHV:HREVHUYHGWKDW
HFWRSLF H[SUHVVLRQ RI PL5E RQO\ LQFUHDVHG HSLWKHOLDO FKDUDFWHULVWLFV RI 0&) FHOOV
GHPRQVWUDWHG E\ WLJKWHU FRORQ\PRUSKRORJ\ ZLWKPDUNHG FHOOFHOO MXQFWLRQV )LJXUH $
7KLV HIIHFW LQGLFDWHG WKDW PL5E PD\ UHJXODWH FHOOFHOO DGKHVLRQ SDWKZD\V LQ YLWUR DV
SUHGLFWHGE\RXUELRLQIRUPDWLFGDWD1H[WZHIRXQGWKDWWKLVHIIHFWZDVLQGHSHQGHQWIURPWKH
H[SUHVVLRQOHYHOVRIWKHFHOOFHOODGKHVLRQJO\FRSURWHLQ(FDGKHULQZKLFKGLGQRWFKDQJHXSRQ
RYHUH[SUHVVLRQ RI WKHPLPLFV )LJXUH %+RZHYHUZHGHWHFWHG QR FKDQJHV WRZDUGV DQ
HSLWKHOLDO SKHQRW\SH LQ PHVHQFK\PDOOLNH0'$0% FHOOV XSRQ RYHUH[SUHVVLRQ RI WKH
LQGLFDWHGSUHPL5V)LJXUH&7KLVVXJJHVWVWKDWPL5ELQGXFHGHIIHFWLVXQOLNHO\WREH
WKH UHVXOW RI UHH[SUHVVLRQ RI DGKHVLRQ PROHFXOHV ORVW GXULQJ WKH (07 SURFHVV EXW UDWKHU
GHULYHVIURPDPL5EIXQFWLRQLQHQKDQFLQJH[LVWLQJFHOOFHOODGKHVLRQV
)LJXUH2YHUH[SUHVVLRQRIPL5
EDQGPL5D LQ%&FHOOV57
3&5DVVD\VGHWHFWPLUEDQGPL5
D LQWUDFHOOXODU OHYHOV DIWHU
RYHUH[SUHVVLRQ RI WKH LQGLFDWHG
PL51$SUHFXUVRUPLPLFV Q0 IRU
K LQ %& 0&) DQG 0'$0%
 FHOOV 0L51$V OHYHOV ZHUH
QRUPDOLVHG WR HQGRJHQRXV 8
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3URORQJHGPL5ERYHUH[SUHVVLRQLQ%&FHOOVHQKDQFHVFHOOFHOO
DGKHVLRQLQYLWUR
 
%DVHGRQWKHVHSUHOLPLQDU\REVHUYDWLRQVZHQH[WLQYHVWLJDWHGDSRVVLEOHLQGXFWLRQRI
WKHPHVHQFK\PDOWRHSLWKHOLDO WUDQVLWLRQ0(7E\RYHUH[SUHVVLQJPL5EIRUDSURORQJHG
SHULRGRIWLPHGD\V7RWKLVHQGZHXVHGLPPXQRIOXRUHVFHQFHWHFKQLTXHVWRH[DPLQH(
&DGKHULQ OHYHOV DQG FHOOFHOO MXQFWLRQ IRUPDWLRQ>@ :H REVHUYHG WKDW PDLQWDLQHG
RYHUH[SUHVVLRQRIPL5EIDLOHG WR LQGXFH0(7LQPHVHQFK\PDOOLNH0'$0%FHOOV
)LJXUH$EXWOHDGWRDVWURQJHUHSLWKHOLDOSKHQRW\SHLQ0&)FHOOFXOWXUHVDVVHHQXSRQ
WUDQVLHQW PL5E RYHUH[SUHVVLRQ ,Q ILJXUH % ZH FDQ DSSUHFLDWH WKDW PL5E
RYHUH[SUHVVLQJ0&)FHOOVIRUPHGPRUHRUGHUO\DQGVWDEOHDGKHUHQVMXQFWLRQVFRPSDUHZLWK
FRQWUROV LQGLFDWLQJ WKDW PL5E DFWV E\ HQKDQFLQJ WHQVLRQ EHWZHHQ H[LVWLQJ FHOOFHOO
MXQFWLRQV:HWKHQTXDQWLILHGWKLVHIIHFWH[SUHVVHGDVDOLQHDULW\LQGH[GHILQHGE\WKHUDWLRRI
MXQFWLRQOHQJWKWRWKHGLVWDQFHEHWZHHQWKHWZRYHUWLFHVPDUNLQJHDFKMXQFWLRQ)LJXUH&
7KH REWDLQHG OLQHDULW\ LQGH[ LQGLFDWHG WKDWPL5ESURORQJHGRYHUH[SUHVVLRQ VLJQLILFDQWO\
HQKDQFHGWKHVWUDLJKWQHVVRIFHOOFHOOMXQFWLRQV3 )LJXUH&
)LJXUH  0L5E RYHUH[SUHVVLRQ HQKDQFHV HSLWKHOLDO SKHQRW\SHV RI %& FHOOV $ 3KDVH
FRQWUDVWLPDJHVRI0&)FHOOVXSRQWUDQVIHFWLRQZLWKPL5DPL5EDQGPL5QFSUHFXUVRUV
Q0 IRU K % :HVWHUQ EORW VKRZLQJ (FDGKHULQ DQG ȕDFWLQ H[SUHVVLRQ LQ 0&) FHOOV
WUDQVIHFWHGZLWKPL5DPL5EDQGPL5QFSUHFXUVRUVQ0IRUKRXUVȕDFWLQZDVXVHGDV
DORDGLQJFRQWURO&3KDVHFRQWUDVWLPDJHVRI0'$0%FHOOVXSRQWUDQVIHFWLRQZLWKPL5D
PL5EDQGPL5QFSUHFXUVRUVQ0IRUK
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)LJXUH0L5ERYHUH[SUHVVLRQHQKDQFHVFHOOFHOO DGKHVLRQ LQYLWUR$)URP OHIW WR ULJKW
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 VWDLQLQJ RI )DFWLQ DQG RYHUOD\ RI WKH WKUHH LPDJHV RI 0'$0% FHOOV
WUDQVIHFWHGZLWKPL5EDQGPL5QFSUHFXUVRUV Q0IRUGD\V6FDOHEDU P%)URP
ULJKW WR OHIW 72352 VWDLQLQJ RI QXFOHL LPPXQRIOXRUHVFHQFH VWDLQLQJ RI (FDGKHULQ 
$OH[D)OXRUSKDOORLGLQ  VWDLQLQJRI)DFWLQDQGRYHUOD\RI WKH WKUHH LPDJHVRI0&)
FHOOV WUDQVIHFWHGZLWKPL5EDQGPL5QF SUHFXUVRUV Q0 IRUGD\V6FDOHEDU P&
4XDQWLILFDWLRQ RI MXQFWLRQ OLQHDULW\ -XQFWLRQ OHQJWK JUHHQ DQG GLVWDQFH EHWZHHQ YHUWLFHV SLQN
ZHUHPHDVXUHGDQGDOLQHDULW\LQGH[ZDVFDOFXODWHGE\GLYLGLQJWKHWZRPHDVXUHVULJKW7KLVLQGH[
GHFUHDVHV LQ PL5ERYHUH[SUHVVLQJ 0&) FHOOV 6FDOH EDU    P  MXQFWLRQV SHU
FRQGLWLRQ LQ WZR LQGHSHQGHQW H[SHULPHQWV ZHUH FRXQWHG 'DWD DUH PHDQ  VHP 3   
6WXGHQWெVWWHVW
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3.1.2.3         Both miR-23b and miR-26a regulate BC cells adhesion on ECM 
 
As our bioinformatics analysis implicated a potential regulation by miR-23b on cell 
adhesion and focal adhesion formation, we assessed the ability of MDA-MB-231 cells to 
adhere on the ECM upon miRNA overexpression. Firstly, we stained MDA-MB-231 cells for 
the focal adhesion (FA) marker Vinculin[408] upon transient transfection with the indicated 
pre-miRs and cell seeding on collagen I films. Interestingly, FAs resulted significantly 
enlarged in cells overexpressing miR-23b or miR-26a precursors comparing with miR-n.c.-
transfected cells (P = 0.04, Figure 24A).   
Secondly, we assessed the effects of these miRNAs on cell spreading capacity, by seeding 
MDA-MB-231 cells transiently transfected with the indicated pre-miRs on collagen I matrices 
for 30, 60 and 120 minutes (Figure 24B). MiR-23b and miR-26a-overexpressing cells spread 
more than controls, and after 30 minutes contained lamellar protrusions, stress fibre-like actin 
bundles and punctate peripheral FAs, whilst the controls remained rounded with no 
appearance of FAs or F-actin bundles (Figure 24B). Whereas this effect appeared transient 
upon miR-23b overexpression, it was reproducibly most pronounced in miR-26a over-
expressing MDA-MB-231 cells, which after 120 minutes on Collagen I matrix, exhibited a 
remarkable expanded morphology with reinforced Vinculin-stained focal adhesion sites 
throughout the cell body and at the periphery of lamellipodia (Figure 24B, bottom panels).  
Furthermore, the increase of intracellular miR-26a levels significantly promote ability of 
MDA-MB-231 cells to adhere on Collagen I matrices compared to miR-23b and miR-n.c. (P 
= 0.01, Figure 24C).   
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Figure 24: MiR-23b and miR-26a affects cell adhesion on ECM. A, Immunofluorescence 
staining of MDA-MB-231 cells using Vinculin antibody (1:400); images were false coloured in a 
black-and-white fashion to highlight focal adhesions (FAs). After transfection with miR-26a, miR-
23b and miR-n.c. precursors (5nM) for 48 hours the cells were left to adhere on coverslips coated 
with 50uM of collagen I for 1 hour before staining. Scale bar = 10 µm. The graph on the right shows 
the FA size per treated cell. Quantification of FA size is represented as the average of FA area per 
cell. Data are shown as mean values ± standard error of the mean (s.e.m.) from three independent 
experiments (P = 0.04, Student‟s t test).B, For spreading assays, MDA-MB-231 cells were 
transfected with the indicated precursors (5nM) for 48h and seeded on collagen I (50µM) matrices 
for 30, 60 and 120 minutes. Cells were than fixed and stained for anti-Vinculin and phalloidin to 
visualise FAs and F-actin, respectively. Nuclei are visualised with TO-PRO-3 stain (blue); scale bar 
= 20 µm. C, For adhesion assays, MDA-MB-231 were transfected with the indicated precursors 
(5nM) and seeded on 50µM of collagen I and cell adhesion was quantified by dye retention 30 min 
after plating. Data are mean of three independent experiments ± s.e.m. (P = 0.01, Student‟s t-test). 
 
Figure 24: MiR-23b and miR-26a affects cell adhesion on ECM. 
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3.1.2.4         The miR-23b overexpression affects formation of lamellipodia 
protrusion 
 
During our transfection assays with miRNA precursors, a detailed observation of BC 
cell morphology revealed that miR-23b-induced overexpression was affecting the formation 
of lamellipodia in MDA-MB-231 cells cultured under normal cell growth conditions, and at 
most these formed only small, narrow protrusions (Figure 25A). We quantified this effect by 
counting the number of formed lamellipodia, the result of which was significantly diminished 
in miR-23b-transfected MDA-MB-231 cells (P = 0.0003, Figure 25A, box plot). In figure 
25B, we can appreciate the ability of miR-23b in impairing lamellipodia formation in MDA-
MB-231 cells stained for F-actin. 
 
 
 
Figure 25: MiR-23b overexpression impairs lamellipodia formation. A, Phase-contrast images of 
MDA-MB-231 cells transfected with the indicated miRNA precursors (5nM) for 48h. Lamellipodial 
structures are indicated by continuous arrows; lack of lamellipodia is indicated by discontinuous 
arrows. Scale bar = 100µm. The box plot on the right indicates quantification of the number of 
lamellipodia formed after treating the cells with the indicated precursors. 50–150 cells per condition 
in three independent experiments were counted. Data are mean ± s.e.m. (P = 0.0003, Student‟s t 
test). B, Immunofluorescence images shows lamellipodia in MDA-MB-231 cells transfected with 
the indicated precursors (5nM) for 48h and stained for F-actin with Alexa Fluor 488 phalloidin.  
 
Figure 25: MiR-23b overexpression affects lamellipodia formation. 
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3.1.3           Loss-of-function strategy: experimental repression of 
miRNA function 
 
In order to confirm that the observed effects mediated by miRNAs were results of 
their intrinsic intracellular function and not of eventual indirect effect mechanisms induced by 
ectopic expression of synthetic molecules, we wished to investigate whether the inhibition of 
miR-23b was able to reverse these effects. Therefore, we adopted a loss-of-function approach 
based on the use of miRNA-sponge vectors, in-house made plasmid constructs that, when 
expressed in cellular systems, encode for transcripts containing multiple, tandem miRNA-
binding sites in their 3‟UTR; these sequester intracellular mature miRNA from interaction 
with its target mRNAs thus inhibiting miRNA activity[325]. We constructed sponge 
oligonucleotides carrying 6 tandem, bulged binding sites specific for miR-23b or miR-26a 
(Figure 26A and B, respectively), and cloned either of them into the 3‟UTR of the pEGFP-C1 
plasmid vector, which encodes for an enhanced form of green fluorescent protein (EGFP). We 
verified the functionality of our miRNA-sponge constructs by using a miRNA-sensor vector 
that expresses a luciferase reporter gene, carrying a sequence of 6 tandem miR-23b or miR-
26a-specific binding sites in its 3‟UTR (see 2.2.3) (Figure 27A and B, respectively). As 
expected, co-expression of the sponge vector and the relative sensor vector increases 
luciferase activity compared to empty vector control, thus confirming the ability of our 
sponge constructs in inhibiting intrinsic activity of miR-23b and miR-26a (Figure 28A and B, 
respectively). We then used these constructs to establish MDA-MB-231 cell lines, that stably 
express either of the two miRNA-sponge vectors (we called them Sp-23b-MDA and Sp-26a-
MDA), or the relative parental plasmid control cells (we called them pEGFP-C1). We 
observed that miR-23b and miR-26a endogenous levels were reduced in different single 
clone-derived MDA-MB-231 cells stably expressing the miR-23b- and miR-26a-sponge 
vector, respectively, compared to the parental control cells (Figure 28C and D). In particular, 
among the different clonal Sp-23b-MDA and Sp-26a-MDA cells, the clone number 10 and the 
clone number 3 show the highest reduction efficiency, decreasing the levels of miR-23b and 
miR-26a by up to 70% and 50%, respectively (Figure 28C and D, respectively).  
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Figure 28: MiRNA-sponges reduce endogenous miRNA levels and activity in vitro. A-B, Relative 
luciferase activity levels were measured after 48h from transfection of HCT116 cells with the miR-
23b-sensor (A) or the miR-26a-sensor construct (B) and the indicated plasmids (100ng). Data are 
mean of triplicate samples in three independent experiments ± s.e.m. C-D, RT-qPCR analysis 
quantifies endogenous levels of miR-23b (C) and miR-26a (D) expressed in different MDA-MB-231 
cell clones stably expressing the correspondent miRNA-sponge vector or the parental control (MDA-
MB-231 cells stably expressing pEGFP-C1 plasmid) and normalised to U6 snRNA levels. Data are 
mean of triplicate samples in three independent experiments ± s.e.m.  
Figure 28: MiRNA-sponges reduce endogenous miRNA levels and activity in vitro. 
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We examined the proliferation rates of different clonal MDA-MB-231 cells stably expressing 
miR-23b- or miR-26a-sponge constructs, in order to investigate the effect of prolonged 
miRNA inhibition on tumour cell proliferation in vitro. As showed in the graph of figure 30, 
silencing of either miR-23b or miR-26a did not  affect the proliferative phenotype of MDA-
MB-231 cells, compared to parental controls, a finding that is consistent with the invariable 
proliferation rates of these cells observed upon overexpression of the two miRNAs (Figure 
29A). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30: MiR-23b or miR-26a inhibition does not affect BC cell proliferation. Growth curves of 
MDA-MB-231 sponge clones and empty vector controls determined performing SRB assays for the 
indicated time. Relative cell numbers are presented as percent over controls (EGFP-MDA). Data are 
calculated as means of two independent experiments performed in quintuplicates ± s.e.m. 
 
Figure 30: MiR-23b or miR-26a inhibition does not affect BC cell proliferation. 
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3.1.5           In vitro investigation of miR-23b function in BC cell 
motility and invasion  
 
3.1.5.1         MiR-23b overexpression reduces BC cell motility  
Cytoskeletal remodelling, cell adhesion and extension of membrane protrusions are 
crucial for the processes of cell migration and invasion[325]. As we observed alterations of 
these phenotypes upon overexpression of the two examined miRNAs, we hypothesised that 
miR-23b and miR-26a may be implicated in the regulation of motile and invasive phenotypes. 
To assess this, we performed Transwell migration assay and cell tracking analysis that 
investigated in vitro chemotaxis-driven cell motility and non-directional cell migration, 
respectively. In these assays we utilised a precursor mimic of miR-31, a miRNA previously 
found to strongly inhibit MDA-MB-231 cell motility and metastasis[376] as positive control. 
Transient overexpression of miR-23b markedly reduced chemotaxis of the highly motile 
MDA-MB-231 cells (P = 0.004) compared to miR-26a and miR-n.c, to the same extent of 
reduction showed by miR-31-overexpressing positive controls (P = 0.001, Figure 31A). 
Accordingly, miR-23b and miR-31, but not miR-26a, reduced cell migratory speed (P < 
0.0001, Figure 31B) and shortened migration trajectory lines (Figure 31C and D) in 
migratory cell tracking assays.   
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3.1.5.2        MiR-23b loss-of-function promotes BC cell motility  
 
To assess the effect of miR-23b inhibition on cell migration, we used MDA-MB-231 
cells, stably expressing the miR23b- or miR-26a-sponge constructs (clones 10 and 3, 
respectively) or the parental vector to perform Transwell migration assays. In contrast to cells 
overexpressing miR-23b (Figure 31), miR-23b silencing in MDA-MB-231 cells significantly 
increased motility compared to cells that stably silenced miR-26a or expressed the pEGFP-C1 
control (P < 0.0001, Figure 32A). Notably, the number of lamellipodia significantly 
increased in cells stably expressing sponge vector able to inhibit miR-23b levels (P < 0.0001, 
Figure 32B), which was consistent with the effect of miR-23b overexpression on lamellipodia 
formation (Figure 25). 
 
 
 
 
 
 
Figure 32: MiR-23b inhibition promotes BC cell migration and lamellipodia formation. A, 
Transwell migration assays of MDA-MB-231 cells stably expressing the indicated construct vectors 
were performed for 9h. The graph on the right indicates cell migration expressed as a percentage of the 
average of migratory cells per field (n=5 fields per transfection). Data are mean of three experiments ± 
s.e.m. performed in triplicates (P < 0.0001 Student‟s t-test). B, MDA-MB-231 cells stably expressing 
the indicated constructs grown in 2D cultures were imaged by phase-contrast microscopy to show 
lamellipodia structures. 50–150 cells per condition in three independent experiments were counted. 
Data are mean ± s.e.m. (P < 0.0001, Student‟s t test).  
Figure 32: MiR-23b inhibition promotes BC cell migration and lamellipodia formation. 
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3.1.5.3        MiR-23b regulates BC cell invasion in vitro  
Next, we wished to evaluate the role of miR-23b in the regulation of invasive 
phenotypes. Therefore, we tested MDA-MB-231 cell migration in 3D- collagen I matrices 
upon experimental induction or inhibition of miR-23b expression. Overexpression of miR-23b 
significantly reduces cell invasion of MDA-MB-231 cells (P = 0.001, Figure 33A), whilst 
silencing of miR-23b sponge construct activity markedly elicits invasive capabilities of MDA-
MB-231 cells (P = 0.04, Figure 33B).  
 
 
3.1.6           Identification and validation of miRNA gene targets 
3.1.6.1         MiR-23b and miR-26a target PAK2 kinase and leads to 
induction of MLC II phosphorylation 
 
Thus far our results implicated both miR-23b and miR-26a in regulation of 
cytoskeletal dynamics, and we chose the PAK2 kinase as a candidate target since both 
miRNAs were identified by Targetscan as potential PAK2 regulators in highly conserved sites 
of its 3UTR (Figure 34A and B). Furthermore, PAK2 is interesting in this context as its 
Figure 33: MiR-23b regulates BC cell invasion in vitro. A, Invasion of MDA-MB-231 cells 
transfected with miR-23b and miR-n.c. precursors (5nM) for 48h was assessed in 3D-collagen-I 
matrices (2.3mg/ml) for 16h. Confocal z sections were collected from each well at 0μm (bottom of the 
well) and 40μm and invasion indexes were calculated as the number of cells at 40μm divided by those 
at 0μm. Invasion indexes are mean of three experiments ± s.e.m. performed in quintuplicates (P = 
0.001 Student‟s t-test). B, Invasion assays using MDA-MB-231 cells stably expressing the miR-23b-
sponge construct or the parental control pEGFP-C1 plasmid vector were performed as in A. Invasion 
indexes are mean of three experiments ± s.e.m. performed in quintuplicates (P = 0.04, Student‟s t-test). 
 
Figure 33: MiR-23b regulates BC cell invasion in vitro. 
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knockdown by small RNA interference (siRNA) in T47D BC cell lines reduces cell motility 
and invasion, increases the size of FAs, and promotes phosphorylation of the myosin light 
chain II (MLC II)[129]. We first demonstrated that PAK2 silencing is also able to reduce 
motility and increase MLC II phosphorylation in MDA-MB-231 cells (P = 0.003, Figure 34C 
and D).  
 
Figure 34: PAK2, a predicted target for miR-23b and miR-26a, regulates cell motility and MLC 
II phosphorylation in BC cells. A, Representation of human PAK2 3‟UTR presenting conserved sites 
for the indicated putative miRNA families; miR-23b and miR-26a families are highlighted by a 
rectangular box (adapted from TargetScan). B, Predicted duplex formation between human 
PAK2 3′UTR and hsa-miR-23b (top) or hsa-miR-26a (bottom). C, MDA-MB-231 cells were 
transfected with the indicated siRNAs (5nM) for 48h and then cell migration was examined by phase-
contrast, time-lapse microscopy for 24h. Cell speed of 50 cells per condition was quantified and is 
presented as mean of the averages of three experiments ± s.e.m. (P = 0.003, Student‟s t-test). D, 
Western blots show PAK1, PAK2, (Thr18/Ser19)-ppMLC II and MLC II levels in MDA-MB-231 
cells after transfection with the indicated siRNAs (5nM). β-actin was used as a loading control. Fold 
changes in protein expression levels normalised for β-actin using ImageJ software are shown 
underneath each relative protein plot. 
 
Figure 34: PAK2, a predicted target for miR-23b and miR-26a, regulates cell motility and MLC II phosphorylation in 
BC cells. 
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Mammals express six isoforms of PAK (1–6), subdivided into two groups: Group I consists of 
PAK1, PAK2, and PAK3 and Group II includes PAK4, PAK5 and PAK6[126]. Only group I 
members are directly activated by CDC42 or RAC[125]. We then measured group I PAKs upon 
miRNA overexpression in three epithelial cancer cell lines (Figure 35A). We could not detect 
PAK3 expression in any of the three cell lines by either western blotting or RT-qPCR, a 
finding consistent with the known restricted tissue expression pattern for this enzyme [409]. 
However, we showed that miR-23b and miR-26a specifically reduced PAK2 levels in all of 
the cell lines tested (Figure 35A). Expression levels of PAK1, although not predicted to be a 
target of miR-23b or miR-26a (Figure 35B), is slightly reduced probably due to a concurrent 
decrease in PAK2 (Figure 35A), as PAK1 levels are seen to decline upon PAK2 silencing 
(Figure 34D). Consequently, the phosphorylation of the cytoskeletal remodelling regulator 
MLC II, an indicator of active contractility, was up-regulated by both miRNAs (Figure 35C). 
 
 
Figure 35: Overexpression of mir-23b and miR-26a results in PAK2 repression and increase of 
MLC II phosphorylation. A, Western blots showing PAK1 and PAK2 levels after transfection for 
48h of the indicated miRNA precursors (5nM) in BC MDA-MB-231 and MCF-7 cells and colon 
cancer HCT116 cells. B, Representation of human PAK1 3‟UTR presenting conserved sites for the 
indicated putative miRNA families (adapted from TargetScan). C, Western blots showing MLC II 
levels and phosphorylation of MLC II at Thr18/Ser19 position, after transfection for 48h of miR-23b 
and miR-n.c. precursors (5nM) in the same cancer cell lines described in A. Fold changes in protein 
expression levels normalised for β-actin using ImageJ software are shown underneath each relative 
protein plot. 
 
Figure 35: Overexpression of mir-23b and miR-26a results in PAK2 repression and increase of MLC II 
phosphorylation. 
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3.1.6.2         Inhibition of miR-23b and miR-26a releases PAK2 expression 
from miRNA-mediated silencing   
 
In order to exclude eventual off-target effects on the repression of PAK2 expression 
upon miR-23b and miR-26a overexpression, we wished to confirm that PAK2 is a 
physiological target of both these miRNAs under loss-of-function conditions. Therefore, we 
transiently transfected miR-26a- and miR-23b-sponge constructs in MCF-7 cells, and 
confirmed that inhibition of both miRNAs was able to release PAK2 expression by miR-23b 
and miR-26a-mediated silencing (Figure 36A). Furthermore, we measured PAK2 levels in 
different clones of MDA-MB-231 cells stably expressing miRNA-sponge constructs; we 
found that where maximal miRNA silencing was achieved by an efficient miRNA-sponge 
activity (clone 10 and 3 for miR-23b and miR-26a, respectively, Figure 28C and D), PAK2 
expression levels increased compared to parental control cells (Figure 36B).  
 
 
Figure 36: Inhibition of mir-23b and miR-26a releases PAK2 expression from miRNA-mediated 
silencing. A, Western blots showing PAK2 levels after transient transfection for 48h of MCF-7 cells 
with the indicated miRNA-sponge constructs or the pEGFP-C1 parental control (2µg). β-actin was 
used as a loading control. Fold changes in protein expression levels normalised for β-actin using 
ImageJ software are shown underneath each relative protein plot. B, Western blot showing PAK2 
expression levels in different clonal MDA-MB-231 cells stably expressing the indicated plasmid 
constructs. β-actin was used as a loading control. 
 
Figure 36: Inhibition of mir-23b and miR-26a releases PAK2 expression from miRNA-mediated silencing. 
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3.1.6.3         PAK2 is a direct target of miR-23b and miR-26a  
 
Next, we wished to confirm that miR-23b and miR-26a repress PAK2 translation by 
direct interaction with their relative miRNA-binding sites contained in PAK2 3‟UTR and 
predicted by TargetScan (Figure 34A and B). For this purpose, we cloned PAK2 3‟UTR in a 
luciferase reporter vector (pMIR-REPORT) (Figure 37A); additionally, we produced two 
variants of the PAK2-3‟UTR-pMIR REPORT construct, each carrying mutations in the 
miRNA-binding site predicted for miR-23b or miR-26a (PAK2 3‟UTR-23b mut and PAK2 
3‟UTR-26a mut), which cause disruption of heteroduplex formation between each miRNA 
and its relative binding site in PAK2 3‟UTR (Figure 37B). By performing luciferase reporter 
assays, we showed that miR-23b and miR-26a regulate PAK2 by interacting directly with its 
3‟UTR, since co-expression of the two miRNAs with PAK2 3‟UTR pMIR-REPORT, reduced 
luciferase levels when the binding sites did not contain mutations (Figure 37C). This 
reduction was not observed when the miRNAs were co-expressed with a pMIR-REPORT 
construct containing PAK1 3‟UTR which do not contain any predicted site of interaction for 
these two miRNAs in its 3‟UTR (Figure 37A and D, and 35B).  
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3.1.7           Regulation of miR-23b transcriptional expression 
 
3.1.7.1         AP-1 transcriptionally suppresses miR-23b expression  
 
 
Next, we wondered whether miR-23b expression is subject to eventual regulatory 
mechanisms relevant to BC. MiR-23b is encoded in the complex transcription unit (TU), 
Chromosome 9 open reading frame 3 (C9orf3), which contains at least three transcriptional 
start sites (TSSs) (Figure 38A). The transcription factor c-MYC has been shown to suppress 
miR-23b expression by directly interacting with its most upstream TSS[299]. We performed in 
silico analysis of the miR-23b gene TU for transcription factors that may regulate expression 
of this miRNA gene; it revealed the presence of conserved and less conserved TPA-
responsive elements (TREs), which are genomic sequences specifically recognised by the 
transcription factor activator protein 1 (AP-1) (Figure 38A). Functional AP-1 is formed upon 
heterodimerisation of c-JUN and c-FOS and plays major roles in transcriptional regulatory 
processes relevant to BC. It is in fact activated through EGFR and HER-2 signalling pathways 
and subsequently recognises TREs in promoter and enhancer regions of target genes involved 
in cell motility, invasion and growth[194]. 
In order to determine whether AP-1 regulates miR-23b expression at the transcriptional level, 
we silenced c-FOS and c-JUN in MDA-MB-231 cells (Figure 38B). We observed that 
individual gene silencing had little effect on miR-23b expression, whereas co-silencing of 
both genes significantly increased primary miR-23b (pri-miR-23b) but not pri-mir-26a-1 and 
pri-mir-26a-2 that do not present conserved TRE‟s along their TUs (P = 0.0008, Figure 38C). 
Furthermore, endogenous mature miR-23b levels were increased after simultaneous 
knockdown of c-JUN and c-FOS, whereas mature miR-26a levels remained unchanged 
(Figure 38D and E). These data implicate AP-1 in the negative regulation of miR-23b 
expression. We then hypothesised that AP-1-mediated regulation of miR-23b levels may 
result in a perturbation of downstream events that are controlled by miR-23b. Indeed, we 
found that c-JUN-c-FOS co-silencing reduced PAK2 levels and greatly increased MLC II 
phosphorylation (Figure 38F).  
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Figure 38: AP-1 transcriptionally suppresses miR-23b expression. A, Schematic representation of 
transcription unit (TU) of miR-23b~27b~24-1 cluster showing conserved, less conserved and non-
conserved AP-1-specific TREs. Switchgear TSS: transcription start site experimentally validated by 
Switchgear Genomics B. Western blot showing c-JUN and c-FOS levels in MDA-MB-231 cells after 
transfection with the indicated siRNAs for 48h. β-actin was used as a loading control. C, Relative 
levels of pri-miR-23b, pri-miR-26a-1 and pri-miR-26a-2 were measured by RT-qPCR and normalised 
to U6 snRNA levels after co-silencing of c-JUN and c-FOS, or single silencing of the two genes by 
using siRNAs (20nM) in MDA-MB-231 cells for 48h. Data are presented relative to the siRNA n.c. 
(40nM) single transfection (dotted line). Data are mean of three experiments ± s.e.m. (P = 0.0008, 
Student‟s t-test). D-E, RT-qPCR of miR-23b (D) and miR-26a (E) relative levels normalised to U6 
snRNA levels after transfection with the indicated siRNAs (20nM) of MDA-MB-231 cells for 96h. 
Data are mean of three independent experiments ± s.e.m. F, Western blot showing PAK1, PAK2, 
(Thr18/Ser19)-ppMLC II and MLC II levels in MDA-MB-231 cells after transfection with the 
indicated siRNAs. β-actin was used as a loading control. Fold changes in protein expression levels 
normalised for β-actin using ImageJ software are shown underneath each relative protein plot. 
 
Figure 388: AP-1 transcriptionally suppresses miR-23b expression. 
5HVXOWV

154 
 
$3GLUHFWO\LQWHUDFWVZLWKPL5ESURPRWHU

:H WKHQ ZLVKHG WR LQYHVWLJDWH ZKHWKHU $3 VXSSUHVVHV PL5E H[SUHVVLRQ E\
GLUHFWO\ELQGLQJ WR WKH75(VSUHVHQW LQ WKH78RIPL5E7KXVZHSHUIRUPHGFKURPDWLQ
LPPXQRSUHFLSLWDWLRQ &K,3 IRU F-81 LQWHUDFWLRQZLWK JHQRPLF UHJLRQV LQ0'$0%
FHOOV2XU&K,3DQDO\VLV UHYHDOHGWKDW$3FRXOGEHGLUHFWO\LQYROYHGLQWKHWUDQVFULSWLRQDO
LQKLELWLRQRIPL5EDVF-81GLUHFWO\ERXQGWRDWOHDVWWZRHYROXWLRQDULO\FRQVHUYHG75(V
LQWKH78RI&RUI)LJXUHDQG$$VH[SHFWHGF-81DOVRERXQGWRWKH,/JHQH
SURPRWHUXVHGDVSRVLWLYHFRQWURO>@EXWQRWDJHQRPLF'1$UHJLRQWKDWODFNVWKHSUHVHQFH
RI75(VDQGZDVXVHGDVQHJDWLYHFRQWURO)LJXUH


 
 
 
)LJXUHF-81GLUHFWO\LQWHUDFWVZLWKPL5ESURPRWHU0'$0%FHOOVZHUHSURFHVVHG
IRU &K,3 DVVD\V DQG 57T3&5 ZDV SHUIRUPHG 7KH F-81LQWHUDFWLRQ VLWH JHQRPLF UHJLRQV DUH
SUHVHQWHGH[SUHVVHGDVSURPRWHURFFXSDQF\0L5EUHSUHVHQWHDFK$3VSHFLILF75(V
SUHVHQW LQ WKH 78 RI PL5E SURPRWHU UHVSHFWLYHO\ ,/ LQWHUOHXFKLQ SURPRWHU UHJLRQ QF D
JHQRPLF UHJLRQ WKDW GRHV QRW FRQWDLQ $3VSHFLILF 75(V 'DWD DUH PHDQ RI WZR LQGHSHQGHQW
H[SHULPHQWVVHP
Results 
 
155 
 
3.1.7.3         EGF stimulation inhibits miR-23b expression 
We next wished to investigate whether activation of AP-1 by upstream signalling 
pathways is able to regulate miR-23b expression. AP-1 is a well-described oncogenic 
transcription factor activated downstream of EGFR/HER2 signalling, triggered by receptor 
stimulation with extracellular ligands, such as EGF[186]. It is known that EGF stimulation 
induces transcriptional expression of the AP-1-component c-JUN via downstream activation 
of AP-1 itself[199]. In order to evaluate whether miR-23b is inhibited by the same treatment, 
we treated EGFR positive BC MDA-MB-468 cell lines with EGF. As shown, levels of c-JUN 
mRNA increased within 20 min to 2 hours upon EGF stimulation confirming the validity of 
our methods (Figure 40A)[199]. We demonstrated that miR-23b levels decreased when c-JUN 
levels increased (Figure 40B), indicating that EGF reduces miR-23b expression through the 
c-JUN transcription factor. 
 
 
. 
 
 
 
 
 
 
 
 
 
 
Figure 40: EGF stimulation inhibits miR-23b expression. A-B, RT-qPCR detected levels of c-JUN 
mRNA (A) and miR-23b (B) after EGF treatment (25 ng/ml) in MDA-MB-468 cells over the time 
course shown. C-JUN and miR-23b levels were normalised to U6 snRNA. Data are mean of three 
independent experiments ± s.e.m. 
 
Figure 40: EGF stimulation inhibits miR-23b expression. 
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3.1.8           MiR-23b plays a role in BC metastasis 
 
3.1.8.1         MiR-23b expression is inversely correlated with BC metastasis 
 
Due to its crucial role in cytoskeletal remodelling, migration and invasion in BC, we 
hypothesised that loss of miR-23b may be involved in BC metastatic spread. Therefore, we 
examined miR-23b levels in MDA-MB-231 cells isolated from primary tumours or metastatic 
loci in different distal organs, formed after inoculation of a parental population of MDA-MB-
231 cells into the mammary fat pads of nude mice[411]. Levels of miR-23b, but not miR-26a 
(measured as control), were higher in cells that formed the primary tumour at the inoculated 
site (TMD-231), compared to the cells that metastasised to the adrenal gland (ADMD-231), 
bone (BMD-231) or lung (LMD-231) (Figure 41A and B). Subsequently, we measured miR-
23b and miR-26a levels in a small number of paired primary tumour and lymph-node 
metastasis specimens isolated from BC patients. Accordingly, miR-23b levels were higher in 
primary tumours, compared to their corresponding lymph-node metastases, whereas miR-26a 
expression did not change (Figure 41C). To increase the statistical significance of this 
finding, we next examined the expression of both miRNAs in a larger cohort of BC patients 
(n=132; 66 primary tumours and matching lymph-node metastases; Table 12). In accordance 
with our previous observations the mean expression of miR-23b, but not miR-26a, was 
significantly higher in the primary tumours than in the matching lymph node metastases (P = 
0.004; Figure 41D) 
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Figure 41: MiR-23b expression levels inversely correlate with BC metastasis. A-B, RT-qPCR 
shows relative expression levels of miR-23b (A) and miR-26a (B) in MDA-MD-231 BC cell lines 
isolated from primary tumour at the inoculation site (TMD-231) and metastatic loci in the adrenal 
gland (AMD-231), bone (BMD-231) and lung (LMD-231) formed after inoculation of a parental cell 
line in the mammary fat pads of nude mice. Data are mean of triplicate samples in one experiment ± 
s.e.m. C, MiR-23b and miR-26a relative levels in 4 pairs of human primary BC samples and their 
matched lymph-node metastases. Data are mean of triplicate samples in one experiment. D, Scatter 
plot shows the mean of miR-23b and miR-26a expression levels in 66 primary breast tumours and 
their corresponding metastatic specimens (P = 0.004, Student‟s t-test). MiRNAs levels were 
normalised to endogenous U6 snRNA levels. 
 
Figure 41: MiR-23b expression levels inversely correlate with BC metastasis. 
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3.1.8.2         MiR-23b inhibition increases in vivo experimental metastasis 
and tumour growth  
 
Based on our observations that miR-23b expression levels are markedly reduced in BC 
metastases, and that miR-23b inhibition promotes BC cell motility and invasion in vitro, we 
wished to further investigate these findings in vivo. MDA-MB-231 cell lines stably 
transfected with miR-23b-sponge or pEGFP-C1 vector control constructs were injected into 
the mammary fat pad of BALB/c Nude mice and primary tumours were allowed to grow until 
the volume reached about 300 mm2 (n=7 per treatment). Histopathological analysis of the 
isolated primary tumours showed that local tumour invasion into the surrounding fat was 
dramatically increased by long-term miR-23b inhibition (Figure 42A), which was consistent 
with our in vitro findings (Figure 33B). In addition, immunohistochemistry of draining lymph 
nodes revealed the presence of extensive metastatic deposits only in the mice injected with 
stably transfected miR-23b sponge cells, indicating an enhanced ability of these cells with 
reduced miR-23b activity, to form spontaneous metastases (P < 0.0001; Figure 42B).  
 
 
Surprisingly, we observed that inhibition of miR-23b elicited tumour growth in vivo (Figure 
43A), which was inconsistent with our in vitro findings, where neither overexpression 
(Figure 29A), nor inhibition of miR-23b (Figure 30) significantly altered proliferation of 
MDA-MB-231 cells. Normally xenografts derived by injection of human breast MDA-MB-
Figure 42: MiR-23b inhibition elicits BC cell invasion and metastasis in vivo. A, Hematoxillin and 
eosin (H&E) stain of primary tumours formed by miR-23b-sponge expressing- or pEGFP-C1 
expressing-MDA-MB-231 cells 2 months after their orthotopic injection in mammary gland fat pads of 
BALB/c nude mice. Black arrows indicate regions of invasion into the surrounding fat. B, 
Representation of a lymph node isolated from an experimental metastatic animal study after injection 
of miR-23b-sponge expressing-MDA-MB-231 cells and stained by H&E. The black arrow indicates 
metastatic areas whereas green arrows indicate residual normal tissue characterised by the presence of 
smaller nuclei (n=7 per treatment). A quantification of the tissue type within the lymph nodes is shown 
in the graph on the right (P < 0.0001, Chi-Square test). 
 
Figure 42: MiR-23b inhibition elicits BC cell invasion and metastasis in vivo. 
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231 cells into the mammary fat pad of immunocompromised mice have an extensive central 
necrotic area [412]. Notably, we found that down-regulation of miR-23b by the sponge 
construct, dramatically reduced tumour necrosis (P = 0.002; Figure 43B). This could explain 
the differential effect on cell growth exerted by miR-23b inhibition, in vivo and in vitro. 
Conversely, the tumours derived from miR-23b-sponge-expressing cells did not show any 
significant difference in the number of tumour microvessels compared to primary tumours 
formed by parental control cells  (Figure 43C), suggesting that miR-23b is not implicated in 
the regulation of neoangiogenesis.  
 
 
Figure 43: MiR-23b inhibition elicits tumour growth and reduces tumour-related necrosis in 
vivo. A, Line chart showing changes in tumour volume (mm3) over time (weeks) after injection of 1 x 
106 miR-23b-sponge expressing- or pEGFP-C1 expressing-MDA-MB-231 cells into the mammary fat 
pad of BALB/c nude mice (n=7 per treatment). B, H&E stain of representative MDA-MB-231 cell 
primary tumours formed 2 months after orthotopic injection of the same cells as in A. Arrow indicates 
region of necrosis. The graph below shows quantification of necrosis expressed as percentage of 
necrotic areas formed within the primary tumours (n=7 per treatment; P = 0.002, Student‟s t-test).  C, 
CD31 stain of representative primary tumours formed as explained in A and B (n=7 per treatment). 
Arrows indicate microvessels formation. Average of intratumoural vessels counts per five high power 
fields, per section (n=4 sections) in three different tumours per treatment was performed. 
 
Figure 43: MiR-23b inhibition elicits tumour growth and reduces tumour-related necrosis in vivo. 
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3.2            MiR-26a plays a role in cytokinesis, aneuploidy and 
anchorage-independent cell growth in BC 
3.2.1           Prolonged miR-26a overexpression leads to formation of 
giant binucleated cells in vitro 
 
So far, our data suggest an unpredicted role for miR-26a in regulation of cytoskeletal 
dynamics. We demonstrated that ectopic overexpression of miR-26a promotes cell spreading 
and adhesion on ECM and leads to formation of enlarged focal adhesion sites in BC cell lines; 
furthermore miR-26a directly targets PAK2 and promotes phosphorylation of the MLC II.  
Owing to its role in cytoskeletal remodelling, we wished to further investigate the effect that  
prolonged miR-26a overexpression may have in BC cell lines, using a similar approach to that 
used to assess miR-23b function.  
We performed long-term (9 days) transfections of both MCF-7 and MDA-MB-231 cells with 
a miR-26a precursor or a pre-miR-n.c. mimic. Unexpectedly we observed that, compared to 
controls, both miR-26a-overexpressing cell lines grown in 2D-cultures exhibit a 
heterogeneous cell population, comprising cells of normal morphology, and giant cells 
displaying enlarged nuclei or two nuclei within their expanded cytoplasm. This effect 
suggests that events of impaired cytokinesis may be occurring upon miR-26a prolonged 
overexpression (Figure 44A and B). We quantified this effect by counting the number of 
multinucleated cells presenting in MCF-7 cell cultures after long-term-transfections with 
miRNA precursors. We found that a significant fraction (20%) of the miR-26a-overexpressing 
cell population was multinucleated compared to 3% of multinucleated cells present in MCF-7 
cell cultures transfected with either miR-n.c. or miR-23b precursor (P = 0.0002; Figure 44C), 
which exhibit overall normal sized nuclei and cytoplasm (Figure 44A and 23B). This 
phenotype indicates that miR-26a activity may lead to impaired cytokinesis, implying the 
occurrence of aneuploidy. Moreover, the population of mononucleated cells overexpressing 
miR-26a appeared to have nuclei almost double in size compared with miR-n.c. or miR-23b 
transfected cells, indicating that nuclear division[413] could also be affected by this miRNA. 
After long-term transfection of miR-26a precursor, MCF-7 cells appeared to undergo a 
redistribution of F-actin in cortical microspikes, whilst E-cadherin levels and cell-cell junction 
were almost completely absent (Figure 44A). 
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3.3            Mir-23b and miR-26a exhibit distinct gene targeting 
relevant to cellular phenotypes regulated by each single 
miRNA 
3.3.1          RNA-seq and bioinformatic analysis reveal regulation of 
distinct gene patterns by miR-23b and miR-26a  
 
By performing experimental phenotypic analysis we found that miR-23b and miR-26a 
have both overlapping and distinct functions, despite regulating at least one common gene, 
PAK2, at the post-transcriptional level (Figure 35, 36 and 37). This suggests that although 
both miRNAs modulate cytoskeletal dynamics partially by targeting PAK2, their general 
function is determined by coordinated regulation of distinct gene sets which is expected since 
miRNAs can target hundreds of different genes within the same tissue or cell[414]. In order to 
characterise the specific gene pattern controlled by each of these miRNAs and gain insight 
into the molecular mechanisms responsible for the observed phenotypes, we adopted a large-
scale experimental approach based on high-throughput RNA sequencing (RNA-seq) analysis. 
Next generation RNA-seq represents a potent and accurate tool to assess transcript level 
changes for the identification of potential miRNA targets, by providing digital data of 
absolute transcript abundance[414]. Therefore, we performed global RNA-seq to analyse 
transcriptome changes mediated by ectopic manipulation of both miR-23b and miR-26a in BC 
cells. Particularly, we induced long-term (9 days) overexpression of each miRNA in epithelial 
MCF-7 cells and used MDA-MB-231 cells stably expressing a miRNA-sponge construct that 
silences each miRNA (Figure 28C and D) along with their relative controls. 
 
3.3.1.1         RNA-seq and bioinformatic analysis confirm a role of miR-23b 
in cytoskeletal dynamics 
 
Considering a significant cut off of 1.5 fold, analysis of our RNA-seq data relative to 
miR-23b manipulation revealed that prolonged overexpression of this miRNA in MCF-7 cells 
affected (down-regulated or up-regulated) levels of 7.4% of transcripts, whereas in MDA-
MB-231 cells stably inhibiting miR-23b, gene expression changes were detected in 22.9% of 
total transcripts.  
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7R XQGHUVWDQG WKH ELRORJLFDO UHOHYDQFH RI WKH JHQHV UHJXODWHG E\PL5E ZH SHUIRUPHG
SDWKZD\ HQULFKPHQW DQDO\VLV RI WKH GHWHFWHG XSUHJXODWHG DQG GRZQUHJXODWHG WUDQVFULSWV
XVLQJZHEEDVHG'$9,'WRRO>@
&RQVLVWHQWZLWK WKH SKHQRW\SHV WKDWZH REVHUYHG LQ0&) FHOOV RYHUH[SUHVVLQJPL5E
)LJXUH  DQGZH DSSUHFLDWHG DQ HQULFKPHQW RI JHQHV LQYROYHG LQ DGKHUHQV MXQFWLRQ
IRUPDWLRQSDUWLFXODUO\ZHIRXQGXSUHJXODWHGDVHWRIJHQHVVXFKDV&711%395/DQG
3ROLRYLUXVUHFHSWRUOLNHDQG7-37LJKWMXQFWLRQSURWHLQDQG/02/,0GRPDLQ
 ZKLFK HQFRGH IRU WKH FHOO DGKHVLRQ PROHFXOHV &DWHQLQ ȕ 1HFWLQ DQG  7-3 DQG
/02UHVSHFWLYHO\7DEOH
2Q WKH RWKHU KDQG UHGXFHGPL5E DFWLYLW\ LQ0'$0% FHOOV ZDV DVVRFLDWHG ZLWK
HQULFKHG JHQHV LPSOLFDWHG LQ WKH UHJXODWLRQ RI DFWLQ F\WRVNHOHWRQ 7KHVH FHOOV VKRZHG XS
UHJXODWLRQ RI JHQHV WKDW SURPRWH ODPHOOLSRGLD DQG ILORSRGLD IRUPDWLRQ VXFK DV /,0.
/,0. DQG &)/ DQG $5+*() HQFRGLQJ IRU /,0 NLQDVH  DQG  &RILOLQ  DQG WKH
5$&&'& JXDQLQH H[FKDQJH IDFWRU  UHVSHFWLYHO\ DV ZHOO DV FHQWUDO PRGXODWRUV RI
F\WRVNHOHWDO G\QDPLFV WKDW SURPRWH PLJUDWRU\ SKHQRW\SHV VXFK DV P\RVLQ OLJKW FKDLQ 
0</WKHQRQPXVFOHP\RVLQKHDY\FKDLQ0<+DQGSDFWLYDWHGNLQDVH3$.
WKHODWWHUVKRZQWREHGLUHFWPL5EWDUJHWRQFHDJDLQFRQILUPLQJRXULQYLWURILQGLQJV
7DEOH
7DEOH*HQHVGLIIHUHQWLDOO\UHJXODWHGLQ0&)FHOOVXSRQSURORQJHGRYHUH[SUHVVLRQRIPL5
ERYBPL5ERUPL5QFRYBPL5QFDQGUHOHYDQWWRDGKHUHQVMXQFWLRQSDWKZD\V53.0
5HDGVSHUNLOREDVHSHUPLOOLRQ&KDQJHIROGRIJHQHH[SUHVVLRQEHWZHHQRYBPL5EDQGRYPL5QF
LQGLFDWHVJHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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
51$VHTDQGELRLQIRUPDWLFDQDO\VLVFRQILUPDUROHRIPL5D
LQF\WRVNHOHWDOG\QDPLFVFHOODGKHVLRQDQGFHOOF\FOH

0DQLSXODWLRQ RI PL5D DIIHFWHG WKH H[SUHVVLRQ RI  DQG  RI WRWDO
WUDQVFULSWV XSRQ SURORQJHG PL5D RYHUH[SUHVVLRQ LQ 0&) FHOOV DQG VWDEOH PL5D
LQKLELWLRQLQ0'$0%FHOOVUHVSHFWLYHO\FRQVLGHULQJDVLJQLILFDQWFXWRIIRIIROG
7DEOH *HQHV GLIIHUHQWLDOO\ UHJXODWHG LQ0'$0% FHOOV VWDEO\ H[SUHVVLQJ WKHPL5E
VSRQJH FRQVWUXFW 6SE RU WKH S(*)3& SDUHQWDO FRQWURO S(*)3 DQG UHOHYDQW WR
F\WRVNHOHWRQ SDWKZD\V 53.0 5HDGV SHU NLOREDVH SHU PLOOLRQ &KDQJH IROG RI JHQH H[SUHVVLRQ
EHWZHHQ6SEDQGS(*)3LQGLFDWHVJHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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3DWKZD\HQULFKPHQWDQDO\VLVRIWKHJHQHVGLIIHUHQWLDOO\UHJXODWHGE\PL5DRYHUH[SUHVVLRQ
LQ0&)FHOOVVKRZHGVLJQLILFDQWFKDQJHVLQH[SUHVVLRQRIF\WRVNHOHWDOUHPRGHOOLQJUHODWHG
JHQHV7DEOHVXFKDV0</.DQG3$. WKDWZHYDOLGDWHGDVPL5DGLUHFW WDUJHWDQG
FRQVLGHUHG WKLVJHQHDV DSRVLWLYH FRQWURORIRXUPHWKRGVJHQHV UHODWLYH WR IRFDO DGKHVLRQ
SDWKZD\V LQFOXGLQJ 9LQFXOLQ 9&/ RU WR PDWUL[FHOO DGKHVLRQ LQWHUDFWLRQV VXFK DV
)LEURQHFWLQ)1DQGDFRKRUWRILQWHJULQVXEXQLWV,7*$0,7*%,7*$,7*%,7*$9
,7*% ,QWHUHVWLQJO\FHOODGKHVLRQ UHODWHGJHQHVZHUH IRXQGFRQYHUVHO\GRZQUHJXODWHG LQ
0'$0%FHOOVWDEO\LQKLELWLQJPL5DDFWLYLW\7DEOH8SUHJXODWLRQRIWKLVJHQH
VHWPD\H[SODLQWKHSKHQRW\SLFHIIHFWVLQGXFHGE\PL5DRYHUH[SUHVVLRQRQIRFDODGKHVLRQ
FHOOVSUHDGLQJDQGDGKHVLRQRQWKH(&0)LJXUHDQG$GGLWLRQDOO\DPRQJWKHJHQHV
HQULFKHG LQ DGKHUHQV MXQFWLRQ SDWKZD\V XSRQPL5D RYHUH[SUHVVLRQ LQ0&) FHOOV ZH
IRXQGXSUHJXODWLRQRI JHQHV WKDWEHORQJ WR WKH7*)ȕ VLJQDOOLQJSDWKZD\NQRZQ WR LQGXFH
GLVUXSWLRQ RI FHOOFHOO DGKHVLRQV VXFK DV7*)ȕ UHFHSWRU DQG  7*)5% DQG60$'
IDPLO\PHPEHU60$'DQG61$,/KRPRORJ61$,>@7DEOH
7DEOH*HQHVGLIIHUHQWLDOO\UHJXODWHGLQ0&)FHOOVXSRQSURORQJHGRYHUH[SUHVVLRQRIPL5
D RYBPL5D RU PL5QF RYBPL5QF DQG UHOHYDQW WR F\WRVNHOHWDO UHPRGHOOLQJ 53.0
5HDGVSHUNLOREDVHSHUPLOOLRQ&KDQJHIROGRIJHQHH[SUHVVLRQEHWZHHQRYBPL5DDQGRYPL5QF
LQGLFDWHVJHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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7DEOH *HQHV GLIIHUHQWLDOO\ UHJXODWHG LQ0'$0% FHOOV VWDEO\ H[SUHVVLQJ WKHPL5D
VSRQJH FRQVWUXFW 6SD RU WKH S(*)3& SDUHQWDO FRQWURO S(*)3 DQG UHOHYDQW WR
F\WRVNHOHWRQ SDWKZD\V 53.0 5HDGV SHU NLOREDVH SHU PLOOLRQ &KDQJH IROG RI JHQH H[SUHVVLRQ
EHWZHHQ6SDDQGS(*)3LQGLFDWHVJHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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,Q DGGLWLRQ WR F\WRVNHOHWDO UHPRGHOOLQJ SDWKZD\V RXU'$9,'DQDO\VLV FRQILUPHGRXUV DQG
RWKHUVSXEOLVKHGILQGLQJV>@  WKDWPL5D LV LPSOLFDWHG LQ WKH UHJXODWLRQRI WKHFHOO F\FOH
SURFHVV DV D ODUJH SDQHO RI JHQHV UHOHYDQW WR FHOO F\FOH SURJUHVVLRQ ZHUH IRXQG ZLGHO\
G\VUHJXODWHG DIWHU PL5D PDQLSXODWLRQ 7KHVH LQFOXGH  QXPHURXV F\FOLQV VXFK DV
&&1(DSUHYLRXVO\YDOLGDWHGPL5DWDUJHW>@ZDVIRXQGGRZQUHJXODWHGLQ0&)FHOOV
RYHUH[SUHVVLQJPL5D7DEOHDQGXSUHJXODWHGLQ0'$0%FHOOVVWDEO\LQKLELWLQJ
WKLV PL51$ DQG &&1% &&1% &&1' DQG &&1( WKH ODWWHU YDOLGDWHG DV PL5D
WDUJHW>@DOOXSUHJXODWHGZKHQPL5DZDVVLOHQFHG7DEOHWKHF\FOLQGHSHQGHQW
NLQDVH  &'. DQRWKHU FRQILUPHG PL5D WDUJHW>@ ZDV GRZQUHJXODWHG E\ PL5D
RYHUH[SUHVVLRQ  VHYHUDO F\FOLQGHSHQGHQW NLQDVH &'. LQKLELWRUV QDPHO\ &'.1%
&'.1$ &'.1& DQG &'.1' ZHUH XSUHJXODWHG DIWHU PL5D RYHUH[SUHVVLRQ LQ
7DEOH*HQHVGLIIHUHQWLDOO\UHJXODWHGLQ0&)FHOOVXSRQSURORQJHGRYHUH[SUHVVLRQRIPL5
DRYBPL5DRUPL5QFRYBPL5QFDQGUHOHYDQWWRDGKHUHQVMXQFWLRQSDWKZD\V53.0
5HDGVSHUNLOREDVHSHUPLOOLRQ&KDQJHIROGRIJHQHH[SUHVVLRQEHWZHHQRYBPL5DDQGRYPL5QF
LQGLFDWHVJHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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0&)FHOOV7DEOHPRGXODWRUVRIPLWRVLVHQWU\DQGSURJUHVVLRQVXFKDV5%DQG
WZR FRPSRQHQWV RI WKH DQDSKDVHSURPRWLQJ FRPSOH[F\FORVRPH $3&& WKH DQDSKDVH
SURPRWLQJ FRPSOH[ VXEXQLW  $1$3& DQG FHOO GLYLVLRQ F\FOH   &'& ZHUH
LQFUHDVHG LQ0'$0%FHOO VWDEO\ LQKLELWLQJPL5D 7DEOH ,QWHUHVWLQJO\ UHODWHG
VHULQHWKUHRQLQH NLQDVHV RI WKH PLWRWLF VSLQGOH FKHFNSRLQW EXGGLQJ XQLQKLELWHG E\
EHQ]LPLGD]ROHV%8%EXGGLQJXQLQKLELWHGE\EHQ]LPLGD]ROHVKRPRORJEHWD%8%%
DQGEXGGLQJXQLQKLELWHGE\EHQ]LPLGD]ROHV%8%ZHUHDOVRXSUHJXODWHGXSRQPL5D
LQKLELWLRQ7DEOH

7DEOH*HQHVGLIIHUHQWLDOO\UHJXODWHGLQ0&)FHOOVXSRQSURORQJHGRYHUH[SUHVVLRQRIPL5
DRYBPL5DRUPL5QFRYBPL5QFDQGUHOHYDQWWRFHOOF\FOHVLJQDOOLQJ53.05HDGVSHU
NLOREDVHSHUPLOOLRQ&KDQJHIROGRIJHQHH[SUHVVLRQEHWZHHQRYBPL5DDQGRYPL5QF LQGLFDWHV
JHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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)LQDOO\ SHUWXUEDWLRQ RI PL5D LQWUDFHOOXODU OHYHOV LPSOLHG DQ HQULFKPHQW RI JHQHV
LPSOLFDWHGLQWKH61$5(YHVLFXODUWUDQVSRUW6WULNLQJO\WZRFHQWUDOSOD\HUVRIWKLVSDWKZD\
6\QWD[LQ67;DQG(QGREUHYLQ9$03DUHUHTXLUHG IRUF\WRNLQHVLV>@7KHLUGRZQ
UHJXODWLRQE\51$LLPSHGHVWKHFRPSOHWLRQRIF\WRNLQHVLVWKXVOHDGLQJWRWKHIRUPDWLRQRI
ELQXFOHDWHG FHOOV>@ 7KHVH JHQHV DUH GRZQUHJXODWHG DQG XSUHJXODWHG XSRQ PL5D
7DEOH *HQHV GLIIHUHQWLDOO\ UHJXODWHG LQ0'$0% FHOOV VWDEO\ H[SUHVVLQJ WKHPL5D
VSRQJHFRQVWUXFW6SDRUWKHS(*)3&SDUHQWDOFRQWUROS(*)3DQGUHOHYDQWWRFHOOF\FOH
VLJQDOOLQJ53.05HDGVSHUNLOREDVHSHUPLOOLRQ&KDQJHIROGRIJHQHH[SUHVVLRQEHWZHHQ6SD
DQGS(*)3LQGLFDWHVJHQHVWKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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RYHUH[SUHVVLRQ DQG LQKLELWLRQ UHVSHFWLYHO\ LQGLFDWLQJ D SRVVLEOH H[SODQDWLRQ IRUZK\PL5
DRYHUH[SUHVVLQJFHOOVWHQGWRFRQWDLQWZRQXFOHL7DEOHDQG
 
 
%LRLQIRUPDWLFDQDO\VLVRIPL5EDQGPL5DWDUJHWRPHV

,QRUGHUWRJDLQLQVLJKWLQWRWKHPROHFXODUPHFKDQLVPVWKDWPD\H[SODLQWKHREVHUYHG
SKHQRW\SHVLQGXFHGE\WKHWZRPL51$VZHSHUIRUPHG51$VHTEDVHGWDUJHWRPHDQDO\VLVWR
HYDOXDWH WKHGLUHFW HIIHFWRI WKHVHPL51$VRQJHQHH[SUHVVLRQ LQ%&FHOOV6LQFHPL51$V
UHSUHVVJHQHH[SUHVVLRQ>@ZHVHOHFWHGDOOWKHJHQHVIRXQGWREHGRZQUHJXODWHGLQ0&)
FHOOVRYHUH[SUHVVLQJHLWKHURIWKHWZRPL51$VDQGWKHJHQHVXSUHJXODWHGLQ0'$0%
FHOOVZKHUHDFWLYLW\RIHDFKPL51$ZDVLQKLELWHGE\WKHPL51$VSRQJHYHFWRUV)LUVWO\ZH
SHUIRUPHG*2 WHUPHQULFKPHQW DQDO\VLVRQ WKHVHSDUWLFXODU JHQHV WR JDLQ LQVLJKW LQWR WKHLU
ELRORJLFDOIXQFWLRQ&RQVLVWHQWZLWKWKHSKHQRW\SHVREVHUYHGLQRXULQYLWURILQGLQJVDQGRXU
SDWKZD\ DQDO\VLV ZH IRXQG JHQHV DVVRFLDWHG ZLWK IXQFWLRQV UHOHYDQW WR F\WRVNHOHWRQ
RUJDQLVDWLRQLQERWKFHOOOLQHVDIWHUPL5EPDQLSXODWLRQ)LJXUH$DQG%2QWKHRWKHU
KDQG *2 WHUP DQDO\VLV RI WKH WUDQVFULSWV PRGXODWHG E\ PL5D SURGXFHG VLJQLILFDQW
7DEOH*HQHVGLIIHUHQWLDOO\UHJXODWHGLQ
0'$0% FHOOV VWDEO\ H[SUHVVLQJ WKH
PL5D VSRQJH FRQVWUXFW 6SD RU WKH
S(*)3&SDUHQWDO FRQWURO S(*)3DQG
UHOHYDQW WR 61$5( YHVLFXODU WUDQVSRUW
SDWKZD\ 53.0 5HDGV SHU NLOREDVH SHU
PLOOLRQ &KDQJH IROG RI JHQH H[SUHVVLRQ
EHWZHHQ 6SD DQG S(*)3 LQGLFDWHV JHQHV
WKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG

7DEOH*HQHVGLIIHUHQWLDOO\UHJXODWHGLQ
0&) FHOOV XSRQ SURORQJHG
RYHUH[SUHVVLRQ RI PL5D RYBPL5D
RU PL5QF RYBPL5QF DQG UHOHYDQW WR
61$5( YHVLFXODU WUDQVSRUW SDWKZD\
53.0 5HDGV SHU NLOREDVH SHU PLOOLRQ
&KDQJH IROG RI JHQH H[SUHVVLRQ EHWZHHQ
RYBPL5D DQG RYPL5QF LQGLFDWHV JHQHV
WKDWDUHXSUHJXODWHGRUGRZQUHJXODWHG
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HQULFKPHQWV RI JHQHV LQYROYHG LQ FHOO F\FOH S VLJQDOOLQJ SDWKZD\V LQ FDQFHU DQG DOVR
F\WRVNHOHWDOUHPRGHOOLQJIRFDODGKHVLRQDQG(&0UHFHSWRULQWHUDFWLRQ)LJXUH&DQG'
7KLVRXWSXWLVFRQVLVWHQWZLWKRXUILQGLQJVRIDPL5DUROHLQFHOODGKHVLRQDQGFHOOF\FOH
SURJUHVVLRQDQGDOVRZLWKGRFXPHQWHGHYLGHQFHVWKDWPL5DUHJXODWHVFHOOF\FOHDSRSWRVLV
DQGWKDWLWVH[SUHVVLRQLVPRGXODWHGE\S>@
)LJXUH*2WHUPDQDO\VHVRIPL5EDQGPL5DUHJXODWHGJHQHVUHWULHYHGDIWHU51$VHT
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Next, to uncover direct target candidates of miR-23b and miR-26a, we intersected all the 
down-regulated genes in MCF-7 cells overexpressing either of the two miRNAs with the up-
regulated genes in MDA-MB-231 cells that stably silence the relative miRNA, we then 
combined the resulting intersection lists with the gene targets predicted for each miRNA by 
TargetScan.  With this analytic approach we obtained an overlap of 103 and 119 gene 
transcripts for miR-23b and miR-26a, respectively (Figure 48A and B, Table 24 and 25). We 
reasoned that the intersection would contain a highly enriched list of direct targets, and 
considered a cut-off expression change of 1.2 fold sufficient, given that miRNAs regulate 
transcripts by promoting destabilisation through deadenylation[284], although mediating a 
stronger effect on protein translation[416]. Higher fold changes may result in omitting many 
relevant targets. Furthermore, the impact of miRNAs on gene targets is variable and usually 
mild[323]. To validate our findings, we performed a thorough literature search and used the 
miRTarBase database[417] to identify and analyse experimentally confirmed targets of both 
miRNAs. 70% and 81% of previously described miR-23b and miR-26a gene targets, 
respectively, were among the intersection representing those genes down-regulated in MCF-7 
and/or up-regulated in MDA-MB-231 cells, and those in the TargetScan prediction list, 
indicating the reliability of our methods (Table 24 and 25). Particularly, within the 103 
overlapping genes regulated by miR-23b, we detected CELF1, MAP3K1, FZD7, TGFBR2, 
PLAU (encoding for uPA), PAK2 ans GLS (Table 24)[353, 418]. On the other hand, previously 
validated targets of miR-26a retrieved in our analysis included CCNE2, CCNE1, RB1, EZH2, 
PTEN, GSK3B and MCL1[362, 364, 366, 368, 369, 419] (Table 25). Moreover, we observed that PAK2 
is present in the same intersections for both miR-23b and miR-26a regulation (Table 24 and 
25), supporting our findings.  
In order to cross-validate both our RNA-seq output and our initial bioinformatic analysis on 
the potential function of miR-23b (Figure 19A), we performed GO term analysis of the gene 
list reported in Table 24, which resulted from the intersection between the down-regulated 
genes in MCF-7 cells overexpressing miR-23b, the up-regulated ones in MDA-MB-231 cells 
upon miR-23b inactivation and the miR-23b potential gene targets predicted by TargetScan.  
Notably, this further analisys retrieved numerous pathways that have been pointed out by our 
first DAVID analysis (Figure 19A); among these, regulation of cytoskeletal and cell-cell 
junction organisation are of particular interest, as they confirm our in vitro findings of a 
crucial role of miR-23b in controlling cytoskeleton remodelling and cell-cell interactions 
(Figure 49). 
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3.3.1.3.1        RT-qPCR validation of a set of transcripts from the RNA-seq 
experiments   
 
Considering that the intersection lists of genes reported in tables 22 and 23 probably 
contain several direct targets of these miRNAs, we wished to experimentally validate our 
RNA-seq analysis by performing RT-qPCR assays on selected transcript belonging to this 
intersection. Our selection and the function of potential direct targets of miR-23b or miR-26a 
are reported in table 24 and 25, respectively.  
 Gene Function Ref. 
 
ANXA2  
(Annexin 2) 
 
Phospholipid-binding protein involved in plasminogen activation, interaction with 
the ECM, cell invasion, neoangiogenesis and metastasis 
 
[68, 70, 73, 74] 
 
ARHGEF6  
(RAC/CDC42 guanine 
nucleotide exchange factor) 
 
Guanine nucleotide exchange factor (GEF) specific for RAC and CDC42 small 
GTPases, induces lamellipodia and filopodia formation, localises PAK at focal 
adhesion sites 
 
[156, 173, 174, 
176] 
 
CFL2 
(Cofilin 2) 
 
Actin filament depolymerisation factor, controls lamellipodia formation, its 
depletion reduced migration and invasion of BC MDA-MB-231 cells  
 
[420-422] 
ENAH 
(Enabled Homolog 
[Drosphila]) 
 
Actin-associated protein, involved in cytoskeletal dynamics, lamellipodia and 
filopodia formation, cell spreading 
 
[423] 
GSK3B 
(Glycogen synthase kinase 3 
beta) 
Serine-threonine kinase mainly involved in glycogen metabolism,  contributes to 
cytoskeletal dynamics, cell-matrix interactions, lamellipodia formation and cell 
migration by activating Rho small GTPases 
 
[424] 
 
LIMK2 
(LIM domain kinase 2) 
Regulates cytoskeletal dynamics by phosphorylating and inactiving cofilin, leading 
to inhibition of cofilin-mediated actin nucleation severing; its depletion reduced 
migration and invasion of BC MDA-MB-231 cells 
 
[124, 425, 426] 
MACF7  
(Microtubule-actin cross 
linking factor 1) 
F-actin-binding protein, mediates interaction of actin cytoskeleton with 
microtubules, necessary for HER2-induced chemotaxis and microtubule capture at 
the leading edge of migrating cells 
 
[427] 
 
PIK3R3 (Phosphoinositide-3-
kinase, regulatory subunit 3) 
Encodes for the p55γ subunit of the phosphoinositide-3-kinase (PI3K) wich 
mediates recruitment and activation of PI3K by membrane receptor-triggered 
signalling cascades that regulates cytoskeletal dynamics and migration in response 
to external stimuli 
 
[428] 
PLAU 
(Plasminogen activator, 
urokinase) 
 
Serine protease involved in plasminogen activator, degradation of the ECM and 
cancer cell invasion; inhibition of its activity abolishes BC invasion and metastasis 
in vivo  
 
[66, 429] 
PPP1R12A1(Protein 
phosphatase 1, regulatory 
subunit 12A)  
Also known as MLC phosphatase targeting subunit 1 (MYPT1) allows myosin 
phosphatase to dephosphorylate MLC, resulting in its inactivation; its depletion 
causes inhibition of MLC dephosphorylation, cell migration and adhesion 
 
[430] 
RAP1A and RAP1B 
(Ras-related protein Krev-1 A 
and B) 
Two isoforms of the RAP1 member of the Ras GTPases family, orchestrate 
signalling pathways that regulate cell-cell and cell-matrix adhesions and ECM 
degradation, leading to cell proliferation migration and invasion 
 
[431] 
SSH2 
(Slingshot homolog 2 
[Drosophila]) 
 
Protein phosphatase, that dephosphorylates cofilin thus leading to its activation, 
promotes lamellipodia formation, cell migration and invasion  
 
[432] 
 
TLN2 
(Talin 2) 
 
Cytoskeletal protein involved in focal adhesion formation by linking integrins to 
vinculin and actin; its depletion inhibits BC cell migration and invasion 
 
[433] 
Table 26: Description and functions of genes differentially regulated by miR-23b after RNA-seq 
analysis and predicted as putative miR-23b targets (TargetScan analysis).  
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Our RT-qPCR experiments confirmed the down-regulation of these genes in MCF-7 cells 
overexpressing either miR-23b or miR-26a, and their up-regulation in MDA-MB-231 cells 
where miR-23b or miR-26a activity was inhibited by the miRNA sponge constructs, thus 
confirming the reliability of our methods (Figure 50 and 51).   
 
 
 
 
 
 
Gene Function Ref. 
ABL2  
(Abelson Tyrosine kinase-
protein 2) 
 
Non-receptor tyrosine protein kinase and F-actin-binding protein, regulates cytoskeletal 
dynamics involved in cell adhesion  
 
[434] 
CHFR 
(Checkpoint with forkhead 
and ring finger doamins) 
E3 ubiquitin-protein ligase and early mitotic checkpoint that delays transition to 
metaphase in response to mitotic stress. Its expression is lost in BC leading to aneuploidy 
and increased tumourigenicity 
 
[213, 
220] 
LARP1 
(La ribonucleoprotein domain 
family member 1) 
RNA-binding protein involved in translational initiation; its knockdown results in cell 
cycle arrest in G2/M due to defective chromosome segregation and cytokinesis, 
apoptosis, inhibition of cell migration and ipaired distribution of actin isoforms 
 
[435] 
MCL1 
(Myeloic cell leukemia 
sequence 1) 
 
Member of the Bcl2 family, with pro-survival and anti-apoptotic functions; reduction of 
its expression sensitizes cells to apoptosis and tumourigenicity in BC 
 
[436] 
[437] 
NRAS2 
(Neuroblastoma RAS viral 
oncogene homolog) 
GTPase member of the Ras oncogene family, functions in signal transduction pathways 
to control cell proliferation, differentiation and survival; regulates cytoskeletal dynamics 
relevant to cell adhesion 
 
[438] 
 
RAP2C 
(Ras-related protein Rap-2c) 
 
GTPase member of the Ras-related protein subfamily of the Ras oncogene superfamily, 
mainly involved in regulation of cytoskeletal re-organisation and cell spreading on ECM 
 
[439] 
 
STX2 
(Syntaxin 2) 
Member of the SNARE protein superfamily implicated in the exocytosis of transport 
vescicles; its knockdown in mammalian cells results in failure of late stages of the 
cytokinesis process leading to formation of binucleated cells  
 
[231] 
YWHAE (Tyrosine 3-
Monooxygenase/Tryptophan 
5-Monooxygenase Activation 
Protein,Epsilon Polypeptide) 
Member Epsilon of the 14-3-3 family of phospho-serine/phospho-threonine-binding 
proteins implicated in a wide variety of biological processes including cell adhesion, 
apoptosis, anchorage-independent growth and cytokinesis; their down-regulation induces 
cytokinesis defects, resulting in enlarged multinucleated cells 
 
[224, 
230, 
440] 
Table 26: Description and functions of genes differentially regulated by miR-26a after RNA-seq 
analysis and predicted as putative miR-26a targets (TargetScan analysis).  
5HVXOWV

181 
 
 
 
 
 
 
 
 
 
)LJXUH9DOLGDWLRQRI51$VHTUHVXOWVUHODWLYHWRJHQHVGLIIHUHQWLDOO\UHJXODWHGE\PL5E
57T3&5 DVVD\V RI WKH LQGLFDWHG P51$V LQ 0&) FHOOV WUDQVIHFWHG ZLWK PL5E RU PL5QF
SUHFXUVRUV Q0 IRU  GD\V DQG LQ 0'$0% FHOOV VWDEO\ H[SUHVVLQJ WKH PL5EVSRQJH
FRQVWUXFWRUWKHS(*)3&SDUHQWDOFRQWUROYHFWRU'DWDDUHPHDQRIWKUHHLQGHSHQGHQW H[SHULPHQWV
VHP
5HVXOWV

182 
 
 
9DOLGDWLRQRIPL5EDQGPL5DVSHFLILFJHQHWDUJHWV
0L5EGLUHFWO\WDUJHWVDVHWRIJHQHVUHOHYDQWWRF\WRVNHOHWDO
UHPRGHOOLQJPLJUDWLRQDQGLQYDVLRQLQ%&
 
,QRUGHUWRYDOLGDWHWKHVHJHQHVDVGLUHFWWDUJHWVRIWKHPL5EZHIXUWKHUVHOHFWHG
RI WKRVH JHQHV /,0. $5+*()&)/ 3,.5 3/$8 $1;$ 7/1 WKDW DUH ZHOO
GHVFULEHGDV UHJXODWRUVRIF\WRVNHOHWRQRUJDQLVDWLRQFHOOPLJUDWLRQ LQYDVLRQDQGPHWDVWDVLV
7DEOH  DQG SHUIRUPHG ெ875 OXFLIHUDVH UHSRUWHU DVVD\V )LJXUH % DQG & 8QGHU
FRQGLWLRQVRIERWKJDLQ DQG ORVVRIIXQFWLRQ IRUPL5EZHFRXOGGHPRQVWUDWH WKHGLUHFW
UHJXODWLRQ E\ PLUE RI  RXW RI  RI WKHVH JHQHV )LJXUH % DQG & ,Q IDFW
RYHUH[SUHVVLRQRIPL5ELQ0&)FHOOVUHVXOWHGLQDVLJQLILFDQWUHGXFWLRQRIWKHOXFLIHUDVH
DFWLYLW\ RI UHSRUWHU FRQVWUXFWV FRQWDLQLQJ WKH ெ875 RI HDFK $1;$ $5+*() &)/
/,0.3,.5DQG3/$8)LJXUH$DQG%&RQWUDULO\LQKLELWLRQRIPL5EDFWLYLW\E\
WUDQVIHFWLRQRI0&)FHOOVZLWKWKHPL5EVSRQJHYHFWRUZDVDEOHWRUHOHDVHWKHOXFLIHUDVH
DFWLYLW\RI WKHVDPHெ875UHSRUWHUFRQVWUXFWV IURPWKHVXSSUHVVLYHDFWLYLW\RIHQGRJHQRXV
PL5E)LJXUH&,QDGGLWLRQZHSHUIRUPHGVLWHGLUHFWHGPXWDJHQHVLVRIWKHPL5E
ELQGLQJ VLWHV SUHVHQW LQ WKH ெ875 RI WKHVH JHQHV H[FOXGLQJ 3/$8 DV LW LV D SUHYLRXVO\
)LJXUH9DOLGDWLRQRI51$VHTUHVXOWVUHODWLYHWRJHQHVGLIIHUHQWLDOO\UHJXODWHGE\PL5D
57T3&5 DVVD\V RI WKH LQGLFDWHG P51$V LQ 0&) FHOOV WUDQVIHFWHG ZLWK PL5D RU PL5QF
SUHFXUVRUV Q0 IRU  GD\V DQG LQ 0'$0% FHOOV VWDEO\ H[SUHVVLQJ WKH PL5DVSRQJH
FRQVWUXFWRUWKHS(*)3&SDUHQWDOFRQWUROYHFWRU'DWDDUHPHDQRIWKUHHLQGHSHQGHQW H[SHULPHQWV
VHP 
5HVXOWV

183 
 
YDOLGDWHGPL5E WDUJHW IROORZHGE\ IXUWKHU ெ875 OXFLIHUDVH UHSRUWHU DVVD\V XSRQPL5
ERYHUH[SUHVVLRQ)LJXUH$DQG%$VVKRZQLQ)LJXUH%PL5EZDVXQDEOH WR
UHSUHVV WKH OXFLIHUDVHDFWLYLW\RI WKHPXWDWHGெ875VFRQVWUXFWVFRPSDUHG WRFRUUHVSRQGHQW
ZLOG W\SH YDULDQW DQG QHJDWLYH FRQWURO 7KHUHIRUH ZH ZHUH DEOH WR SUHFLVHO\ GHILQH WKH
LQWHUDFWLRQVLWHXVHGE\PL5EWRGLUHFWO\UHSUHVVWKHVHJHQHWDUJHWV
)LJXUH0L5EWDUJHWV$1;$$5+*()&)//,0.3,.5DQG3/$8P51$VE\
GLUHFWO\LQWHUDFWLQJZLWKWKHLUUHODWLYH¶875V$5HSUHVHQWDWLRQRIWKHPL5EDQGWKHLQGLFDWHG
WDUJHWP51$ெ875KHWHURGXSOH[HVEDVHSDLULQJEHWZHHQWKHPL5EELQGLQJVLWHLQEROGDQGWKH
PL5E³VHHG³UHJLRQLQEOXHLVGLVUXSWHGZKHQWKHPL5EELQGLQJVLWHDUHPXWDWHGLQUHG%&
5HODWLYHOXFLIHUDVHDFWLYLW\OHYHOVZHUHPHDVXUHGDIWHUKIURPFRWUDQVIHFWLRQRI0&)FHOOVZLWK
WKH LQGLFDWHG ெ875OXFLIHUDVH UHSRUWHU FRQVWUXFWV HLWKHU ZLWK PL5E RU PL5QF SUHFXUVRUV
Q0RUZLWKPLEVSRQJHFRQVWUXFWRUS(*)3&SDUHQWDOFRQWURO QJ'DWDDUHPHDQRI
WKUHH LQGHSHQGHQW H[SHULPHQWV HDFK RI WKHP SHUIRUPHG LQ WULSOLFDWH  VHP 3   3 
3 
Results 
 
184 
 
3.3.1.3.2.2       MiR-26a directly targets a set of genes relevant to cytokinesis and 
apoptosis 
 
We then validated additional targets of miR-26a using the same experimental 
approach undertaken for miR-23b. In this case, we selected 5 genes (CHFR, LARP1, NRAS, 
MCL1, and YWHAE) with important functions in cytoskeletal remodelling, cytokinesis and 
apoptosis (Table 26). As shown in figure 53A all the chosen genes present one miR-26a-
binding site in their 3‟UTR, except LARP1 which contains three miR-26a interaction sites that 
are found highly conserved (1LARP1 and 2LARP1) or poorly conserved (3LARP1) across 
vertebrates. By performing 3‟UTR luciferase reporter assays, we demonstrated that miR-26a 
overexpression in MCF-7 cells significantly suppresses the luciferase activity of reporter 
constructs containing the 3‟UTR of CHFR, LARP1, MCL1 and YWHAE (Figure 53B), which 
was conversely increased upon inhibition of the miRNA by co-transfecting these cells with 
the miR-26a-sponge vector, compared to relative controls (Figure 53C). NRAS 3‟UTR-
relative luciferase activity did not change upon miR-26a overexpression suggesting that 
NRAS is not a direct target of this miRNA (Figure 53B). 
We then wished to describe the precise 3‟UTR-embedded interaction sites by which miR-26a 
regulate expression of these reporter constructs. Therefore, we mutated or deleted all the 
predicted miR-26a-binding sites included in the 3‟UTR of the genes that are regulated by 
miR-26a; in the case of LARP1 3‟UTR, we also created reporter construct variants in which 
any of the three miR-26a interaction sites were mutated or deleted (Figure 53A). In figure 
53B, it is observed that miR-26a-mediated repression of CHFR, MCL1 and YWHAE is 
impaired when they carry mutated or deleted binding-sites for the interaction of this miRNA. 
Concerning LARP1 regulation, we observed that miR-26a suppresses luciferase activity of the 
reporter containing the wild type 3‟UTR by binding to the second (2LARP1) and the third 
interaction site (3LARP1), the latter seemingly less functional for miR-26a-mediated LARP1 
repression (Figure 53B), but not to the first one (1LARP1). Indeed, deletion of 2LARP1 site 
completely abrogates repression of LARP1 3‟UTR luciferase activity by miR-26a, whereas 
mutated 3LARP1 only partially affects miR-26a activity in targeting this gene. Mutations in 
the first interaction site (1LARP1) instead fail to impair miR-26a-mediated repression of 
LARP1 3‟UTR (Figure 53B).  
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4.1            Roles of miR-23b and miR-26a in BC 
The role of microRNAs (miRNAs) in regulation of molecular pathways relevant to 
tumourigenesis and cancer progression has been largely investigated[247, 406]. In the course of 
this thesis, we have described two miRNAs, miR-23b and miR-26a, as crucial regulators of 
BC pathogenesis. By using a strategic approach based on both bioinformatic and experimental 
evaluation, we show that miR-23b and miR-26a participate in multiple processes during BC 
development, by performing both similar and distinct functions. 
Initially we focused on miR-23b, as its involvement in hepatocellular carcinoma was 
known[405], but its global function in BC was poorly understood. Using a bioinformatic 
approach based on pathway enrichment analyses, we proposed a role for miR-23b in 
cytoskeletal remodelling, subsequently demonstrating this experimentally and validating 
PAK2, a key modulator of cytoskeletal dynamics, as its direct target. Interestingly, we 
demonstrated that miR-26a also targets PAK2 at a different site on its 3‟UTR, thus implicating 
this miRNA in regulation of cytoskeletal remodelling. We demonstrated that experimental 
expression of miR-23b and miR-26a in BC cells promotes focal adhesion and cell spreading 
on the ECM, phenotypes that are partly ascribed to miRNA-mediated regulation of PAK2. 
Nevertheless, the phenotypic changes observed following manipulation of either miRNA did 
not entirely overlap. In fact, we observed that miR-23b alone controls cell-cell adhesion and 
lamellipodia formation, whereas miR-26a enhances BC cells capabilities to adhere to the 
ECM. Further investigation pinpointed a striking ability of miR-23b in the control of BC 
progression, as it affects cell migration, invasion and metastasis both in vitro and in vivo. On 
the other hand, miR-26a seems to affect cytokinesis and to enhance aneuploidy occurrence 
and tumourigenicity in vitro. 
The observation that miR-23b and miR-26a mediate different cellular phenotypes, despite 
regulating a common gene target (PAK2) is expected, as it is well-known that a single miRNA 
is able to control multiple genes [272]. In order to evaluate the entire gene set regulated by 
either miRNA, we performed high throughput RNA-sequencing (RNA-seq) analysis upon 
engineered manipulation of the intracellular levels of either miRNA. Notably, we 
experimentally induced long-term (9 days) overexpression or stable inhibition of miR-23b or 
miR-26a in two BC cell lines, MCF-7 and MDA-MB-231 cells, respectively, as maximal 
effect of miRNA activity on gene expression is achieved under conditions of prolonged 
miRNA-specific deregulation[326]. It is well established that miRNAs mediate destabilisation 
of target mRNAs by inducing their deadenylation and degradation[284-286]. With this in mind, 
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we reasoned that, among the transcripts found to be down- or up-regulated upon miRNA 
overexpression or inhibition, respectively, those that contain predicted sites for the specific 
interaction with miR-23b or miR-26a are to be considered as high confident targets of either 
miRNA. By performing 3‟UTR-luciferase reporter assays, we validated a specific subset of 
genes as direct targets of miR-23b or miR-26a; the physiological roles of these genes is 
relevant to distinct molecular pathways implicated in the cellular phenotypes observed 
following targeted miRNA manipulation. Coordinated repression of these targets along with 
specific miRNA-mediated perturbation of the transcriptome state of BC cells enabled our 
understanding of the molecular mechanism(s) that underlies the cellular functions of miR-23b 
and miR-26a.   
 
 
4.1.1           Roles of miR-23b and miR-26a in cytoskeletal dynamics 
4.1.1.1          MiR-23b regulates cell-cell adhesion in epithelial BC cells 
Firstly, we outlined a role of miR-23b in the regulation of cell-cell interactions. Under 
transient transfection conditions, we observed that ectopic overexpression of miR-23b, but not 
miR-26a, enhanced epithelial characteristics of BC MCF-7 cells (Figure 22A), without 
affecting protein expression levels of the epithelial molecular marker E-cadherin (Figure 
22B). Under the same conditions, miR-23b failed to induce an epithelial phenotype in MDA-
MB-231 cell line (Figure 22C), a mesenchymal model of BC cells in which E-cadherin is 
normally not expressed, probably because miR-23b was unable to promote E-cadherin 
expression or form new adherens junctions (AJs). E-cadherin is, in fact, a key component of 
AJs, adhesive structures that mediate interaction of two adjacent cells by anchoring their actin 
cytoskeleton at the intracellular level via α- and β-catenin[139]. During the course of our study, 
several groups have reported the ability of miR-23b in promoting epithelial characteristics of 
colon and prostate cancer metastatic cell models, by inducing up-regulation of E-cadherin and 
repression of mesenchymal markers, such as Vimentin and Snail[353, 355, 356]. On this basis, we 
hypothesised that miR-23b may have a role in inhibiting epithelial-to-mesenchymal transition 
(EMT) during BC progression and that its potential regulation of E-cadherin expression may 
depend on a temporal factor. Therefore we performed long-term (9 days) overexpression of 
miR-23b in both MCF-7 and MDA-MB-231 cells, in order to potentially revert EMT and 
release E-cadherin from its mesenchymal marker-mediated repression in the latter cell line[326, 
375]. However, we observed that prolonged miR-23b overexpression failed to revert EMT in 
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mesenchymal-like MDA-MB-231 cells (Figure 23A) and to induce E-cadherin up-regulation 
in both MDA-MB-231 and MCF-7 cells, neither at the protein nor at the mRNA level (Figure 
23A and B). On the other hand, maintained miR-23b levels improved the overall architecture 
of epithelia formed by 2-D cultures of MCF-7 cells, which exhibited more orderly and stable 
AJs compared to control-treated cells (Figure 23B and C). Taken together, these data suggest 
that in the context of BC, miR-23b reinforces epithelial characteristics by different 
mechanisms that do not imply E-cadherin up-regulation and de novo formation of AJs, but 
that rather confer enhanced tension between existing E-cadherin-mediated cell-cell adhesions. 
Nevertheless, analysis of our RNA-seq data revealed that prolonged overexpression of miR-
23b in MCF-7 cells induced transcriptional up-regulation of Nectin 1 (PVRL1) and Nectin 2 
(PVRL2), β-catenin (CTNNB1) and LMO7, encoding for cell adhesion molecules highly 
involved in cell-cell junction formation[136, 137, 143, 441] (Table 15). Particularly, Nectin1 and 2 
are members of the Nectin family of transmembrane receptors that are involved in early 
establishment of cell-cell contacts, known as tight and adherens junctions[136]. These findings 
suggest that miR-23b may actually induce de novo formation of both tight and AJs through a 
mechanism that requires Nectin1 and Nectin2 overexpression and is independent of E-
cadherin; in order to address this point, experimental analysis of protein levels and sub-
cellular localisation of both Nectin 1 and Nectin 2 isoforms upon prolonged miR-23b over-
expression in MCF-7 cells should be further investigated. Alongside the potential 
establishment of new cell-cell contacts, miR-23b may be involved in cell-cell contacts 
development, by stabilising existing and newly formed AJs via up-regulation of β-catenin and 
LMO7, adaptor molecules that mediate aggregation of E-cadherin- and Nectin-based adhesive 
clusters and strengthen the adhesive capabilities of E-cadherin[143, 441]. Moreover, mir-23b 
likely contributes to enhance the junctional tension during assembly of the epithelia, by 
indirectly promoting local myosin II activity, which is required to produce the contractile 
force that mediates aggregation of E-cadherin clusters and maintains the tension during AJs 
maturation. Indeed, we detected increased myosin light chain II (MLCII) phosphorylation, 
indicative of myosin II activity, upon miR-23b overexpression in different cell lines, 
including MCF-7 cells. 
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4.1.1.2         MiR-23b and miR-26a share limited overlapping functions 
4.1.1.2.1        MiR-23b and miR-26a target PAK2 and induce MLCII 
phosphorylation 
 
We identified PAK2 as a candidate target of both miR-23b and miR-26a, as its 3‟UTR 
contains a specific binding site for the interaction with either miRNA (Figure 34A). By 
combining different experimental techniques, we demonstrated that both miR-23b and miR-
26a directly target PAK2, inducing its repression both at the protein and the mRNA level. 
Western blot analysis showed that miR-23b overexpression reduces PAK2 protein levels up to 
60% and 50% in BC MDA-MB-231 and MCF-7 cells, respectively, and up to 80% in 
HCT116 colon cancer cell line (Figure 35A), consistently with the observation by Zhang et 
al.[353]. Although at a minor extent compared to miR-23b activity, ectopic expression of miR-
26a was also able to decrease PAK2 protein levels in all three of the cell lines analysed (40%, 
40% and 60%, respectively) (Figure 35A), indicating for the first time PAK2 as a target of 
miR-26a. Moreover, miRNA loss-of-function investigation using miRNA-sponge constructs, 
confirmed that inhibition of the endogenous activity of either miRNA enabled the release of 
PAK2 expression from miRNA-mediated repression in both MCF-7 and MDA-MB-231 cells 
(Figure 36). Our RNA-seq data showed that PAK2 mRNA levels were greatly down-
regulated in MCF-7 cells upon prolonged overexpression of miR-23b or miR-26a and up-
regulated in MDA-MB-231 cells that stably express a sponge construct that mediates specific 
inhibition of miR-23b or miR-26a (Table 24 and 25). These data confirmed not only the 
experimental validity of our RNA-seq analysis, but also that miR-23b and miR-26a are 
implicated in the repression of PAK2. In addition, by performing 3‟UTR-luciferase reporter 
assays, we confirmed that miR-23b or miR-26a mediates PAK2 repression by interacting 
directly with its own predicted binding site embedded in the PAK2 3‟UTR, as site-direct 
mutations that disrupt this interaction impede each miRNA to repress PAK2 3‟UTR-relative 
luciferase activity (Figure 37B and C). However, our miRNA-sponge constructs failed to 
induce an increase of luciferase activity of PAK2 3UTR (data not shown). This suggests that 
the regulation exerted by miR-23b and miR-26a on PAK2, by binding to the analysed site, 
makes a minor contribution to the repression of PAK2, indicating that other mechanisms 
indirectly mediated by either of the miRNA may be involved. Our 3‟UTR-luciferase reporter 
analysis also showed that neither miRNA mediates post-transcriptional regulation of PAK1 
(Figure 37D), an expected finding as it is not a predicted target for miR-23b or miR-26a 
(Figure 35B). However, we observed that overexpression of miR-23b or miR-26a in three 
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cell lines, where PAK2 is greatly down-regulated, slightly reduced PAK1 protein levels 
(Figure 35A). This effect is consistent with our observation that PAK2 knockdown by siRNA 
in MDA-MB-231 cells is accompanied by a marked reduction of PAK1 (Figure 34D). 
Although an off-side effect in the specificity of PAK2 siRNA is not to be excluded, it is 
plausible that a decrease of intracellular PAK2 levels leads to a consequent reduction of 
PAK1 protein levels. Accordingly, it has been demonstrated that PAK1 and PAK2 trans-
interact to form heterodimers in order to inhibit each other activity and stabilise their 
cytoplasmic forms. In addition, altered expression of either isoforms disrupts 
heterodimerisation, thus enhancing their sensitivity to degradation[442, 443].     
Additionally, we found that miR-23b and miR-26a overexpression greatly promoted 
phosphorylation of the MLCII in MDA-MB-231, MCF-7 and HCT116 cells (Figure 35B). 
Since we observed that siRNA-mediated PAK2 depletion in MDA-MB-231 cells was 
accompanied by a marked increase of MLCII phosphorylated levels (Figure 34D), which was 
consistent with the effect observed upon PAK2 silencing in BC T47D cells[129], it seems that 
miR-23b/miR-26a promote MLCII phosphorylation through down-regulation of PAK2. 
Moreover, our RNA-seq analysis showed a dramatic increase of the MLCK transcript levels 
in MCF-7 cells overexpressing miR-26a, suggesting that increased MLCII phosphorylation by 
miR-26a occurs also through MLCK up-regulation (Table 17).  
 
 
4.1.1.2.2      MiR-23b and miR-26a promote focal adhesion maturation and 
cell spreading on the ECM 
 
Our results suggest that both miR-23b and miR-26a modulate maturation of FAs and 
increase the properties of cells to spread on the ECM (Figure 24). We observed that MDA-
MB-231 cells spreading on collagen I matrixes and stained for the FA marker Vinculin 
exhibit larger FA sites upon transient transfection of either miR-23b or miR-26a mimic 
compared to control-treated cells (Figure 24A). The average of FA areas was shown to be 
significantly increased in cells overexpressing either miRNA, and this increase was slightly 
more pronounced in miR-26a-transfected cells (Figure 24A, graph). FAs are adhesive 
complexes that connect the actin cytoskeleton to elements of the ECM in order to support cell 
morphology and movement along the ECM[153, 408]. Multiple cytoplasmic proteins are 
implicated in the formation and maturation of FAs, including integrins, Vinculin and PAKs. 
Larger FA sites manifest upon excessive maturation of newly formed FAs, a process that 
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requires local activity of myosin II[162, 408]. At FA sites, myosin II activity is tightly regulated 
by the PAKs. PAKs control the activation state of myosin II either by directly 
phosphorylating MLCII or by inhibiting the activity of MLCK, which results in reduced 
myosin II phosphorylation[126, 442]. PAK2 seems to have a major role in FA maturation, by 
limiting the size of FA sites. Indeed, it has been shown that PAK2 depletion in T47D BC cells 
resulted in larger FA sizes, increased MLCII phosphorylation and reduced migratory 
capabilities of these cells[129]. Accordingly, we demonstrated that PAK2 silencing is able to 
increase phosphorylated MLCII levels and reduce cell migration in MDA-MB-231 cells 
(Figure 34C and D). These data along with our findings that miR-23b or miR-26a 
overexpression in MDA-MB-231 cells led to repression of PAK2 and enhanced MLCII 
phosphorylation (Figure 35) indicate that these two miRNAs contribute to FA maturation 
partly via repression of PAK2 and stimulation of myosin II activity.  
Moreover, miR-23b may also enhance FA development by limiting PAK2 localisation and 
activity at the FA sites through repression of ARHGEF6, which we found to be a miR-23b 
direct target (Figure 52). ARHGEF6, also known as PAK-interacting exchange factor alpha 
(αPIX) or Cloned out of library 2 (COOL2) is a well-described activator of RAC and CDC42 
small GTPases; it directly interacts with PAKs and mediate their localisation at FA sites 
where it induces PAK activation through local stimulation of RAC and CDC42. 
Additionally, since fully developed FAs are associated with slower migration rates[32], miR-
23b-mediated negative regulation of PAK2 expression and effect on FA maturation can partly 
contribute to miR-23b ability in inhibiting migratory capabilities of MDA-MB-231 cells 
(Figure 31A). However, our findings that miR-26a did not affect cell migration, but yet 
shared with miR-23b overlapping functions in the regulation of FA, PAK2 expression and 
myosin II activity imply that miR-23b exert a negative control of migratory phenotypes by 
regulating other specific genes.  
Moreover, it is well-known that maturation of FAs promote cell spreading on the ECM[444], 
which is in accordance with increased spreading abilities on ECM exhibited by MDA-MB-
231 cells overexpressing miR-23b or miR-26a (Figure 34B). Although both miRNAs 
enhanced the ability of MDA-MB-231 cells to spread on Collagen I substrates after only 30 
minutes, miR-26a was more effective in inducing this effect, as cells expressing this miRNA 
exhibited a markedly expanded morphology with increased number and area of Vinculin-stain 
FA sites under prolonged cell spreading conditions compared to miR-23b- or miR-n.c.-treated 
cells. Thus, it seems that miR-26a mediates a more robust activity compared to miR-23b in 
the formation and development of FAs and in cell spreading. Analysis of our RNA-seq data 
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pinpointed that Vinculin transcript (VLC) is among the genes up-regulated in miR-26a-
overexpressing MCF-7 cells (Table 17). Moreover, these cells showed a conspicuous up-
regulation of genes encoding for ECM receptors crucial for cell adhesion and FA formation, 
including several integrin subunits, which were conversely down-regulated in MDA-MB-231 
cells stably inhibiting miR-26a (Table 18). Taken together, these data suggest that miR-26a 
may contribute to cell spreading, maturation and de novo formation of FA sites at later stages 
by indirectly inducing up-regulation of key components of FAs. The regulation of these genes 
by miR-26a may also underlie the molecular mechanism by which miR-26a promotes cell 
adhesion on the ECM in MDA-MB-231 cells (Figure 34C). 
 
4.1.1.3         MiR-23b impairs lamellipodia formation 
 
Beside the regulation of cellular pathways implicated in cell-cell interactions, focal 
adhesion and cell spreading on ECM, miR-23b exerts a broader effect in modulation of 
cytoskeletal remodelling with a robust impact on the formation of lamellipodia protrusions. 
We found that miR-23b-overexpressing MDA-MB-231 cells exhibited a significantly 
impaired formation of lamellipodia protrusions at their leading edge and, in contrast, MDA-
MB-231 cells stably inhibiting miR-23b activity extended larger lamellipodia (Figure 25 and 
32B). Analysis of our RNA-seq data show that several genes involved in cytoskeletal 
dynamics that induce lamellipodia and filopodia formation at the cell leading edge were 
differently modulated upon overexpression or inhibition of miR-23b. Among these genes, we 
confirmed that ARHGEF6, LIMK2 and CFL2 were down-regulated in miR-23b-expressing 
MCF-7 cells and up-regulated in MDA-MB-231 cells in which miR-23b was stably silenced 
(Figure 50). In addition, we validated each of these genes as direct targets of miR-23b by 
both experimental miRNA gain- and loss-of function approaches (Figure 52). ARHGEF6, 
LIMK2 and CFL2 are well-known modulators of cytoskeletal dynamics with major 
involvement in the formation of plasma membrane protrusion at the leading edge of motile 
cells. Indeed, it has been shown that ARHGEF6 overexpression dramatically promotes 
formation of lamellipodia and filipodia protrusions, likely as result of ARHGEF6-mediated 
activation of RAC and CDC42[176]; this is consistent with our observation that ARHGEF6 is 
overexpressed in MDA-MB-231 cells that stably inhibit miR-23b and exhibit pronounced 
lamellipodia protrusions. Moreover, LIMK2 and Cofilin 2 are key cytoplasmic effectors of 
the RAC/CDC42-activated PAK1/LIMK/cofilin pathway, which orchestrates actin 
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polymerisation and appropriate formation of lamellipodia at the cell leading edge[425]. Indeed, 
through activation of LIMK, which results in the phosphorylation and inhibition of cofilin, 
PAK1 ensures correct lamellipodia formation by limiting their expansion extents, that are 
under the control of cofilin activity[425]. Owning to its ability in inducing severing of actin 
filaments (F-actin), cofilin, in fact, promotes lamellipodia assembly by enhancing F-actin 
turnover that produces free barbed end for the polymerisation of new actin filaments[421]. 
Nevertheless, uncontrolled cofilin activity leads to accelerated F-actin turnover resulting in 
widening of the lamellipodium[425]. In light of this, it is reasonable to infer that the 
coordinated repression of ARHGEF6, LIMK2 and CFL2 by miR-23b disrupts crucial steps of 
the molecular pathway that supervises correct lamellipodia extension. Nevertheless, to 
confirm a direct involvement of these proteins in the miR-23b-regulation of lamellipodia 
formation, further investigation is required; this would focus on analysis of ARHGEF6, 
LIMK2 and CFL2 protein levels upon miR-23b manipulation, as well as evaluation of 
lamellipodia formation upon either silencing of each of these genes or their simultaneous 
expression with miR-23b in MDA-MB-231 cells. 
 Notably, miR-23b-induced corruption of lamellipodia formation likely encompasses the 
suppressive effect of miR-23b on MDA-MB-231 cell migration, as protrusion of lamellipodia 
at the leading edge is essential for cells to migrate[102]. 
 
4.1.2           Roles of miR-23b in BC cell migration, invasion and 
metastasis 
 
4.1.2.1         Roles of miR-23b in BC cell migration 
The ability of miR-23b and miR-26a of regulating similar and distinct aspects of 
cytoskeletal remodelling suggested a potential role for these miRNAs in the control of 
migratory phenotypes. By performing two different experimental techniques of cell migration 
analysis, we observed that overexpression of miR-23b, but not miR-26a, greatly inhibited 
both chemotaxis and random migration of highly motile MDA-MB-231 cells (Figure 31). 
Notably, reduction of migratory phenotypes induced by miR-23b was equivalent to that 
observed upon overexpression of miR-31 (Figure 31), a tumour suppressor miRNA that was 
previously shown to abolish MDA-MB-231 cell migration, invasion and metastasis both in 
vitro and in vivo[376]. In contrast, we found that stable inhibition of miR-23b activity via 
expression of a miR-23b-sponge construct was able to improve migratory capabilities of 
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MDA-MB-231 cells; accordingly, experimental suppression of miR-23b function is 
associated with increased migratory abilities of BC MCF-7 cells, as reported by Zhang et 
al.[353]. Moreover, we demonstrated that miR-23b-mediated alteration of cell migration was 
independent of eventual ongoing effects on cell proliferation or apoptosis, as neither 
overexpression nor inhibition of miR-23b affected proliferative and apoptotic phenotypes of 
MDA-MB-231 cells (Figure 29A-C and 30).  
To understand the molecular mechanism(s) that lies behind the robust ability of miR-23b in 
regulating cell migration, it is essential to uncover the physiological significance of genes 
differentially modulated by miR-23b in the contest of BC. Down-regulation of PAK2 by miR-
23b could partially explain the inhibition of cell motility as its role in cytoskeletal remodelling 
and cell migration in BC is well established[129]; additionally, we confirmed a reduction in 
MDA-MB-231 cell motility upon silencing of PAK2 using small RNA interference (Figure 
34C). Nevertheless, PAK2 down-regulation by miR-23b cannot completely explain the effect 
of miR-23b on cell migration, since miR-23b induces a stronger inhibition of MDA-MB-231 
cell motility compared to the effect mediated by PAK2 depletion in the same cells (notably 
our PAK2 siRNA treatment was more effective in reducing PAK2 levels compared to miR-
23b over-expression)  (Figure 31B and 34C). This suggested that miR-23b suppresses BC 
cell migration by regulating other genes with functions relevant to this cellular phenotype. We 
validated as miR-23b direct targets, two crucial cytoskeletal modulators, LIMK2 and CFL2 
(Figure 50), of which down-regulation has been previously reported to abolish migration and 
invasion of MDA-MB-231 cells[124, 422]. Notably, none of these genes other than PAK2 are 
modulated by miR-26a inhibition and/or over-expression, for which we did not see any effect 
on cell motility. 
 
4.1.2.2         Role of miR-23b in BC cell invasion 
Additionally, we reported that overexpression of miR-23b greatly reduced invasion of 
MDA-MB-231 cells in 3-D collagen I matrixes; whereas inhibition of miR-23b activity 
strongly enhanced the invasive properties of these cells both in vitro and in vivo (Figure 33 
and 43A). This effect was consistent with several pieces of evidence that support a role of 
miR-23b in suppressing cell invasion in different types of cancer[353, 355, 356].   
Along with the ability of the newly discovered miR-23b cytoskeletal targets, such as PAK2, 
LIMK2 and CFL2 in affecting BC cell invasion[124, 129, 422], miR-23b could be implicated in 
the regulation of invasive processes, owing to its ability for directly repressing expression of 
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uPA (PLAU) and Annexin 2 (ANXA2) (Figure 50 and 52), two main components of the 
cellular invasive machinery. Indeed, uPA and Annexin 2 play crucial roles in the extracellular 
cascade that converts plasminogen in plasmin, a serine protease largely implicated in 
invasion, neoangiogenesis and metastasis[68, 70, 73, 429, 445]. Regulation of uPA by miR-23b has 
already been described in different tumour types[353, 354, 405] and we demonstrate that miR-23b 
is able to repress uPA expression also in BC (Table 24, Figure 50 and 52). Moreover, it has 
been shown that inhibition of uPA activity abolishes BC invasion and metastasis in vivo[66], 
which is consistent with our data showing that miR-23b suppression promotes invasion and 
metastasis in animal BC models (Figure 42). On the other hand, overexpression of Annexin 2 
is found in many tumours, including highly aggressive BCs where it correlates with increased 
invasiveness, neoangiogenesis and metastasis[74]; conversely, silencing of Annexin2 reduced 
migration of MDA-MB-231 cells[73]. These observations suggest that miR-23b may further 
inhibit the invasive and metastatic potential of BC cells through repression of Annexin 2.   
 
4.1.2.3         EGF controls transcriptional expression of miR-23b via AP-1 
By combining small interference RNA (siRNA) techniques and ChIP analysis, we 
showed that miR-23b is a miRNA transcriptionally suppressed by the transcription factor AP-
1 in BC MDA-MB-231 cells (Figure 38 and 39). Indeed, we demonstrated that the AP-1 
component c-JUN directly interacts with TPA response elements (TREs) present in the 
promoter region of miR-23b (Figure 39), and that depletion of the AP-1 components c-JUN 
and c-FOS resulted in specific up-regulation of the expression levels of both precursor (pre-
miR-23b) and mature miR-23b, whereas miR-26a expression remained unaltered (Figure 
38C-E). Importantly, miR-23b is part of a cluster composed of miR-23b, miR-27b and miR-
24-2 that are transcribed as a unique primary transcript[350]. This may indicate that AP-1 
mediates its effect by regulating all the miRNA components of this cluster, but this hypothesis 
requires further investigation. 
Notably, disruption of AP-1-mediated repression of miR-23b expression establishes important 
features observed upon miR-23b-overexpression, such as reduction of PAK2 levels and 
increase of MLCII phosphorylation (Figure 38F and 35). The discrepancy in PAK2 
repression levels observed in the two analyses (Figure 35A and 38F) may depend on the 
different intracellular abundance of mature miR-23b achieved upon experimental miR-23b 
overexpression (Figure 21) and AP-1 depletion (Figure 38D). Mature miR-23b up-regulation 
after AP-1 knockdown can only partially explain the massive increase of MLCII 
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phosphorylation (Figure 38F), thus indicating that other mechanisms, likely dependent on 
AP-1 reduced activity, contribute to promote the phosphorylation state of MLCII.  
Additionally, we observed that EGF stimulation induces an early inhibition of miR-23b levels 
in MDA-MB-468 cells (Figure 40). EGF is an extracellular ligand that specifically activates 
EGFR, a member of the ERBB family of receptor tyrosine kinases. Activated EGFR 
dimerises with its preferred partner HER2 and triggers multiple signalling cascades leading to 
survival and metastatic outcomes, through activation of several cytoplasmic effectors and 
transcription factors, including AP-1[184, 194]. Importantly, EGFR-induced AP-1 activity is 
mediated by PAK2 itself, which, once activated by EGFR promotes AP-1 nuclear activity via 
stimulation of the JNK pathway[191-194, 198, 446]. EGFR-mediated activation of PAK2 occurs 
through different intracellular pathways: (1) via recruitment by EGFR of the adaptor NCK 
which directly activates PAK2[192, 193], (2) through RAC and CDC42 stimulation by EGFR-
mediated activation of their specific activator, the nucleotide exchange factor 
ARGHEF6/αPIX/COOL2[190], which we demonstrate to be a direct target of miR-23b (Figure 
52), and (3) via recruitment and activation of regulatory subunits of PI3K, which, in turn, 
activates RAC and CDC42, leading to PAK2 activation[186, 188]. Notably, it has been shown 
that siRNA molecules directed against the PI3K regulatory subunit gamma or 3 (PIK3R3) 
gene, which is directly targeted by miR-23b as shown by our data (Figure 52), completely 
abrogate the AP-1 activation following growth factor stimulation[446]. Moreover, PI3K3 has 
been directly associated with acquisition of oncogenic phenotypes, as its repression by miR-7 
leads to inhibition of tumour growth, invasion and metastatic potential[447]. Although further 
investigation of the direct effect of miR-23b-mediated repression of PAK2, ARHGEF6, and 
PIK3R3 on downstream AP-1 activation is required, it is reasonable to delineate a positive 
feedback loop mechanism that regulates miR-23b expression: signal transduction cascades 
involving cytoplasmic effectors, such as PAK2, ARHGEF6 and PIK3R3, activate AP-1, 
which in turn, suppresses miR-23b expression, thus releasing these three factors from miR-
23b-mediated post-transcriptional regulation  and facilitating AP-1 action (Figure 54). It is 
likely that, in the contest of BC, where amplification or hyperactivation of EGFR and HER2 
is frequently observed[178, 179], the miR-23b regulatory mechanism is impaired, thus resulting 
in excessive inhibition of miR-23b expression and consequent release of pro-invasive targets, 
such as PAK2, LIMK2, CFL2, uPA and ANXA2, from their post-transcriptional repression. 
Recently published data have suggested a different regulation of mir-23b expression by 
EGFR-associated activity. Lin et al. observed that EGF stimulation in BT-474 BC cells 
induces expression of miR-23b and its paralogue miR-27b; moreover they observed that 
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overexpression of HER2 in MCF10A induces miR-23b/27b up-regulation through activation 
of the PI3K/AKT/NF-κB pathway[357]. In contrast, miR-23b and miR-27b expression levels 
were found to be markedly down-regulated in HER2-trasformed MCF10A mammary 
epithelial cells[358], an observation that supports our findings. The use of BC cell models that 
exhibit distinctive molecular and phenotypical features might explain the discrepancy 
between these and our data relative to the molecular mechanisms that control miR-23b 
expression. Moreover, it is possible that EGFR/HER2 signalling differentially regulates miR-
23b expression depending on the molecular state of AKT/NF-κB or AP-1, which may vary 
between distinct BC cells.   
 
4.1.2.3         Role of miR-23b in BC initiation and progression 
Our evidence of the robust effect of miR-23b on cytoskeletal remodelling, cell 
migration and invasion in BC cell lines has suggested that miR-23b is potentially involved in 
the regulation of the metastatic process associated with BC. Establishment of mammary 
xenograft tumours in nude mice after implantation of MDA-MB-231-cells stably expressing 
the miR-23b sponge construct or the parental control vector allowed us to investigate the 
effect of miR-23b inhibition on BC growth and metastasis in vivo. By monitoring tumour 
volume rates over the time required for the formation of mammary xenografts, we observed 
that inhibition of miR-23b activity resulted in increased tumour growth (Figure 43A). This 
was consistent with previous evidence that miR-23b inhibited tumour proliferation of prostate 
and colon cancer cells in vivo[353, 355]. The effect of miR-23b in regulating tumour growth was 
unexpected, since our in vitro analysis showed that neither overexpression nor inhibition of 
miR-23b altered proliferation of MDA-MB-231 cells (Figure 29A and 30). Contrarily, a miR-
23b effect on cell growth has been appreciated in other tumour types, such as prostate cancer 
and B-cell lymphoma, where c-MYC-induced inhibition of miR-23b results in increased cell 
proliferation, due to release from miR-23b-mediated repression of the mitochondrial 
glutaminase (GLS)[299]. Our characterisation of xenograft  tumours by H&E staining showed a 
dramatic reduction of necrosis when miR-23b was inhibited (Figure 43B), suggesting that 
reduced miR-23b function may enhance the metabolic activity of these tumours, thus 
promoting in vivo tumour growth. Accordingly, our RNA-seq analysis shows that GLS is up-
regulated in MDA-MB-231 cells in which miR-23b was stably inhibited (Table 24). 
Importantly, we observed that suppression of miR-23b induced spontaneous lymph-node 
metastases, which were not detected in the control mice (Figure 42B). This finding suggests 
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that reduction of miR-23b expression is required for BC cells to metastasise in vivo.  Notably, 
we found that the expression of miR-23b, but not of miR-26a, is inversely correlated with BC 
metastasis. MiR-23b is selectively down-regulated in BC cell lines that metastasised to 
different distal organs compared to cells derived from mammary primary tumours after 
inoculation in the mammary fat pads of nude mice (Figure 41A). Accordingly, we detect that 
miR-23b is greatly reduced in a large cohort of lymph-node metastatic samples in comparison 
with their matched primary tumours derived from BC patients (Figure 41C and D). Since we 
observed that miR-23b expression is negatively regulated by EGF stimulation and 
consequently by AP-1, this could contribute to the metastatic impact of AP-1 in BC cells[186, 
194, 195, 198]. AP-1 mediated suppression of miR-23b expression may then promote release of 
pro-invasive miR-23b gene targets from their post-transcriptional repression, thus eliciting BC 
invasion and metastasis (Figure 54). Taken together, these data suggests that loss of miR-23b 
expression and consequently disruption of its regulatory network, are crucial events in the 
initiation of BC progression. Thus, replacing miR-23b in BC patients may represent a novel 
therapeutic strategy to prevent tumour progression and metastatic spread.  
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4.1.2.3.1         Evidences show conflicting roles of miR-23b in BC  
A recently published research article by Lin et al.[357] showed conflicting functions of 
miR-23b and its family member miR-27b in BC initiation and progressioncomparing to our 
findings. They demonstrated that miR-23b/27b function as oncogenic miRNAs in BC by 
promoting proliferation, anchorage-independent cell growth, migration and invasion in vitro. 
By performing a number of experimental assays, they observed that independent gain- and 
loss-of-function of the two miRNAs increases and inhibits both migratory and invasive 
capabilities of BC cell lines, respectively. These findings are in contrast with our in vitro data 
where miR-23b overexpression and inhibition abolishes and enhances migration and invasion 
of our BC cells, respectively. The use of different BC cell lines (ZR35/MDA-MB-231-4135 
versus MCF-7 and MDA-MB-231 cells) and technical approaches could rely behind this 
discrepancy. Beside these experimental variances, it is noteworthy to highlight that Lin et al. 
did not discriminate between the pro-proliferative and pro-migratory/invasive effects of miR-
23b in BC cells, which is of fundamental importance when investigating phenotypes such as 
cell motility and invasion[353, 355, 375]. By performing independent assays (scratch wound 
healing and transwell assays), they found that mir-23b/27b modulation deregulates the 
migratory and invasive capabilities of BC cell lines; nevertheless, these assays were 
performed by incubating the cells for times longer than their doubling times (24-48h). As they 
observed that both miRNAs affect also cell proliferation, the possibility that 
increased/decreased proliferative rates of cells expressing miR-23b or miR-27b could 
contaminate the enhanced/reduced effect on their migration and invasion remains really high. 
Our choice to investigate the effect of miR-23b modulation on BC cell migration and invasion 
by performing different experimental techniques comparing to those used by Lin and 
colleagues (time-lapse tracking and type I-collagen 3D invasion assays) has allowed us to 
visualise single cells in their migrating/invasive cycles, thus analysing them independently 
from their proliferating state. Differently to the investigative approach adopted by Lin et al., 
we performed the migration assays by using cells overexpressing, alongside with miR-23b, 
also miR-31 (a pleiotropic suppressor of BC cell migration and invasion[375]), by which 
motility was reduced at the same extent as for miR-23b-overexpressing cells, and miR-26a, 
which did not affect cell migration, thus functioning as a reliable, further negative control.  
Furthermore, we demonstrated that miR-23b suppresses migration and invasion independently 
of cell proliferation by highlighting its effect on distinct features of cytoskeletal organisation 
(cell-cell junctions, lamellipodia and FA formation), on cell spreading on the ECM, and on 
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MLC phosphorylation state. Whereby, Lin and colleagues have appointed the effect of miR-
23b on deregulated proliferation/migration to the physiological function of Nischarin, a miR-
23b target identified in their study. They had previously shown that Nischarin knockdown 
increases both proliferation and migration/invasion in the same BC cell lines[448]; thus they 
confirmed that rescuing Nischarin expression in miR-23b-overexpressing cells partly reverts 
the miR-23b-mediated advantages on cell proliferation and motility. In order to validate their 
findings, they analysed the endogenous protein levels of other 6 predicted miR-23b targets, 
including PAK2, upon miR-23b inhibition and they observed that none of these genes were 
real targets of miR-23b, except for Nischarin. 
These findings are highly inconsistent with evidences showed in our and Zhang et al.‟[353] 
studies, that PAK2 is effectively a physiological target of miR-23b in breast (Figure 35, 36 
and 37) and colon cancer. We demonstrated that PAK2 is a real target of miR-23b by using a 
number of assays (Figure 35A, 36 and 37). Notably, we also found PAK2 to be up-regulated 
by the miR-23b-sponge construct and down-regulated by miR-23b overexpression in our 
RNA-seq data (Table 24). Moreover, we proved that miR-23b directly targets uPA in BC 
(Figure 52), thus confirming several reports of a direct control of miR-23b on the regulation 
of this crucial metastatic gene[353, 418]; additionally, we observe that 70% of previously 
validated miR-23b targets are found to be deregulated by miR-23b manipulation in BC cells, 
as shown by our RNA-seq data, many of which are pro-metastatic genes (Table 26). 
Noteworthy, no differential expression of Nischarin was detected upon miR-23b modulation 
in our RNA seq analysis, indicating that miR-23b is not able to regulate these two putative 
targets in our BC cell models, at least at the mRNA level. Our cross-validating approach 
proves not only the reliability of our experimental methods, but also that the physiological 
function of miR-23b in BC relies on the coordinated down-regulation of a broader set of 
genes. Consistently, we demonstrated that miR-23b coordinates the repression of a cohort of 
gene targets (Figure 50 and 52, Table 24), crucial for cytoskeletal dynamics, cell migration, 
invasion and metastatic dissemination that likely encompass its pleiotropic activity in 
negatively regulating these cellular phenotypes.    
In accordance with the effect of miR-23b/27b manipulation on BC cell proliferation and 
migration seen in vitro, Lin and colleagues observed that inhibition of these two miRNAs 
reduces both tumour growth and metastasis in vivo. After injection of BC cells into the 
mammary fay pad of immunocompromised mice, they found that miR-23b/27b silencing 
reduces tumour volume of the formed BC xenografts; this is in contrast with the tumour 
suppressor activity of miR-23b in BC in vivo models (as shown in our study, Figure 42 and 
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43), and other animal models of different tumour types (human colon and prostate cancer)[353, 
355]. Moreover, by performing a long-term lung colonisation assay upon tail vein injection, Lin 
et al. showed that miR-23b/27b inhibition represses the metastatic potential of human BC 
cells. This experimental approach of in vivo metastasis does not allow to reproduce with high 
fidelity the pathological multi-step process which cancer cells undertake in order to 
metastasise (local migration and invasion, intravasation, extravasation and organ 
colonisation). In fact, under these conditions, cancer cells enter directly the hematogenous 
stream, bypassing the invasion and intravasation steps. We used BC mammary gland 
xenograft models to investigate the impact of miR-23b inhibition on both tumour growth and 
metastasis in vivo. This method replicated our in vitro findings that miR-23b silencing elicits 
the ability of BC cell to invade the ECM (Figure 33B). Moreover, inhibition of miR-23b 
increased the extravasation and the metastatic spread of BC cells from the primary tumours to 
the lymph nodes (Figure 42B). Unfortunately, we did not detect metastatic dissemination to 
any bodily organ in our BC animal models, probably due to the limited time given to BC cells 
to systemically spread, as primary tumours had to be harvested early during the experiment 
course in accordance with licence restrictions.  
Finally, Lin and colleagues investigated the clinical relevance of miR-23b and miR-27b by 
measuring their endogenous levels in BC patients. Since they pinpointed a role of miR-23b 
and 27b as oncomiRs and metastatic miRNAs in their in vitro and in vivo findings, they 
compared their expression between primary breast tumour samples and normal tissues. They 
found that expression of both miRNAs is higher in BC patients and inversely correlates with 
Nischarin levels; moreover, they could be used as markers for BC prognosis and metastasis as 
their endogenous abundance correlates with poor overall survival and with the invasiveness of 
BC cell lines. On the other hand, we showed that miR-23b is expressed at lower levels in 
metastatic BC cell lines compared to primary tumour cells (Figure 41A), which was 
consistent with the data reported by Patel et al.[411], where they profiled miRNAs expression 
in the same BC cell lines which have been isolated from BC primary tumours and different 
metastatic loci after orthotopic injection in immunocompromised mice. Additionally, we 
report that miR-23b expression is significantly decreased in lymph node metastases compared 
to matched primary BC samples (Figure 41C-D), indicating that reduction of miR-23b levels 
is a physiological event during BC progression. Although our clinical data provide a more 
realistic picture of the relevance of miR-23b expression during BC cancer metastatic 
development comparing to Lin et al.‟ findings, a more accurate analysis of miR-23b and its 
paralogs abundance in metastatic tissues of BC origin would require further investigation.     
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4.1.3           Roles of miR-26a in BC tumourigenesis 
 
4.1.3.1          Roles of miR-26a in BC cell proliferation and apoptosis 
Beside the activity of miR-26a in modulating cytoskeletal dynamics to promote focal 
adhesion maturation, cell spreading and adhesion on ECM, we also pinpointed a role for this 
miRNA in the regulation of BC cell proliferation and apoptosis. 
In hepatocellular carcinoma, miR-26a shows robust activity in inhibition of cell proliferation 
and cell cycle progression, owing to its ability in directly repressing cell cycle key 
modulators, such as the cyclins CCND1, CCNE1 and CCNE2, the cyclin-dependent kinase 
CDK6 and RB1[361, 362]. We also showed that overexpression of this miRNA in MCF-7 cells 
reduces proliferation rates (Figure 29B), as well as expression of CDK6, CCNE1, and RB1 
(Table 20 and 25). Additionally, inhibition of miR-26a activity in MDA-MB-231 cells is 
associated with increase of RB1, CCNB1 and 2, CCNE1 and 2, and CCND3 (Table 21); this 
indicates that miR-26a may impair proliferative properties also through down-regulation of a 
wider cohort of cyclins.  
In confirmation of the ability of miR-26a in slowing cell proliferation rates, we observed that 
its overexpression induces MDA-MB-231 cells to undergo apoptosis (Figure 29C). Notably, 
we identified and validated as a miR-26a direct target, the myeloid leukemia cell 
differentiation protein 1 (MCL1), a key member of the BCL2 family with antiapoptotic and 
pro-survival functions (Figure 53 and Table 26). In keeping with our findings, miR-26a has 
recently been implicated in BC as a negative regulator of cell proliferation by promoting cell 
cycle arrest and apoptosis, via down-regulation of EZH2  and MCL1[367-369]. Interestingly, we 
retrieve EZH2 in our miR-26a targetome list of genes down-regulated or up-regulated after 
miR-26a overexpression or inhibition, respectively (Table 26). Moreover, siRNA-mediated 
knockdown of the RNA-binding protein LARP1, a novel miR-26a direct target validated in 
our study (Figure 53), has been shown to induce apoptosis of mammalian cells[435].  Taken 
together, these data strongly suggest that miR-26a controls apoptosis and proliferation 
pathways through coordinated repression of MCL1, EZH2 and LARP1 in our experimental 
BC cell models.  
Detailed analysis of our RNA-seq data revealed that the number of genes involved in cell 
cycle progression which are dysregulated by miR-26a manipulation is actually much larger 
than previously appreciated. Importantly, cyclin-dependent kinase (CDK) inhibitors, 
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including CDKN1A, CDKN2B, CDKN2C and CDKN2D were highly up-regulated in MCF-7 
cells after overexpressing this miRNA (Table 20). This indicates that concomitant reduction 
of cell cycle-promoting genes and up-regulation of cell cycle-inhibiting genes may represent a 
broader line of action adopted by miR-26a in inhibiting BC cell proliferation. 
Transcriptome analysis of MDA-MD-231 cells upon miR-26a manipulation shows instead a 
balance between cell cycle-promoting genes and cell cycle-inhibiting genes, as distinct 
cyclins and CDK inhibitors are both up-regulated or down-regulated (Table 21). This 
observation may explain why miR-26a inhibition or overexpression did not alter proliferation 
of MDA-MB-231 cells (Figure 29A and 30). However, the discrepancy in finding that MDA-
MB-231 cells displayed increased apoptosis, but exhibited the same proliferation rates as the 
control cells, upon miR-26a transient transfection (Figure 29C and B), remains unsolved and 
would require further investigation.  
Our pathway enrichment analysis of the miR-26a targetome revealed that several miR-26a 
predicted targets are implicated in the p53 signalling pathways. MiR-26a has been shown to 
be transcriptionally up-regulated by p53 and p53 activation is known to induce cell cycle 
arrest through down-regulation of cell cycle-promoting genes and up-regulation of the CDK 
inhibitor CDKN1A[449]. This suggests that miR-26a increases CDK inhibitor levels through 
p53 stabilisation and/or activation, because in miR-26a-overexpressing MDA-MB-231 cells, 
which express mutated p53, CDK inhibitors are not regulated and cell cycle progression does 
not seem to be affected (Figure 29A). Interestingly, the F-box protein 11 (FBXO11), known 
to inhibit p53 transcriptional activity by promoting its neddylation[450], is a predicted target of 
miR-26a and it also appears to be down-regulated upon miR-26a overexpression of in MCF-7 
cells (Table 25). Finally, miR-26a over-expression increases two members of the TGFβ 
(Transforming growth factor beta) receptor family, TGFBR1 and TGFBR2, and also their 
effector SMAD3 (Table 19), which is known to directly increase the expression of 
CDKN2B[451], indicating that miR-26a may also inhibit cell cycle progression by promoting 
the TGF signalling pathway. 
 
4.1.3.2         Mir-26a implication in cytokinesis, aneuploidy and BC 
tumourigenesis 
 
Prolonged administration of a miR-26a precursor mimic induced dramatic 
morphological changes in MCF-7 and MDA-MB-231 2-D cell cultures, leading to formation 
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of giant, expanded cells frequently containing two nuclei or a single enlarged nucleus (Figure 
45). This characteristic phenotype implies a robust involvement of miR-26a in cytoskeletal 
rearrangements and also in late stages of the cell cycle progression (mitosis), such as 
cytokinesis and karyokinesis. 
Maintenance of the intracellular miR-26a abundance at high levels may enhance the ability of 
this miRNA in promoting focal adhesion development, as well as cell spreading and adhesion 
on the substratum, thus contributing to the expanded, flat morphology displayed by MCF-7 
and MDA-MB-231 cells (Figure 44). The biological functions of specific transcripts found 
differentially modulated in our RNA-seq analysis after manipulation of miR-26a in BC cells 
support this hypothesis. Indeed, as previously discussed, miR-26a overexpression in MCF-7 
cells greatly up-regulates a cohort of genes involved in cell-matrix adhesion pathways, such 
as Vinculin (VLC) and several integrin subunits (Table 17), which were consistently down-
regulated in MDA-MB-231 cells stably inhibiting miR-26a activity (Table 18). Additionally, 
in epithelial contests (MCF-7 cells), prolonged miR-26a overexpression appears to affect cell-
cell interactions, as these giant cells display disrupted adherens junctions with scanty E-
cadherin accumulation at cell-cell adhesion sites (Figure 44A). Nevertheless, expression 
levels of the E-cadherin (CDH1) transcript were not affected in MCF-7 cells overexpressing 
miR-26a or MDA-MB-231 cells stably inhibiting this miRNA (RNA-seq data not shown); 
this suggests that miR-26a may cause aberrant E-cadherin expression at the post-
transcriptional level, a hypothesis that is a matter of future investigation. 
Manifestation of giant mononucleated or binucleated cells is a characteristic consequence of 
impaired nuclear division and/or cytokinesis, respectively, as well as a striking cause of 
aneuploidy/polyploidy occurrence and increased chromosome instability (CIN)[222, 413]. Here 
we show for the first time that prolonged overexpression of miR-26a significantly enhances 
the aneuploid state of both MCF-7 and MDA-MB-231 cells, which exhibited a larger 
percentage of cells with near-tetraploid (or higher than tetraploid) karyotypes compared to 
relative controls (Figure 46). This phenotype implies that these cells encounter difficulties in 
the completion of nuclear division and/or cytokinesis, with consequent acquisition of a 
polyploid karyotype. Although further investigation is required to demonstrate the direct 
involvement of miR-26a in affecting karyokinesis or cytokinesis events, our RNA-seq data 
and experimental validation of novel miR-26a gene targets strongly suggest that this miRNA 
may actually impair these cellular pathways.  
In support of a possible karyokinesis failure, we observed that several genes involved in 
crucial steps of chromosome segregation during mitosis are dysregulated after miR-26a 
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perturbation. Indeed, different members of the mitotic spindle assembly checkpoint (SAC), 
BUB1, BUB1B, BUB3 and the mitotic arrest deficient, yeast, homolog-like 1 (MAD2L1) are 
greatly up-regulated in MDA-MB-231 cells that stably inhibit miR-26a activity (Table 21). 
Similarly, increased transcript levels of two crucial promoters of sister chromatids 
detachment, ANAPC10, encoding for the subunit 10 of the anaphase-promoting 
complex/cyclosome (APC/C) and its partner cell division cycle 20 (CDC20) were observed in 
the same cells (Table 21). This suggests that miR-26a may indirectly induce  dysregulation of 
these crucial players, which is believed to induce karyokinesis failure and tetraploidisation 
due to impaired mitotic checkpoint response and/or failed chromatids separation[217]. 
Moreover, a potential deregulation of these proteins by miR-26a imply a high risk of 
aneuploidy occurrence and consequent enhancement of CIN[217].  
On the other hand, failure of cytokinesis is mainly caused by defects in different steps of this 
process, such as central spindle formation, actinomyosin ring assembly/closure and final 
abscission, due to dysregulation of several cytokinetic proteins that orchestrate all these 
events. We depict a potential role of miR-26a in early-middle steps of the cytokinesis, by 
directly targeting YWHAE, the member epsilon of the 14-3-3 protein family, which is found 
to be down-regulated in MCF-7 cells overexpressing miR-26a and up-regulated in MDA-MB-
231 cells stably inhibiting this miRNA (Figure 51, 53 and Table 25). 14-3-3 members form 
functional heterodimers to ensure both proper formation of the central spindle in collaboration 
with Aurora B, and efficient closure of the actinomyosin ring by associating with PKCε; their 
down-regulation has been shown to imply a broad range of cytokinesis defects with 
consequent formation of binucleated cells[224, 225, 230, 440]. However, miR-26a activity could 
also participate in later phases of the cytokinesis process, by impairing furrow ingression, and 
consequent abscission, necessary for the separation of the two daughter cells. Indeed, 
prolonged miR-26a overexpression in MCF-7 cells causes down-regulation of the Ras small 
GTPase RAB21 (Table 25), which has been shown to yield binucleated cells, due to delayed 
furrow ingression and consequent cytokinesis failure[227]. Interestingly, RAB21 3‟UTR 
contains a specific binding site for the mature miR-26a[351](Table 25), strongly suggesting 
that its direct interaction and repression by miR-26a can occur in physiological conditions. 
Moreover, we demonstrated that miR-26a overexpression in MCF-7 cells and its inhibition in 
MDA-MB-231 cells down-regulates and up-regulates, respectively, the expression of two 
members of the SNARE vesicle transport system, Endobrevin (VAMP8) and Syntaxin 2 
(STX2) (Table 22 and 23). These proteins are required for membrane fusion events that allow 
efficient separation of the two daughter cells, and their depletion has been shown to severely 
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impair cytokinesis completion leading to binucleation[231]. Interestingly, STX2 is a predicted 
target of miR-26a, as shown by our targetome analysis (Table 25), thus implicating a direct 
regulation of its expression by this miRNA.  
Additional direct targets of miR-26a validated in our study are the RNA-binding protein 
LARP1 and the early mitotic checkpoint CHFR (Figure 53), which are consistently found to 
be down-regulated and up-regulated upon miR-26a overexpression and inhibition in MCF-7 
and in MDA-MB-231 cells, respectively (Table 25). Potential miR-26a-mediated repression 
of these two gene targets in physiological conditions greatly supports a role for this miRNA in 
affecting cytokinetic events, as depletion of both LARP1 and CHFR results in cytokinesis 
failure and tetraploidisation[213, 435]. In particular, LARP1 knockdown in mammalian cells 
causes several aberrant mitotic features, such as failure of bipolar mitotic spindle formation, 
aberrant centrosome migration, abnormal nuclear morphology and impaired cytokinesis[435]. 
Moreover, it was associated with mitotic arrest and increased apoptosis, which is consistent 
with our observation that miR-26a induces apoptosis, whereas it affects cell proliferation in 
BC cells (Figure 29C and B). On the other side, depletion of CHFR produces severe CIN, 
arising from centrosome amplification, spindle mis-organisation, aneuploidy and 
cytokinesis/karyokinesis failure, which are associated with increased tumourigenicity[213]. 
CHFR is, in fact, a well-established tumour suppressor, as its down-regulation or complete 
loss is frequently observed in a wide variety of cancers, including primary tumours of the 
breast[213, 220]. CHFR-deficient mice display higher tumour incidence and formation of 
spontaneous aneuploid and polyploid tumours[213]; moreover, CHFR knockdown results in 
enhanced aneuploidy and induced transforming potential of human immortalised MCF10 
breast cells[220]. These data represent an example of the direct link between 
aneuploidy/polyploidy occurrence and malignant transformation. Indeed, it is well 
documented that aneuploid cells, derived from events of cytokinesis or karyokinesis failure, 
exhibit enhanced tumourigenic and transforming potentials due to increased CIN[200, 201, 204, 205, 
222, 235]. Here, we show that prolonged miR-26a overexpression in MCF-7 cells promotes the 
tumourigenic potential of these cells in vitro. MCF-7 cells transfected for 9 days with a miR-
26a precursor mimic form a significantly increased number of colonies, which were also 
larger in size, compared to control-treated cells in soft agar colony formation assays (Figure 
46), a clear indication of enhanced tumourigenic and transforming capabilities[143]. This is in 
contrast with recently reported data where miR-26a exhibits tumour suppressor abilities in BC 
both in vitro and in vivo[366, 368]. Zhang et al. demonstrated that delivery of miR-26a using a 
retrovirus-based system in MCF-7 cells reduces soft agar colony formation and 
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tumourigenesis in vivo, due to miR-26a-induced apoptosis and inhibition of cell proliferation, 
via down-regulation of the anti-apoptotic EZH2 and MTDH[366]. A second study by Gao et al. 
reported that transient miR-26a overexpression in MCF-7 cells impairs cell proliferation and 
soft agar colony formation, and promoted apoptosis via repression of MCL1[368]. The 
difference in the temporal and technical administration systems adopted in these and our 
studies may lie behind the discrepant effect of miR-26a on tumourigenic abilities of MCF-7 
cells. Noteworthy, we also demonstrate that miR-26a overexpression reduces MCF-7 cell 
proliferation and induces apoptosis of MDA-MB-231 cells (Figure 28B and C); furthermore, 
we also confirm MCL1 as direct target of miR-26a (Figure 53), and that expression of both 
MCL1 and EZH2 is inversely correlated with miR-26a overexpression or inhibition in our BC 
cell models (Table 25). The reproducibility of these findings supports a major role for miR-
26a in negative regulation of apoptosis and cell proliferation. Despite this, we observe that 
prolonged miR-26a overexpression promotes the establishment of a subpopulation of 
bi/mononucleated, polyploid cells, likely derived from events of cytokinesis/karyokinesis 
failure. This finding provides, for the first time, evidence of the ability of miR-26a to control 
additional steps of the cell cycle (mitosis), beside its previously reported role in inducing cell 
cycle arrest in G1 phase in BC cells[367]. We suppose that ectopic overexpression of miR-26a 
may differentially affect cell cycle progression, depending on the specific cycling state that 
these cells are experiencing at the timing of administration of this miRNA. Cells that 
overpassed phase G1 of the cell cycle may be affected by the continued administration of 
miR-26a. Therefore, increase and maintenance of miR-26a levels in cells that are entering or 
proceeding through later stages of the cell cycle may impair mitosis completion, due to 
cytokinesis/karyokinesis failure, thus resulting in polyploidisation. Polyploid cells are able to 
succeed cell cycle progression by escaping cell death or cell cycle arrest, and after completing 
cytokinesis, produce a progeny of aneuploid cells with enhanced CIN and increased 
transforming potential[229, 232, 235]. The observation in time-lapse experiments that giant, 
bi/mononucleated MCF-7 cells overexpressing miR-26a are able to accomplish cell division, 
although at much slower rates compared to miR-n.c.-treated (data not shown), suggests that 
these cells are viable and in advanced passages they may give origin to a cell population with 
worsened aneuploid and CIN phenotypes and increased tumourigenic abilities. This may 
explain the effect of prolonged miR-26a overexpression in improving the in vitro 
tumourigenicity of MCF-7 cells, observed in our study (Figure 46). Nevertheless, this 
hypothesis requires further investigation, to better characterise the proliferative and 
transforming properties of these cells.  
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A major consequence of polyploidisation is the acquisition of an aberrant number of 
centrosomes (centrosome duplication), which dramatically elicits CIN and aneuploidy 
occurrence following successful mitosis of tetraploid cells. About 80% of invasive breast 
carcinomas manifest abnormal number and/or structure of centrosomes, indicating that the 
risk to develop CIN and aneuploidy increase with tumour progression[233]. Although miR-26a 
has been found to be down-regulated in patients with primary breast carcinomas compared to 
control normal specimens[366, 368], it would be interesting to investigate miR-26a expression 
profile in advanced stages of BC progression associated with an aneuploid/polyploid state. 
 
4.1.4           Future directions  
 
In light of the results presented in this thesis, several aspects of the overall function of 
miR-23b and miR-26a remain to be addressed.  
Concerning the miR-23b role in BC progression, we demonstrate that this miRNA regulates 
cytoskeletal dynamics, migration and invasion of BC cells.  
We show that miR-23b overexpression enhances the epithelial architecture of MCF-7 cells, 
probably by inducing up-regulation of cell-cell adhesion molecules, including Nectin 1 and 
Nectin 2 at the transcriptional level, as suggested by our RNA-seq analysis. To address this 
hypothesis, it would be necessary to assess: 
 the endogenous protein levels of these cell-cell adhesion mediators after miR-23b 
manipulation in BC cells; 
 whether their potential deregulation by miR-23b affects their localisation and 
functionality at cell-cell adhesions sites; 
 the mechanism(s) used by miR-23b to eventually regulate their expression. Although 
the ability of miRNAs to induce transcriptional expression of specific genes at their 
promoter levels has been demonstrated[290], they mainly function in repressing gene 
target expression at the post-transcriptional level[248]. Therefore, miR-23b could down-
regulate potential transcriptional suppressors of these cell-cell adhesion molecules, 
thus increasing their expression. However, eventual indirect effects induced by miR-
23b overexpression could also determine the up-regulation of these adhesion genes. 
 
We further demonstrate that miR-23b inhibits lamellipodia formation, cell migration and 
invasion in BC cells and we validate a subset of genes with crucial functions in these cellular 
processes as miR-23b direct targets. Experimental down-regulation of most of these genes in 
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the same BC cell model has been shown to induce similar effects to the overexpression of 
miR-23b. Nevertheless, to investigate how repression of each single miR-23b target 
contributes to the phenotypic effect induced by miR-23b, it would be necessary to 
overexpress each miR-23b target in order to restore its intracellular levels upon 
overexpression of miR-23b.  
We also show that the transcription factor AP-1 transcriptionally represses miR-23b 
expression; the AP-1 component c-JUN directly interacts with the miR-23b promoter region 
and silencing of both C-JUN and c-FOS results in increased levels of both precursor and 
mature miR-23b. Since miR-23b is part of a miRNA cluster, along with its paralogs miR-27b 
and miR-24-1[350], it is likely that AP-1 also controls the expression of these two miRNAs. 
Therefore, investigation of miR-27b and miR-24-2 levels after AP-1 silencing would be 
required. Additionally, we show that mature miR-23b levels are reduced after stimulation of 
BC cells with EGF, which is known to induce AP-1 activation through EGF receptor signal 
transduction[194]. In order to confirm that EGF represses miR-23b expression via AP-1 
activity, disruption of the EGFR signalling pathway by silencing or inhibiting crucial 
effectors, would be required.  
On the other hand, we show that miR-26a impairs cell proliferation and induces apoptosis in 
BC cells and regulates cytoskeletal dynamics, inducing several phenotypes, some of which 
are shared by miR-23b activity.  
MiR-26a overexpression in BC cells promotes cell adhesion on the ECM, probably due to up-
regulation of several ECM-cell adhesion genes. Analysis of protein levels of these genes and 
investigation of the mechanism(s) that trigger their up-regulation would be required.  
We show that long-term overexpression of miR-26a determines the establishment of 
characteristic sub-populations of cells, displaying a dramatic enlargement of their cell body, 
often containing two nuclei or one oversized nucleus. In epithelial contests (MCF-7 cell 
cultures), these effects are also accompanied by an apparent disruption of E-cadherin-
mediated cell-cell adhesions. Since we observe no changes in E-cadherin transcript levels in 
our RNA-seq data, it is possible that post-transcriptional deregulation of E-cadherin indirectly 
induced by miR-26a could explain this phenotype. Therefore, further investigation, such as 
Western blot analysis of E-cadherin protein levels upon miR-26a overexpression and/or 
eventual mechanisms that might control this gene post-transcriptionally, is required to 
uncover this hypothesis.  
The formation of giant, bi/mononucleated cells observed upon miR-26a long-term 
transfection indicates that defects in cytokinesis/karyokinesis events may occur in these cells. 
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In support of this point, we find that (1) overexpression of miR-26a increases the number of 
cells with a polyploid karyotype; (2) miR-26a directly targets genes, such as YWHAE, CHFR 
and LARP1, relevant to cytokinesis and/or nuclear division pathways; (3) miR-26a 
manipulation procures changes in the expression of genes crucial for the proper execution of 
these processes. In order to unravel whether and how failure of cytokinesis/karyokinesis 
occurs upon miR-26a overexpression, and to unravel the molecular mechanism(s) responsible 
for these phenotypes, we aim to perform: 
 analysis of the ploid content of cells by flow cytometry, in order to confirm the 
increased observed aneuploidy; 
 systematic investigation of mitotic features, such as mitotic spindle formation, 
chromosome segregation, nuclear division and cytokinetic progression aspects, by 
using light/fluorescence, time-lapse microscopy and cellular markers, such as 
fluorescent dyes for the staining of nuclei (DAPI), microtubules, and plasma 
membranes; 
 RNA interference (RNAi) of miR-26a gene targets in our BC cell models, and their 
overexpression in cells overexpressing miR-26a followed by investigation of eventual 
effects on cell division; 
 
Additionally, the observation that giant, bi/mononucleated MCF-7 cells overexpressing miR-
26a are able to complete mitosis is a manifestation of cell viability. Nevertheless, further 
investigation is necessary to confirm this hypothesis and a variety of experimental assays can 
be performed to assess cell cycle progression, apoptosis, cell proliferation, cell death, or 
senescence upon prolonged overexpression of miR-26a.  
Finally, we aim to confirm the tumourigenic potential of miR-26a in BC, because of the 
clinical relevance that this may imply. Since miR-26a-overexpressing cells display increased 
polyploidy, it is likely that miR-26a confer tumourigenic and transforming abilities, by 
promoting aneuploidy and CIN. In this respect, we aim to investigate:  
 the ability of miR-26a in inducing in vitro transformation of immortalised, normal 
breast cells, such as MCF-10 breast cell line, under conditions of long-term (9 days) 
transfection; 
 how miR-26a impacts tumourigenicity of MCF-7/MDA-MB-231 cells in vivo, by 
inducing xenograft tumours formation following ectopic implantation of these cells in 
immunocompromised mice, either after in vitro long-term miR-26a transfection, or by 
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performing a series of intratumoural injections of miR-26a mimics and relative 
controls;  
 the euploidy state of xenograft tumours after completion of the in vivo analysis; 
 miR-26a expression in BC specimens manifesting aneuploidy/polyploidy 
characteristics. 
 
4.1.5           Conclusions 
 
This work has enabled us to characterise the specific roles of miR-23b and miR-26a in 
BC pathogenesis.  
In particular, we have pinpointed miR-23b as a potent suppressor of BC progression, by 
affecting motile and invasive abilities necessary for cancer cells to metastasise. By picturing 
the overall action that miR-23b takes in the contest of BC, we extrapolated a complex 
regulatory network that miR-23b orchestrates to impede acquisition of aggressive traits. This 
network employs mechanisms of post-transcriptional repression, transcriptomic changes and 
intracellular dynamics affecting multiple genes that differentially promote or inhibit BC 
progression. We demonstrate the clinical importance of miR-23b down-regulation in BC 
metastasis and we propose that loss of miR-23b expression and consequent disruption of its 
regulatory network are crucial events in the initiation of BC progression. Therefore, it is 
conceivable that replacing miR-23b in patients affected by BC may represent a novel 
therapeutic strategy to prevent tumour progression and metastatic spread. 
On the other hand, we confirm a major role for miR-26a in inhibiting BC cell proliferation, 
and inducing apoptosis and cell cycle arrest, as previously demonstrated. Moreover, we 
describe novel additional functions of miR-26a in BC cells. It is involved in cytoskeletal 
remodelling pathways, leading to enhanced cell adhesion, and in later steps of cell cycle 
progression by promoting binucleation and polyploidy occurrence. Finally, we demonstrate 
the ability of miR-26a to elicit tumourigenicity of BC cells, likely due to increased aneuploidy 
and CIN. 
Since miR-26a exhibits tumour suppressor activity by inducing cell cycle arrest and apoptosis, 
it has been proposed as a potential therapeutic candidate of both breast and hepatocellular 
carcinoma. However, we believe that caution should be taken when considering miR-26a as 
an anti-cancer therapeutic agent; indeed, its persistent administration could elicit delayed 
manifestation of mechanisms, such as aneuploidy and  CIN, that could be a prelude to 
tumourigenesis.  
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